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 Chapter 1 










1. Drug Discovery and Development 
Modern drug discovery consists of sequential steps (Figure 1), which 
usually start with identification and validation of a target in a disease process, 
using recent advances in human biology, genomics, proteomics and 
computational power. The majority of targets selected for drug discovery efforts 
are proteins. Two classes predominate: G protein-coupled receptors (GPCRs) 
and kinases. Next step involves discovery of lead compounds that interact with 
the target chosen. High-throughput screening (HTS) process is the most common 
way that leads are usually found. Hundreds of thousands of compounds can be 
tested for their ability to affect the activity of the target protein, and then identify 
any that might be potential drugs. Based on the results, several lead compounds 
are selected for further optimization with suitable pharmacodynamics (affinity, 
selectivity, efficacy, physiochemical properties) and pharmacokinetics (metabolic 
stability and oral bioavailability). Once a compound that fulfills all of these 
requirements has been identified, it will be submitted to pre-clinical trials (on 
animals) and eventually clinical trials (on humans). 
 
Figure 1. Modern drug discovery and development is a 10–17 year process from idea to 
marketed drug. For every 5,000 - 10,000 compounds that enter the R&D process, ultimately only 
one receives approval.  
 
2. GPCRs: the Most Important Drug Targets 
G protein-coupled receptors (GPCRs) are critical eukaryotic signal 
transduction gatekeepers and form a large and important protein family in the 
human genome, over 800 members.1 They are located in the plasma membrane 
of all cell types. GPCRs respond to a variety of extracellular signals, from 
photons, protons, ions and small organic molecules, to peptides and 
glycoproteins. GPCRs mediate the actions of extracellular signals across the 
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plasma membrane over a distance of ~30 Å, and then convert them into 
intracellular responses via coupling to cytoplasmic heterotrimeric G-proteins, β-
arrestins and kinases, which then activate downstream effectors and trigger 
cascades of cellular and physiological responses.2 GPCRs play a crucial role in 
regulating the pathophysiology of numerous diseases, so they are one of the 
most important target families for drug discovery.  
 
 2.1 GPCRs Classification and Pharmacology 
All GPCRs share a common structural topology of seven-transmembrane 
helical domains (TMD), an extracellular N-terminus, and an intracellular C-
terminus. They can be classified into five major groups: Rhodopsin-like; Secretin-
like; Adhesion; Glutamate; and Frizzled/Taste 2.1 These families can be further 
divided into numerous subfamilies based on structural and sequence similarities. 
The largest subfamily is the rhodopsin family (family A), having a short 
extracellular N-terminus and having several highly conserved amino acids in the 
TMD bundle. In addition, an eighth helix is present at the C-terminus (Figure 2). 
The family A receptors can be activated by a variety of small molecules including 
amines, purines, lipids, peptides, as well as large glycoproteins. Almost a quarter 
of marketed small molecule drugs target this subfamily of GPCRs.3 In this family, 
the endogenous small molecule (orthosteric) binding site is in the top of the TMD 
bundle (Figure 2, green hexagon).4 Many molecules also bind to this site and are 
competitive with the natural ligands. As shown in Figure 3, the binding of agonists 
results in an increase of receptor activity. The binding of inverse agonists 
reduces receptor activity. Antagonists act to block GPCR activation by preventing 
the binding of agonists to the receptor. Molecules that bind to the receptor at 
distinct sites from orthosteric binding site, are called allosteric modulators. 
Binding of allosteric ligands can either enhance or inhibit the binding of the 
orthosteric agonist, and ligands are termed positive or negative allosteric 
modulators (PAM and NAM), respectively. Allosteric ligands can be promising 
drug candidates since they are more specific to the subtype receptors and have 
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less side effects.5 For family A receptors, it is thought that the binding of allosteric 
modulators often specifically takes place on the top of the helices and the 
extracellular loops of receptors (Figure 2, red triangle).6  
 
Figure 2. Schematic representations of overall structures of family A, family B, and family C 
GPCRs. The binding pockets of orthosteric and allosteric ligands are present as green hexagon 




Figure 3. Classification of ligand efficacy for GPCRs. Permission and copyright 2009 Nature. 
 
The secretin and adhesion families (family B) have a large extracellular N-
terminal domain containing several conserved cysteine residues that form a 
network of disulphide bridges. The secretin family is activated by hormone 
peptides including glucagon, secretin, calcitonin and parathyroid hormone. The 
binding occurs at the N-terminal domain and the upper part of the TMD, which 
results in an essentially unoccupied TMD bundle. Moreover, allosteric binding 
sites for family B GPCRs have been identified within the TMD7 (Figure 2). 
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Several drugs (peptides) were launched on the market, targeting this family of 
receptors, such as Byetta8 (exenatide, glucagon-like peptide 1 agonist) and 
Miacalcin9 (calcitonin). However, to date, this family has proven to be very 
difficult for small molecule drug discovery. For the adhesion family, the 
extracellular domain usually contains a wide variety of protein modules that are 
known to be involved in protein-protein interactions, such as lectin-like, 
immunoglobulin-like and cadherin-like motifs. The majority of this family consists 
of orphan receptors, and few attempts have been made to de-orphanizate to 
yield new drug targets.10  
 The final major class is the glutamate family (family C), which contains 
receptors for the metabotropic glutamate and γ-aminobutyric acid (GABA) as well 
as the calcium sensing receptors.11 These receptors are characterized by a long 
N-terminus (500-600 residues) that forms a separate ligand-binding domain 
called the Venus flytrap module (VFTM, composing of two domains that form a 
cavity), distinct from the TMD.4 Drugs acting on this class of receptors either bind 
at N-terminal domain (e.g., baclofen,12 agonist of the GABAB receptors) or are 
allosteric modulators that bind within the TMD (e.g., cinacalcet,13 allosteric 
modulator of the calcium-sensing receptors).  
 
2.2 High-Resolution GPCR Structures 
Until recently, the field of membrane protein structural biology was 20-30 
years behind the study of soluble proteins. However, this field has quickly caught 
up by developing better ways to produce, purify and crystallize membrane 
proteins. The first crystal structure of a membrane protein, a bacterial 
photosynthetic reaction centre, was solved at 3 Å resolution in 1985.14 It 
supported the fact that membrane proteins could be crystallized. Fifteen years 
after, the first high-resolution three-dimensional structure of a GPCR, rhodopsin, 
was solved by a collaboration of the groups of Okada and Palczewski.15 This 
structure revealed the architecture of the seven transmembrane helical domain, 
which has been used as the basis for most GPCR homology models. Okada 
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developed a simple method for purifying rhodopsin from rod outer segment 
membranes using detergent extraction, which can improve the protein stability 
and facilitate the crystallogenesis. However, rhodopsin is an unusual GPCR 
because of its relatively high biochemical stability and its high expression level 
from natural tissue, bovine retina.16 The major obstacles to obtain structures of 
other GPCRs include protein production, purification (inherent hydrophobicity), 
protein stability and conformational flexibility. In terms of production, it is now 
possible to generate sufficient quantities (tens of milligrams) of GPCRs using 
insect cell (sf9 and Hi5 cells) expression systems.17 To overcome the 
thermodynamic and protein instability, several innovative protein engineering 
techniques have been developed (described in further detail below), which 
resulted in an increasing number of solved structures since 2007, when 
researchers solved the structure of a second GPCR: the human β2-adrenergic 
receptor.18,19 In the past thirteen years, using these newly developed techniques, 
more than 75 structures of 21 different family A GPCRs have been determined in 
complex with ligands, peptides, antibodies and a G-protein (heterotrimeric Gs), 
as shown in Table 1. 
Table 1. GPCR crystal structures. 
Receptors subfamilies Receptors 
rhodopsin bovine rhodopsin 20, squid rhodopsin 21 
aminergic GPCR family β-adrenergic receptors (avian β1AR 22 and 
human β2AR ,19,  
muscarinic acetylcholine receptors (human 
M2R 23 and rat M3R 24),  
human H1 histamine receptor 25,  
human D3 dopamine receptor 26, 
human serotonin receptors (5-HT1B 27 and 5-
HT2B 28) 







human CXCR1 30 and CXCR4 31 chemokine 
receptor,  
opioid receptors (human nociceptin receptor 32 
and κ-OR 33 and mouse µ-OR 34 and δ-OR 35),  
rat neurotensin receptor (NTSR1) 36,  





human sphingosine-1 phosphate (S1P1) 38 
receptor, 
human GPR40 free fatty-acid receptor 1 
(FFAR1)39 
glycoprotein-binding GPCR smoothened receptor (SMO) 40 
Class B GPCRs corticotropin releasing factor receptor 141, 
glucagon receptor42 
Class C GPCRs human metabotropic Glutamate Receptor 1   
(mGlu1)43, 
human metabotropic Glutamate Receptor 5 
(mGlu5)44 
glutamate GPCR GABA(B) receptor45 
 
2.3 Human Adenosine A2A Receptors – Therapeutic Potential 
 The adenosine A2A receptor (A2AR) is one of four adenosine receptor 
subtypes (A1, A2A, A2B and A3) belonging to the family A GPCRs.46 It is widely 
distributed throughout the body, and can be activated by extracellular adenosine, 
thereby stimulating the cyclic AMP-protein kinase A pathway by coupling to Gs 
protein. A2AR activation occurs in response to stress, cell damage or ischemia,47 
and protects tissues by controlling inflammation. For this reason, A2AR agonists 
are candidates for development of anti-inflammatory drugs. Nearly all of the 
known A2AR agonists are derived from purine nucleosides;48 a representative 
selection of A2AR ligands is shown in Figure 4. Several of them are promising 
cardiovascular clinical candidates.49–51 The A2AR agonist BVT.115959 is currently 
in phase II clinical trials for the treatment of diabetic neuropathic pain.52 
Regadenoson is the only clinically approved A2AR agonist and is used as a 
coronary vasodilator in myocardial perfusion imaging.53 
A2AR antagonists have generally been derived directly from xanthine, or 
contain a heterocyclic ring in place of the xanthine core.54 The natural products 
caffeine and theophylline act as weak A2AR antagonists. The purine-like 
derivative ZM241385, a potent and selective A2AR inverse agonist, has been 
widely used in research. A2AR has been shown to be a novel, non-dopaminergic 
therapeutic target for Parkinson’s disease (PD). A2AR is co-expressed with 
dopamine D2 receptor in the striatum and functionally opposes the actions of the 
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D2 receptor.55 The pathologic hallmark of PD is the gradual loss of dopamine and 
hence reduced dopamine D2 receptor activity. Blockade of A2AR might reduce the 
striatal dopamine depletion and dopaminegic cell loss.56 Several A2AR 
antagonists/ inverse agonists have been evaluated in clinical trials as alternative 
therapeutic agents for the treatment of PD, because of their efficacy and 
advantages in reducing motoric dysfunction and suppressing L-DOPA-induced 
dyskinesias, which experienced by patients following long-term levodopa 
therapy.52 Preladenant (SCH420814; Merck) is currently being evaluated in 
phase III clinical trials for the treatment of PD.57 The A2AR antagonists also have 
potential indications for other neurodegenerative diseases, such as Alzheimer’s 
disease, depression, and addiction.58 
 
Figure 4. A representative selection of A2AR ligands. 
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To date, twelve high-resolution crystal structures of A2AR, with agonist or 
antagonist/inverse agonist bound, have been solved. The binding site position 
and protein conformation have been determined in both active and inactive 
states. This structural information could be used to aid in designing specific 
compounds with drug-like properties for A2AR.  
 
2.4 GPCRs Drug Discovery – Successful and Challenging 
GPCR drug discovery has been very successful, a large number of small 
molecule drugs have been developed in multiple therapeutic areas. Sixty-three 
new GPCR drugs have been launched in the past 10 years and in total they 
account for an estimated 30-40% of all drugs currently on the market.59 GPCR 
drug discovery presents an important area for the pharmaceutical industry. More 
than a quarter of the 100 top-selling drugs target GPCRs, with annual sales of 
over 65 billion dollars.60 However, research in this area is still very challenging, 
and only one novel GPCR has been drugged per year by a new chemical entity 
(NCE). In addition, over 100 clinically relevant GPCRs still remain undrugged. 
They are orphan GPCRs with unknown endogenous ligands and in most cases 
unknown function.61 Traditional GPCR drug discovery efforts have relied on cell-
based assays combined with HTS of large collections of compounds (tens to 
hundreds of thousands of compounds), with typical molecular weights ranging 
from 350 to 500 Da. While this approach has been successful for many GPCRs 
(like adrenergic, muscarinic, and histamine receptors)60, recent clinically 
validated high-value targets such as neuropeptide receptors, chemokine 
receptors, peptide-hormone receptors and metabotropic glutamate receptors 
have represented a big challenge and been intractable to small molecule drug 
discovery. Fragment-based drug discovery (FBDD) is now established as an 
alternative strategy to HTS for ligand discovery, where low molecular weight 
compounds, known as fragments, are screened as new chemistry starting points. 
The screening of fragment libraries usually employs biophysical screening 
methods, several techniques have been validated for GPCRs drug discovery.62–64 
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In addition, recent impressive progress in obtaining GPCR structural information 
has enabled the use of structure-based drug design methods for hit identification 
and optimization. Until recently, application of both fragment- and structure-based 
drug discovery to GPCRs is still challenging, primarily because of the instability of 
the proteins when isolated and purified from the cell membrane. New advances 
in protein stabilization by using different protein engineering methods have 
facilitated GPCR structural and biophysical studies.65 These approaches will be 
discussed in next section.   
 
3. Fragment-Based Drug Discovery  
3.1 Small is Beautiful: Why Fragments?  
Over the past two decades, pharmaceutical industry invested significantly 
into HTS for identifying potent compound “hits” against a drug target, typically 
proteins.66 HTS involves screening of large compounds libraries, typically 
containing a million complex “drug-like” compounds which have been selected to 
comply with the Rule of Five as formulated by Lipinski et al. 67 : molecular mass < 
500 Da, cLogP (the calculated logarithm of the partition coefficient between water 
and 1-octanol) < 5, number of hydrogen-bond donors ≤ 5 and number of 
hydrogen-bond acceptors ≤ 10. The Rule of Five is used to maximize an oral 
drug molecule’s probability of surviving development, i.e. has good 
pharmacokinetic and ideal ADMET (Absorption, Distribution, Metabolism, 
Excretion, and Toxicity) properties. Despite many success cases with high-value 
hits, there are many obvious limitations to drug-sized compounds screening. Hit 
rates are often low, particularly when screening against challenging targets; and 
many hits fail in the process of lead optimization.68,69 In the recent decade, HTS 
has not delivered on its promise of increasing the numbers and quality of new 
drugs entering clinical trials. This lack of success is in part due to the complexity 
and the relatively large size of the compounds routinely being screened. Large 
HTS compound libraries represent only a small fraction of chemical diversity 
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space (i.e. all possible compounds that could exist) and poor sampling by HTS 
libraries is a limitation for finding a good starting point for further lead 
optimization. Moreover, optimization into more potent compounds often tends to 
reduce their initial drug likeness properties,70–72 such as bioavailability, 
absorption and solubility. Finally, even if the three dimensional (3D) structure of 
an HTS hit binding to the target protein can be obtained, it may still not be clear 
which parts of the molecule contribute most to the binding energy, leading to 
ambiguity about how to increase potency. 
In 1981, William Jencks first proposed the theory behind FBDD.73 Over the 
past 15 years, FBDD has developed as an alternative approach to HTS for hit 
identification. Screening starts with low-molecular weight drug fragments, which 
typically conform to the “Rule of Three” 74: molecular mass of <300 Da, up to 
three hydrogen bond donors, up to three hydrogen bond acceptors, and cLogP of 
≤3, in addition, up to three rotatable bonds and polar surface area ≤ 60 Å2. Due 
to the simplicity of the fragments it is possible to screen a large proportion of 
chemical space with a small collection of fragments.71 The basic promise is that, 
instead of searching a huge collection (million) of potential drug-like molecules 
(up to 30 heavy atoms, 1060 possible molecules),75,76 one could screen smaller 
(few thousands) collections of fragments (up to 12 heavy atoms, 107 possible 
molecules).77 Lower complexity of fragments gives a higher probability at probing 
the key binding areas of a protein binding site, and results in a higher and more 
reliable hit rate than HTS.70 Because of the small size of fragment molecules, 
they typically bind to the target proteins with lower affinity 78 (micromolar to 
millimolar range) compared to drug-like compounds, which can form more 
interactions (nanomolar to micromolar range). Although fragments are weak 
binders, they can adopt optimum orientations in the active site, demonstrated by 
high ligand efficiency (LE, that is, binding energies per atom of a ligand to its 
target protein).79 LE has emerged as a useful guide to optimize fragment and 
lead selection in the discovery process. All the factors mentioned above are 
crucial in successful drug development. However, the low KD requires a more 
elaborate optimization to obtain a lead compound. Traditional bioassays used in 
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high-throughput screening are generally unable to detect such small fragments 
because of their low potency binding (KD > 1 µM) 80 to the protein target. In order 
to detect these weak binders, FBDD employs highly sensitive biophysical 
techniques, such as nuclear magnetic resonance (NMR) spectroscopy, surface 
plasmon resonance (SPR) and protein X-ray crystallography for screening. 
Today, these biophysical techniques are extensively used in fragments 
screening, because they are highly sensitive to detect low affinity fragments 
binding, and more interestingly, provide the structural information on target-
fragment binding.  
The first practical implementation of fragment-based screening was 
carried out in the pioneering studies at Abbott using structure−activity relationship 
(SAR) by NMR 81 in the late 1990s, and at Astex using protein X-ray 
crystallography since the early 2000s.82,83 This sparked a revolution in FBDD and 
there is a substantial number of published works to support this approach, from 
both drug discovery companies and academic institutes. Initially, FBDD was 
employed against soluble targets, principally on kinases that had shown the 
ability to bind small molecules with high affinity. Then, FBDD approach was 
successfully applied to other soluble protein families for which structural 
information was readily available. There are examples of success with fragment-
based methods against targets that have proven to be very difficult with 
traditional HTS approaches.84 For example, the aspartic protease β-secretase 
(BACE) was considered an intractable target fifteen years ago. But now several 
companies have used FBDD approach to find high affinity inhibitors and have 
advanced compounds into clinical trials.85,86 Fragment-based methods are now 
being used against targets as diverse as protein−protein interactions,87 
transcription factors,88 protein chaperones, and RNA.89 The approach has yielded 
one market drug in 2011: vemurafenib.90,91 It took only 6 years since Plexxikons’ 
researchers started to look for the low-molecular-weight hits against kinases until 
the FDA approval of vemurafenib for metastatic melanoma. Implementation of 
FBDD in the GPCR field has lagged behind the soluble protein families, primarily 
because GPCRs are highly unstable when extracted from cell membranes, 
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making them very difficult to isolate, purify and obtain in sufficient quantities for 
biophysical screening. However, in recent research, biophysical fragment 
screening methods such as NMR, SPR have been validated for GPCR target 
families.62,63 
 
3.2 Methods for Finding Fragments  
Reliably detecting ligand binding in the affinity range of fragments is a 
technical challenge, as traditional bioassay methods are often unsuitable to 
screen weak protein-ligand binding. Over the past decade, this issue has been 
successfully overcome by developing a variety of sensitive biophysical methods 
for detection, of which NMR, SPR and X-ray crystallography (which will be 
discussed in next section) have been the most widely used. A significant 
advantage of biophysical screening methods is that we can directly detect the 
binding of hits with target in a reversible manner.  
 
Nuclear Magnetic Resonance 
NMR-based fragment screening was firstly introduced in 1996 as “SAR by 
NMR” by Fesik 92 and co-workers at Abbott laboratories. The protein is 15N 
isotopically labelled and [1H,15N] Heteronuclear Single Quantum Coherence 
(HSQC) NMR spectra are recorded in the presence and absence of fragments 
that are added in a mixture of up to 30 at a time. Chemical shift changes in 
protein spectra in the presence of a fragment indicate binding, and if the 
resonance assignment is available, the location of ligand-binding site can be 
determined. This approach is called “protein-observed” NMR, which relies on 
changes in the NMR spectrum of the protein. Such a powerful approach with very 
low false positive rates, has led to a large number of high-affinity inhibitors, and 
some of them have moved to clinical trials,93 for example: ABT-518 94 and ABT-
263 95 for the targets matrix metalloproteinase 3 and Bcl-2, respectively. 
However, it is limited to relatively small proteins (around 30 - 40 kDa), due to 
relaxation time and signal broadening. Moreover, the approach requires large 
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quantities of labelled protein, generally at least 200 mg.92 Furthermore, both the 
protein and the fragments need to be soluble in the experimental buffer. In 
addition, a low hit rate requires a rather large fragment library, typically more than 
15,000 compounds. 
For all the above reasons, a number of NMR-based methods have been 
developed to detect binding via changes in the NMR spectrum of the ligand. This 
approach presents large advantages in that it doesn’t suffer the limitation of 
protein size, and the protein concentration can be 10-100 fold lower compared to 
protein observed methods. Moreover, the target proteins need not be isotopically 
labelled. In addition, ligand-based approaches get a higher hit rate (in general 5-
10 fold), therefore, the library size can be reduced. There are a number of 
methods in use: the most popular in practice are the saturation transfer difference 
(STD) 96 method and the WATERLOGSY 97 method. Both methods rely on the 
selective transfer of magnetization from the protein to the ligand upon target 
binding. An interesting ligand-detected approach called Interligand nuclear 
Overhauser Effects (SAR by ILOE) identifies pairs of weak binders for a target 
protein, facilitating linking,98 although false positives need to be avoided due to 
aggregation of compounds.99 Another interesting ligand-detected method is 
called target-immobilized NMR screening (TINS) (Figure 5).100 TINS uses a 
single sample of immobilized protein to screen the entire library with very low 
false positive rates, due to the use of a reference protein.101 Utility of TINS 
methodology for identification of fragment ligands for challenging targets such as 
integral membrane proteins will be discussed in this thesis. TINS is compatible 
with competition mode screening in which displacement of a known ligand is 
used as the readout.62 It should be noted that the tight binding ligand are not 
suitable for detection by ligand observed NMR methods, which are dependent on 




Figure 5. A patent protected TINS screening station has been developed by ZoBio B.V. in 
collaboration with Bruker. The system is built around a 500 MHz NMR spectrometer. The target 
and reference proteins are immobilized on a sepharose resin and packed into separate cells of 
the dual cell sample holder (right). The sample holder is inserted into the magnet and the 
mixtures of fragments to be screened are injected into each cell. A spatially selective NMR 
experiment is used to acquire a 1D 1H spectrum of the soluble material in each cell (blue & red 
overlaid spectra) (left). Binding of a fragment is detected by a reduction in the height of all its 
peaks, conveniently expressed as a ratio of peak height in the target to that in the presence of the 
reference (T/R ratio). Figure reproduced from Bartoli et al.103 Permission and copyright 2006 Drug 
Discovery Today: Technologies. 
 
Surface Plasmon Resonance 
Today, the use of surface plasmon resonance (SPR) to characterize 
fragment binding becomes a primary screening technique, because of recent 
improvements in SPR biosensors and instrumentation. In direct SPR fragment 
screening, solutions of fragments flow past a target biomolecule that has been 
immobilized onto a coated chip and the binding can be detected by the increase 
of mass at the sensor surface. In some cases, the binding kinetics can be 
measured and the binding affinity calculated from the fragment 
association−dissociation response.104 Now, SPR allows detection of binding of 
small molecules with molecular weights as low as 100 Da.105 The use of suitable 
control proteins could significantly reduce the number of false positives from non-
specific binders. For example, we can choose unrelated proteins that are 
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solubilized and immobilized in the same way as target protein, or proteins with 
binding sites being blocked with known high affinity ligands. 
Another interesting approach has been developed by Graffinity 
Pharmaceuticals.106 All compounds are linked to the same proprietary spacer 
molecule (ChemTag®), which serves as an attachment point for the covalent 
immobilization on the array surface. Assessment of the protein binding is then 
carried out by measuring the change in refractive index. The experiments could 
also be performed in a competition mode, in which a known ligand is immobilized 
on the surface and the target is allowed to bind. When a competing fragment is 
introduced, the dissociation of the target from the surface is detected as a large 
signal change. SPR experiments are relatively rapid and straightforward to set 
up, so screening of entire fragment libraries by SPR is now possible within a few 
weeks, requiring as little as 25−50 µg of protein. SPR can be a very useful tool: 
not only can it provide the affinity and dissociation constants, it can also provide 
the stoichiometry of binding.  
SPR is emerging as a powerful technique for fragment screening against 
difficult targets such as GPCRs.107 As with TINS, SPR is also a “label-free” 
method that measures the direct binding of ligand to the receptor. Moreover, SPR 
measures in real time and kinetics and affinity can be determined. In addition, 
SPR can be applied to purified, detergent solubilized thermostable receptors108 
and also native receptors directly captured from crude cell lysates. Nevertheless, 
a known ligand must be available to assess the validity of the assay.  
 
X-Ray Crystallography  
X-ray Crystallography and protein-observed NMR are unique in providing 
detailed structural binding information. Unlike NMR, crystallography has no 
limitation on the protein size and can provide validated hits and structural binding 
information in one step. The use of high-throughput X-ray crystallography for 
FBDD was pioneered by Astex Therapeutics 109 and rapidly increased over the 
past 15 years. In a successful case in Astex, approximately 500 fragments were 
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screened by X-ray crystallography against cyclin-dependent kinase 2 by soaking 
apo CDK2 crystals. A fragment progressed into a drug candidate, AT7519, that is 
currently in phase II clinical trials.110 
In fragment screening, crystals of the target protein are soaked with high-
concentrations of cocktails containing 3-10 compounds (in general 10 mM per 
compound). In some case, multiple hits can bind to the target with partial 
occupancies. To avoid the ambiguous electron density assignment, the 
compounds in each cocktail should contain distinctive shapes and the average hit 
rate should be less than one compound per cocktail.111 The protein crystal must 
be robust, exhibit a good diffraction, generally better than 2.5 Å resolution. 
Otherwise, the low-resolution can yield a wrong position or conformation of the 
ligand. The ligand binding site should be accessible in the crystal, and the 
fragment binding should not induce a large conformational change that cracks 
the crystal,112 and the number of fragments in each cocktail should be kept low. 
X-ray crystallography provides very limited information on ligand binding affinity, 




NMR, X-ray crystallography, and SPR are the best-known biophysical 
methods for FBDD today, but several other approaches can also be used, such 
as Mass Spectrometry (MS). MS can be used to detect fragments that bind to a 
protein either covalently or non-covalently. Sunesis Pharmaceuticals developed 
an approach called “Tethering”,114 which relies on formation of a disulfide bond 
between a cysteine residue in the target protein and sulfur-containing fragments. 
Fragments that bind near the cysteine form disulfide bonds with the protein, 
increasing the mass of the protein and allowing the detection of the fragment 
binding by mass spectrometry. Because of the equilibrium of the disulfide bond 
formation, Tethering can discriminate weakly bound fragments from those that 
have no intrinsic binding affinity to the protein. A potent selective inhibitor of 
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aurora kinases SNS-314 was optimized after identification of a precursor using 
Tethering.115 It is also possible to detect fragment binding to proteins via native 
MS, successfully developed by NovAlix.116 
 
In silico Fragment Screening 
In recent years, virtual screening has become widely used and is maturing 
as a hit identification strategy. In most experimental FBDD studies, a few 
thousand fragments can be screened. In contrast, at least 250,000 fragments are 
commercially available, leaving a large portion of potential fragment libraries 
untested. Because commercially available fragments are too numerous to be 
screened experimentally, virtual fragment screening by molecular docking is a 
complementary approach. Moreover, in silico screening offers a way to identify 
novel scaffolds as starting points for further structure-based lead optimization. 
There are many ways to successfully find and characterize fragments in 
silico, each with its own set of strengths and weaknesses. Several orthogonal 
methods should be used in combination. The general fragment-based process 
starts by fragment library design and target validation; it is followed by fragment 
screening, using biophysical techniques to detect non-covalent binding to a 
target; then fragment is optimized by a combination of structural information, in 
silico design, and chemical synthesis.   
 
4. New Advanced Strategies to Enable GPCRs for FBDD and 
SBDD Campaigns  
4.1 Methods for Stabilizing GPCRs 
GPCRs are inherently dynamic proteins, and have numerous 
thermodynamic conformations between active and inactive states. In addition, 
low expression and poor stability once extracted from cell membrane 
environment represent major obstacles for biophysical studies and 
crystallogenesis.17 In order to overcome these limitations with GPCRs, several 
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innovative protein engineering methods have been developed. The disordered 
extra-membranous loop regions and flexible N- and/or C-terminal domains of the 
receptor have been deleted. The receptor was predominately stabilized in one 
conformation by adding high affinity ligands. A recent method introduces a 
number of points mutations into the receptor construct in order to increase the 
thermostability of the protein.117 This latter approach, called stabilized receptors 
or “StaR”, locks the receptor in one specific conformation that greatly facilitates 
protein purification, structure determination, and biophysical screening for drug 
discovery. The StaR approach has been used to obtain the structure of avian 
β1AR,118 human adenosine A2AR,119,120 and neurotensin receptors 36.  Use of A2A 
StaR for NMR based fragment screening is demonstrated in this thesis. An 
alternative strategy, as the T4 lysozyme (T4L) engineering method, the third 
intracellular loop (ICL3) was replaced with lysozyme from bacteriophage T4. 
Usually when the third intracellular loop (ICL3) of the receptor is present in the 
construct, it leads to conformational heterogeneity and is found disordered in 
crystallized GPCRs. Here, the fusion proteins were introduced to minimize 
conformational flexibility and improve the crystal contacts, rather than increase 
thermal stability. So far, this method enabled the crystallization of 13 GPCRs.121 
More recently, replacement of ICL3 by the thermostabilized apocytochrome 
b562RIL showed great utility in the crystallization of multiple GPCRs.27,28,40 A 
final strategy introduces a fusion protein and creates a complex of the receptor 
with monoclonal antibody fragments (Fab5,28 Fab2838,122 and Nanobody 
Nb80123), which were generated to recognize conformational epitopes of GPCRs. 
This strategy has been applied to a growing number of GPCRs.  
 
4.2 New Solubilization Strategies for GPCRs in Aqueous Solution  
Membrane proteins (MPs) are naturally embedded in a mosaic lipid 
bilayer, which is a heterogeneous and dynamic environment. Biophysical studies 
require an isolated pure stable protein in a functional folded form. Detergents 
play a critical role in the MP extraction and purification, because they present an 
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amphipathic environment that can mimic lipid bilayers, thus maintaining the 
function and structure of the protein.124 In fact, detergents do not stabilize 
membrane domains as efficiently as natural lipidic membranes, and the excess 
detergent micelles pose a hazard to MP stability as well as significant levels of 
non-specific partitioning of compounds into micelles during biophysical fragment 
screening.102 Detergents often co-concentrate with protein and lead to a loss of 
activity/stability during protein extraction and purification.125 This limits the 
subsequent biophysical studies, such as NMR and X-ray crystallography.  
Recently, non-detergent surfactants and novel detergent alternatives have 
been developed in order to better solubilize and stabilize MPs for structure 
determination and function studies.126 Amphipols (APols) are amphipathic 
polymers which have been designed to keep individual MPs stable in aqueous 
solutions.127 APols are relatively short polymers (8-20 kDa) that carry a 
hydrophilic backbone grafted with hydrophobic side chains. APols present high-
affinity/low off-rate for the transmembrane domain and form a protein-APol 
complex stable for long periods of time.128 APols can be used to trap detergent 
solubilized MPs into less destabilizing conditions, keep their native structure and 
preserve their functionality. Several membrane proteins have been studied in 
complexes with APols including the acetylcholine receptor,129 OmpA, FomA, and 
bacteriorhodopsin.130 APols have proven to be efficient for GPCR refolding. This 
procedure can start from the protein in a denaturing environment, typically urea 
for β-barrel MPs and SDS for α-helical ones, and to (re)fold the protein to their 
native state by adding the APol and removing the detergent by dialysis.131  
One novel model membrane system called “Nanodiscs” (NDs) has also 
been used to study integral membrane proteins. Nanodiscs are self-assembling 
complexes that consist of a phospholipid bilayer core surrounded by two 
molecules of an amphipathic α-helical membrane scaffold protein (MSP). The 
MSP is a fragment of human apolipoprotein A-1 engineered by Sligar and 
colleagues.132 Target protein can be incorporated into the self-assembly process 
in which detergent is removed from initial detergent-phospholipid micelles, either 
by dialysis or addition of detergent-removal Bio-beads. This procedure 
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reconstitutes the target protein into a native-like environment and the final 
complex can be handled in aqueous conditions. Many MPs (bacteriorhodopsin, 
human β2AR, and cytochrome P450)132,133 have been successfully embedded 
into NDs, with preserved functionality, and subsequently used for biochemical 
and biophysical studies. In the thesis, the first complete biophysical screen of a 
fragment library against an integrate membrane protein DsbB which was 
solubilized in both detergent micelles and NDs is reported.102 It has been shown 
that NDs are suitable for biophysical studies of fragment binding to membrane 
proteins, with reduced non-specific partitioning of compounds into solubilization 
medium, specifically for hydrophobic compounds.  
Another model membrane system, bicelles, micelles formed of lipid 
bilayers, make an excellent membrane mimic environment for membrane 
proteins. Bicelles have found successful applications in solution and solid-state 
NMR,134,135 and more recently in membrane protein crystallography.136   
 
4.3 GPCR Overexpression in Bacterial Inclusion Bodies 
Currently, there are three major approaches to obtain structural 
information on the ligand-target interaction: X-ray crystallography, solution-state 
NMR (solNMR) and solid-state NMR (ssNMR). X-ray crystallography and ssNMR 
can be performed with large proteins, in conditions similar to those of native cell 
membrane. However, they present some significant difficulties, for example, 
producing crystals and obtaining good diffraction, and lack of dynamic 
information. SolNMR methods have therefore become more commonly used in 
the study of protein-ligand interactions. SolNMR can be used to investigate weak 
protein-ligand interactions and obtain 3D structural information of target-ligand 
complexes, where X-ray crystallography is not successful.  
Jean-Louis Banères developed a new strategy to produce large amounts 
of functional GPCRs from Escherichia coli, which enable structural 
characterization of GPCRs in solution.131 Once the target can be expressed in E. 
coli, then stable isotope labels can be incorporated, enabling the full range of 
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NMR tools to be applied. Addition of an α5 integrin fragment (α5I, 31 kDa) as a 
fusion partner can facilitate the recombinant expression of many rhodopsin-like 
GPCRs from E. coli inclusion bodies (IBs). Expression of GPCRs from IBs 
presents many advantages. IBs are stable and resistant to proteolytic 
degradation, and they are not toxic to the cell. GPCR production in IBs can be 
achieved at very high level. This strategy has been used to successfully over-
express rat olfactory OR5 receptor, human leukotriene BLT1 and BLT2 receptors, 
and human serotonin 5-HT4A receptor.137–140 However, the expressed GPCRs 
must be subsequently folded into their native state. Before refolding, the 
recombinant GPCRs accumulated in IBs need to be solubilized in denaturing 
conditions (SDS and/or urea). After removing the fusion partner, transfer of the 
receptor from SDS to APol, with lipid supplementation, can be used to achieve 
folding. Using this APol folding strategy, the leukotriene receptors BLT1 and 
BLT2 and the serotonin 5-HT4A can be folded as functional proteins with an 
efficiency of 60% as shown in radioligand binding assays.141 Most biochemical 
and biophysical techniques can be applied to APol-trapped MPs.126 In the past 
few years, several MPs in complex with APols have been successfully used for 
solNMR for studying the structure of ligand binding and conformational 
transition.142,143 Banères and colleagues used transferred nuclear Overhauser 
effects (trNOEs) to determine the structure of ligand binding on an APol-trapped 
GPCR.144 A deuterated BLT2 receptor was folded and stabilized using a partially 
deuterated APol A8-35, the ligand leukotriene LTB4, was then added and the 
receptor-ligand complex structure was determined from the trNOE signals. These 
studies provide a novel approach for GPCR ligand binding determination.       
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Aim and Outline of this Thesis: 
“To demonstrate an NMR-based methodology for characterization of 
fragment binding on solubilized integral membrane proteins, such as GPCRs” 
 
TINS has been successfully applied to soluble proteins for investigating 
small molecule binding.  In order to validate the proof of concept on membrane 
proteins, which are at the forefront of pharmacological interest, in Chapter 2, 
TINS screening has been performed against a bacterial membrane protein, the 
Disulphide Bond Forming protein B (DsbB). DsbB is chosen as a TINS candidate 
since it can be produced in large quantities from E. coli, has a robust enzymatic 
activity, and its 3D structure is available. A bacterial Outer Membrane Protein 
(OmpA), which has minimal small molecule binding, is selected as reference 
protein. The reference protein serves to cancel non-specific binding of 
hydrophobic compounds to lipids and/or detergents used to solubilize the 
membrane proteins. The reference protein was solubilized in the same detergent 
micelle conditions as the target protein. The suitability of TINS for fragment 
screening of membrane proteins, which was functionally solubilized in a non-
detergent medium, has also been tested. The ND system has been explored as 
an alternative solubilization medium, which consists of a lipid bilayer surrounded 
by two amphipathic α-helical membrane scaffold proteins (MSP). The small 
molecule binders from both detergent- and nanodisc-solubilized DsbB screens 
have been validated and characterized using an enzymatic inhibition assay. The 
binding modes of validated fragments were confirmed by Heteronuclear Single 
Quantum Coherence (HSQC) using 15N enriched protein. These results 
demonstrated the feasibility of using a fragment-based strategy to discover new 
chemistry starting points for subsequent development of compounds targeting 
membrane proteins. Chapter 3 addressed the feasibility of TINS for fragment 
screening on an inverse agonist stabilized, StaR GPCR, the human adenosine 
A2A receptor. A moderately sized fragment library was screened for binding to the 
A2A StaR with OmpA as a reference protein, both solubilized in DDM micelles. 
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Multiple hits were validated by pharmacologic assays with wild-type receptor. 
Potential A2AR allosteric modulators discovered by TINS are described in this 
chapter. In parallel, the same fragment library was screened using molecular 
docking against an A2AR crystal structure, as described in Chapter 4. Further, 
the virtual screening was extended to 328,000 commercially available fragments. 
Novel A2AR ligands were then explored by structure-activity relationship, guided 
by molecular docking and molecular dynamics simulations. Elaboration of weak 
binding hits to lead-like compounds is still challenging for FBDD. Obtaining high-
resolution 3D structures of protein-fragment complexes is a key to efficient hit 
optimization. In order to enable future NMR structural studies, in Chapter 5, a 
novel methodology to over-express A2A StaR from Escherichia coli inclusion 
bodies has been employed. The receptor is subsequently refolded in its native 
state using Amphipols. The preliminary protein production results are presented. 
Finally, Chapter 6 presents concluding remarks about the research work in this 
thesis and perspectives regarding the future of GPCR research when applying 
fragment- and structure-based approaches to GPCR drug discovery.  
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 Membrane proteins are important pharmaceutical targets, but they pose 
significant challenges for fragment-based drug discovery approaches. Here, we 
present the first successful use of biophysical methods to screen for fragment 
ligands to an integral membrane protein. The Escherichia coli inner membrane 
protein DsbB was solubilized in detergent micelles and lipid bilayer nanodiscs. 
The solubilized protein was immobilized with retention of functionality and used to 
screen 1071 drug fragments for binding using target immobilized NMR 
Screening. Biochemical and biophysical validation of the eight most potent hits 
revealed an IC50 range of 7–200 µM. The ability to insert a broad array of 
membrane proteins into nanodiscs, combined with the efficiency of TINS, 




 With 60% of currently marketed drugs targeting membrane proteins1, it is 
clear that finding small molecules to modulate the function of such proteins is 
essential.  High throughput screening (HTS) methods have been successful in 
identifying such compounds, but because the methods of detection rely on 
functional assays, they are generally only sensitive to submicromolar 
interactions. Such relatively tight interactions are generally only observed for 
larger compounds (300-500 Da). However, it has proved challenging to 
simultaneously optimize potency and absorption, distribution, metabolism, and 
excretion (ADME) properties of these “lead-like” or “drug-like” compounds. 
Furthermore, such large compounds inefficiently explore the binding sites of 
proteins2. Fragment-based drug discovery (FBDD) has become a powerful 
complementary approach to HTS for generating novel chemical modulators of 
pharmaceutical targets. FBDD screens small libraries (1,000-20,000 compounds) 
of so-called drug “fragments” that are often described by a “rule of threes”3 (Ro3, 
Mr < 300 Da, cLogP < 3, H-bond donors < 3, H-bond acceptors < 3, number of 
rotatable bonds < 3 and TPSA (total polar surface area) < 60 Å2) for binding to 
the target. Ro3 compliant compounds typically bind the target with KD greater 
than 10 µM. In order to detect such weak binding, sensitive biophysical 
techniques are typically required, particularly when the target s not an enzyme. 
Commonly used techniques for detecting fragment binding include NMR, X-ray 
crystallography and surface plasmon resonance (SPR)4.  
 Although biophysical methods have been successfully applied to an array 
of soluble protein targets5, they have failed in one way or another when applied 
to membrane proteins. There are two primary reasons for this failure: insufficient 
quantity of the target and problems related to the solubilization media. Many 
biophysical methods require tens or even hundreds of mg of purified, functional 
protein and most membrane proteins are difficult to produce in these quantities. 
However, recent advances have enabled the production of low mg quantities of a 
variety of MPs6-8. Membrane proteins that can be produced in sufficient quantity 
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must then be solubilized in a surfactant while maintaining their functional state, 
which is also often challenging. Finally, non-specific partitioning of fragments into 
the surfactant has been a severe problem leading to high levels of false positives.  
 The use of detergent micelles to solubilise MPs has only met limited 
success in retaining the native function of the protein while at the same time the 
micelles often interfere with biophysical assays. A possible solution to this 
bottleneck would be to employ non-detergent media to functionally solubilize 
MPs. The Nanodisc (ND) has been developed as an alternative, surfactant free 
approach to solubilize MPs. NDs consist of a lipid bilayer that is surrounded by 
an amphiphilic α-helical membrane scaffold protein (MSP). A variety of proteins 
have been functionally solubilized in NDs9-11, which are much better mimics of 
the native membrane than detergent micelles. However, the suitability of NDs for 
biophysical assays of ligand binding to MPs has yet to be determined. 
 An NMR-based fragment screening approach has been developed and 
has proven capable of overcoming many of the challenges posed by membrane 
proteins12. The approach, called Target Immobilized NMR Screening (TINS)13, 
involves immobilizing a target and a reference in two compartments of a dual-cell 
sample holder14 and simultaneously injecting mixtures of fragments in an 
automated process.  For each mixture a 1D 1H NMR spectrum is recorded while 
fragment binding to the target protein results in a decrease in peak amplitude. 
The reference, which is selected for minimal specific small molecule binding, 
serves to cancel out non-specific binding of fragments to protein surfaces. Hits 
can therefore be detected by comparing spectra of the compounds recorded in 
the presence of the target to those recorded in the presence of the reference.  By 
repeatedly using the same sample to screen the entire fragment collection 
(>1,000 compounds), typically only ~25 nmol of protein is required, thus bringing 
many MPs within the requirements for TINS. Furthermore, the reference system 
is expected to account for non-specific binding of fragments to the media in which 
the membrane protein is solubilized.  
 It was sought to apply TINS to a bona fide, integral membrane 
pharmaceutical target that could be functionally solubilized in detergent micelles 
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and NDs. The inner membrane protein of E. coli Disulphide bond forming protein 
B (DsbB), and its homologs in other gram-negative bacteria, is an oxidoreductase 
that is essential for protein disulfide bond formation in the periplasm15. 
Periplasmic DsbA functions as the catalyst for protein disulfide bond formation 
and is reoxidized by DsbB with concomitant reduction of bound ubiquinone or 
menaquinone. Since many bacterial virulence factors are secreted proteins that 
require disulfide bonds for proper folding and function, the DsbA/DsbB system is 
a potential antimicrobial drug target16-18.  DsbB is an ideal candidate to test the 
TINS methodology since it can be produced in large quantities and solubilized in 
detergent micelles where it retains a robust enzymatic activity which is easily 
assayed. In addition, a wealth of biochemical data is available that describes the 
enzymatic activity of the wildtype as well as numerous relevant mutants15,19-21. 
Finally, the 3D structures of wildtype DsbB bound to its redox partner DsbA22 and 
of a mutant representing an enzymatic intermediate are available23. Selection of 
an appropriate reference system is critical to insure the robust performance of 
TINS. Our previous experience using the E. coli Outer membrane protein A 
(OmpA) transmembrane domain, which has native structure under the same 
detergent micelle conditions as DsbB suggested that it had minimal small 
molecule binding24 and would therefore serve as a good reference.  
 In this chapter, the joint work between the author and previous PhD 
candidate Dr. Virginie Früh is presented. The first complete screen of a fragment 
library against an integral membrane protein is reported. The applicability of TINS 
for fragment screening using both micelle and ND solubilized protein has been 
tested. The initial work of fragment screening using micelle solubilized DsbB has 
been performed by Dr. Früh, including validation and hit characterization with 
respect to the mode of action using an enzyme inhibition assay and investigation 
of the binding mode of two classes of inhibitors by analysis of chemical shift 
perturbations in 15N-labeled mutant DsbB. These results are included in the 
appendix. The author’s work is focused on characterization of small molecule - 
ND solubilized protein interactions and the results are compared with those for 





DsbB Functional Immobilization and Enzymatic Activity 
 Wildtype DsbB (containing endogenous quinone) has previously been 
solubilized in DPC micelles, which we refer to as DsbB/DPC, with retention of 
enzymatic function23. Next DPC solubilized DsbB and OmpA were trapped in 
NDs. Gel filtration analysis of our preparations revealed Stokes diameters of 
9.63, 9.68, and 9.52 nm for empty NDs (-/ND), NDs with embedded DsbB 
(DsbB/ND), and NDs with embedded OmpA (OmpA/ND), in accordance with 
literature values25. The DsbB/ND was immobilized on a Sepharose resin via a 
Schiff’s base intermediate. At the pH selected (7.4), this reaction is relatively 
specific for the free N-terminus. A final concentration of approximately 100 µM 
DsbB/ND (nmol protein per ml settled bed volume) was achieved with an overall 
yield of 75%. Non-immobilized and immobilized DsbB/ND were assayed for 
enzymatic activity for comparison to DsbB/DPC. As shown in Table 1, both 
preparations had a kcat that was somewhat greater than the micelle solubilized 
protein, indicating that they remained completely functional. The increased kcat for 
DsbB in NDs could possibly result from a more native functionality of the enzyme 
in the lipid bilayer environment of the ND. 
 
Table 1. Enzymatic activity of solubilized vs immobilized DsbB. 
Enzyme kcat (M UQ1/M DsbB-min-1) 
DsbB wt/DPC 267 ± 14 
DsbB wt/DPC (immobilized) 238 ± 27 
DsbB wt/ND 346 ± 13 
DsbB wt/ND (immobilized) 329 ± 26 
 
Stability of the Immobilized Protein to Repeated Sample Application Cycles 
 In a method such as TINS where a single sample of the target is used to 
screen an entire compound collection, the integrity of the immobilized protein is 
clearly critical. Soluble proteins are routinely stable over more than 200 cycles of 
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sample application and washing13. Solubilized MPs however, include two 
components, the surfactant and the protein itself, both of which must remain 
stable in order to ensure proper ligand screening. Preliminary studies of 
DsbB/DPC and OmpA/DPC clearly demonstrated that repeated cycles of 
compound application and washing in the absence of added detergent resulted in 
rapid degradation of DsbB activity12. Therefore deuterated DPC was included at 
a minimum concentration of 5 mM (approximately 3 x critical micellar 
concentration) in the buffer used to wash the compounds from the sample holder. 
The library, which consisted of 1,071 fragments at the time, was then screened in 
mixtures that averaged approximately 5 compounds each. Including control 
experiments designed to monitor the physical integrity of the target and reference 
samples, approximately 200 sample application/washing cycles were performed. 
To monitor the integrity of the DsbB sample during the screen, the binding of 
synthetic UQ1 was observed (Figure 1a). In TINS, binding of a fragment is best 
described by the T/R (target/reference) ratio, defined as the average ratio of the 
amplitude of peaks in the presence of the target, DsbB, to that in the presence of 
the reference, OmpA. It is clear from Figure 1a that binding of UQ1 to DsbB/DPC 




Figure 1. Stability of the DsbB in Micelles and NDs. The stability of DPC solubilized (a) and ND 
solubilized (b) DsbB after multiple cycles of compound application and washing was assessed by 
binding of a known ligand. Binding is displayed as the average ratio of peak heights for the 
compound in the presence of DsbB over that in the presence of the reference (T/R ratio). The 
reference in (a) was DPC solubilized OmpA and in (b) -/ND. 
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 Since it was not practical to rescreen the entire fragment collection 
multiple times, we selected a subset of 20 compound mixtures containing positive 
hits from the DsbB/DPC screen and 20 mixtures containing no positive hits from 
the DsbB/DPC screen (a total of 183 compounds) to assess the suitability of the 
ND system for ligand screening. The 40 mixes, along with the control 
experiments used for DsbB/DPC, were applied sequentially to the immobilized 
DsbB/ND using -/ND as the reference. We wanted to assess whether DsbB/ND 
and -/ND were stable in the absence of added phospholipid. As with DsbB/DPC, 
we monitored the integrity of DsbB/ND, as determined by binding of a known 
ligand (UQ1), during multiple cycles of compound application and washing in lipid 
free buffers. The T/R ratio for ligand binding to DsbB/ND vs -/ND is shown in 
Figure 1b. This data suggests a possible, initial small degradation in binding 
behaviour (although the variation is similar to that seen in Figure 1a), after which 
the ligand binding capacity of DsbB/ND remained constant. The constant T/R 
ratio during cycles 22 through 61 suggests that both DsbB/ND and -/ND 
remained intact.  
 
Comparison of Micelle Solubilized vs ND Solubilized Protein for Ligand 
Binding Studies 
 The influence of detergent or ND on the quality of the NMR spectra of the 
fragments is shown in Figure 2(d and e). In both cases the compound whose 
spectrum is shown in 3c can be identified as specifically binding to DsbB.  
However, the signal-to-noise ratio of the aromatic resonances of the compounds 
(Figure 2a and b) in 2e is nearly double that in 2d. The improved quality of the 
spectra allows more reliable analysis of the peaks at 7.3 and 7.4 ppm, which are 
now clearly seen to indicate specific binding of this compound to DsbB/ND, 
consistent with behaviour of the peaks at 2.8 and 2.2 ppm.  The reduced signal in 
the presence of detergent solubilized protein is likely due to non-specific 




Figure 2. Detection of ligand binding to immobilized DsbB using TINS. The 1D 1H NMR spectrum 
of 3 different fragments in solution (a - c) is shown for reference. The 1H NMR spectrum of a mix 
of the 3 fragments in the presence of DsbB/DPC (red spectrum) or OmpA/DPC (blue spectrum) 
that have been immobilized on the sepharose support is shown in d. The spectra of the same mix 
recorded in the presence of DsbB/ND (green) or -/ND (magenta) is shown in e. The asterisk 
indicates the resonance from residual 1H DMSO and the bracket shows residual sugar 1H 
resonances from the sepharose media. The residual H2O resonance at 4.7 ppm has been filtered 
out. 
 
 The stability of the empty ND (-/ND) as shown in Figure 1b, affords the 
possibility to use NDs directly as a generic reference to account for non-specific 
ligand binding to the phospholipid bilayer and the scaffolding protein. To 
investigate this, we screened all 183 compounds for binding to DsbB/ND using 
either OmpA/ND or -/ND as a reference. By plotting the T/R for each compound 
from the screen using -/ND versus that using OmpA/ND we derive a two-
dimensional plot that gives an overview of the performance of the screen (Figure 
3a).  Overall there was a reasonable correlation in ligand binding to DsbB/ND 
using either empty NDs or OmpA/ND as the reference (R2 =0.78). In general 
however, the T/R ratio of fragments is lower with -/ND as a reference, indicating 
that specific binding to DsbB/ND is more pronounced. Since the NMR spectra of 
the fragments in the presence of DsbB/ND in the screen vs -/ND or OmpA/ND 
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are similar, this suggests a higher level of non-specific binding of the fragments 
to OmpA/ND. We conclude therefore that -/ND is the preferred reference.  
 
 
Figure 3. Comparison of TINS screening in micelles vs NDs. A total of 70 fragments were as-
sayed for binding to DsbB solubilized in either detergent micelle or ND. a) The 70 fragments were 
screened for binding to DsbB/ND using either empty ND (-/ND) or OmpA/ND as a reference. The 
T/R (see text) for each compound is plotted for one screen versus the other. R2 = 0.78. b) The 
T/R for each compound in the DsbB/ND vs -/ND screen is plotted against the value from the 
DsbB/DPC vs OmpA/DPC screen. Hits common to both screens are show in red. Hits found only 
in the ND screen are shown in blue while those found only in the DPC screen are in green. 
 
Table 2. Fragment hits from the screen of DsbB in micelles and NDs. 
 Hits cLogP BioAssay in ND BioAssay in DPC 
Micelle 8 1.34 - + 
ND 7 2.21 ++ ++ 
Both 14 2.13 ++ ++ 
Note: - poor correlation between enzyme inhibition and binding assay, + reasonable correlation 
(approximately 50% hits bioactive), ++ good correlation (80-90% bioactive) 
 
 We then compared the ligand screening results from DsbB/DPC 
(OmpA/DPC as reference) to those from DsbB/ND (-/ND as reference). Upon 
inspection of the raw NMR data from the DPC screen we observed that although 
183 compounds were present in the 40 mixes selected, only 127, about 2/3, gave 
observable NMR spectra. Presumably, those compounds missing from the NMR 
data had non-specifically adsorbed to the micelle. In contrast, 164 of 183 
compounds gave observable spectra in the ND screen. Of the 127 compounds 
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with observable spectra in the DPC screen, 70 were of sufficiently high quality to 
allow a reliable comparison with the ND screen and we therefore focused our 
efforts on these. Inspection of Figure 3b clearly shows that the correlation 
between the micelles and NDs is much less pronounced than between the two 
ND references. Using the same criteria for hit selection for both, 22 hits were 
identified for DsbB/ND and 22 were identified for DsbB/DPC. Of these 
biophysically detected hits, 14 were common to both the micelle and ND (red) 
screen while 7 were unique to the ND screen (blue) and 8 unique to the micelle 
screen (green, see also Table 2). We analyzed the solubility of each of the 
fragment hits using the calculated Log of the octonal/water partition coefficient 
(cLogP). Interestingly, the hits specific for the ND screen are on average slightly 
less soluble in water than the hits found in both screens, but the hits specific to 
the micelle screen are considerably more soluble (Table 2). A possible 
explanation for this observation is that the less soluble fragments exhibited 
greater non-specific binding to the micelle, thus masking specific binding to 
DsbB. This observation is consistent with the NMR data in Figure 2.  
  
Hit Validation using Enzymatic Assays 
 The TINS assay simply identifies compounds that bind to DsbB, but not 
necessarily in a biologically relevant manner. Therefore we felt it was critical to 
validate the hits in terms of biological activity. An enzymatic assay was used to 
assess the ability of the compounds to inhibit electron transfer mediated by 
DsbB. Each of the 93 fragments identified as TINS hits in the micelle screen was 
assayed for inhibition of DsbB-dependent reoxidation of DsbA at 250 µM, as 
shown in appendix. The bioassay was also used to compare hits selected in the 
micelle screen to those selected in the ND screen (see Table 2). As expected, 
fragments common to both the micelle and ND screens yielded a strong 
correlation with biological activity with 12/14 exhibiting medium (30-70%) or high 
(>70%) inhibition of DsbB in both micelles and NDs. We observed a good 
correlation between ligands detected in the ND screen and biochemical activity 
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against both micelle and ND solubilized DsbB where 6/7 compounds had 
medium inhibitory activity and the seventh was a mild stimulator. In contrast, 
while the micelle specific ligands correlated reasonably well with the bioassay 
using detergent solubilized DsbB where 5/8 were medium or strong inhibitors, 
none inhibited DsbB/ND.  
 
3. Discussion 
 The use of Ro3 compliant, “drug fragments” as a starting point for drug 
discovery has delivered a number of innovative compounds against soluble 
targets which are currently in clinical trials26. Membrane proteins have not made 
good targets for FBDD due to their challenging physicochemical properties. In 
particular, the difficulty of generating sufficient quantities of purified, functional 
protein and of detecting specific binding to the target, as opposed to non-specific 
partitioning into hydrophobic phases, have limited the applicability of biophysical 
ligand screening approaches. Here we have addressed these two issues by a) 
immobilizing the target and reusing a single sample to screen an entire fragment 
collection and b) using a reference sample to cancel out non-specific interaction 
of the fragments with the hydrophobic phase. Using TINS we have screened a 
collection of nearly 1,100 fragments with a single sample of less than 2 mg of 
protein and demonstrated that the protein was stable throughout the procedure. 
The stability of DsbB to repeated cycles of fragment application and washing 
depends on detergent micelles and the quinone cofactor. The detergent 
requirement could be overcome by including it in the buffer or using NDs to 
solubilize the protein. Endogenous UQ-8 binds DsbB very tightly and is quite 
resistant to repeated detergent washing27.  
 Screening of the fragment library resulted in 93 ligands that were specific 
for DsbB. A number of observations suggest that most of these ligands are 
directly binding to DsbB and not indirectly via the micelle (see appendix). First, 
the DsbB binding detected using TINS was relative to OmpA solubilized in 
identical conditions. Second, there is a range of potencies in the enzyme 
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inhibition studies that includes a small number of non-inhibitors and activators. 
Third, and perhaps more critically, inhibition is saturable and occurs over 2 log 
orders, strongly suggesting a stoichiometric interaction. Fourth, titration of 8 
different fragments into 15N labelled DsbB resulted in chemical shift perturbations 
at well defined sites in both solvent exposed and micelle buried portions of the 
protein. In particular, the similarity of the chemical shift perturbations induced by 
the synthetic quinone UQ1 and fragment 2 indicate the compounds are binding to 
the same or overlapping sites. An additional, likely important, factor contributing 
to the low false positive rate is that the fragments that make up the collection are 
highly soluble, with each having been tested at 500 µM in an aqueous buffer 
alone and in a mixture. Nonetheless, an appreciable fraction of these fragments 
exhibit sufficient nonspecific binding to the micelle that they were only poorly or 
even not detected in the NMR spectra. These data suggest that ligand screening 
in the presence of micelle-solubilized membrane proteins may bias the chemical 
nature of the fragment library. The median cLogP for observable compounds in 
the presence of ND-solubilized proteins is slightly greater (0.9 versus 1.1) 
suggesting a reduced tendency of hydrophobic compounds to partition into the 
nanodisc. 
 As described in appendix, the eight fragments with greatest potency in the 
single concentration enzyme inhibition assay were fully characterized for 
potency, mode of action, and binding site on DsbB. A simplistic analysis suggests 
that these fragments can be divided into two groups, one that competes only with 
quinone for DsbB binding and a second that perturbs the apparent affinity of 
DsbB for both quinone and DsbA. The different mode of action is best exhibited 
by the differing effect on the apparent Km for UQ1 or DsbA for each. Addition of 
fragment 2 reduced Km for UQ1 more than 8-fold, while it had only a marginal 
effect on the Km for DsbA (only 5% greater than experimental error). In contrast, 
addition of 8 reduced Km for UQ1 more than 4.4-fold and Km for DsbA more than 
2-fold.  
 Functional solubilization of membrane proteins in detergent micelles is a 
challenging process that must be individually optimized for each protein. NDs 
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offer the potential to enable a more generic approach to handling membrane 
proteins since they can be used to functionally solubilise a variety of membrane 
proteins and can obviate the requirement for an intermediate micelle solubilized 
step10,25. Furthermore, immobilization can be made generic for all MPs with 
minimal effect on functionality by appropriate engineering of the MSP portion of 
the ND. Use of NDs as a generic solubilization/immobilization system for ligand 
screening is further enabled by the stability of the empty ND and the fact that it 
represents a high quality reference system to remove false positives. This 
conclusion is strongly supported by the observation that the 8 DsbB/DPC specific 
hits failed to inhibit DsbB/ND while 7 of 8 DsbB/ND hits also inhibited DsbB/DPC. 
Apparently, despite the reference sample, some compounds interact with DsbB 
in a micelle specific manner. This problem would be eliminated by using NDs. 
 
4. Significance 
 Integral membrane proteins make up a significant portion of the human 
genome, carrying out numerous important normal as well as disease-related 
functions. More than 50% of drugs currently on the market target a membrane 
protein, demonstrating the utility of targeting this class of proteins. Approaches 
for the development of drugs targeting this class of proteins have focused 
principally on the use of high-throughput screening methods. Recently, FBDD 
has emerged as a powerful additional drug discovery approach. Because of the 
typically modest binding affinities of the small, functional group rich, i.e., high 
ligand efficiency, compounds utilized in FBDD, various biophysical techniques, 
including NMR, are typically used to detect binding. To date, several compounds 
developed using FBDD have advanced to clinical trials.26 However, thus far 
FBDD has been demonstrated only for soluble proteins, not membrane proteins.  
 Herein, we describe the first complete screen of a fragment collection 
against an integral membrane protein. The screen was performed using a 
detergent micelle-solubilized protein using a simple and rapid 1D NMR method 
we described previously (TINS). The 93 hits were subsequently validated in an 
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enzyme inhibition study. The use of a reference sample in the TINS experiment 
eliminated the well-documented problem of nonspecific binding of compounds to 
the detergent. As membrane protein activity is enhanced in more bilayer-like 
environments, we have also solubilized the protein in NDs and shown that the 
screening approach is effective with this preparation as well. The use of NDs 
further ameliorates issues with nonspecific binding and should also extend the 
method to proteins which typically do not behave well in detergents such as 
GPCRs.  
 Our results clearly establish the feasibility of using a fragment-based 
approach for finding starting matter for subsequent development of compounds 
targeting membrane proteins, including the all-important GPCR class of proteins. 
In addition, increasing success in the preparation of membrane proteins in 
reasonable quantities should make many such proteins amenable to the use of 




 DsbA, DsbB, and OmpA were expressed and purified as previously 
reported28-30. All proteins have a 6x-His tag at the N-terminus or C-terminus for 
affinity purification.  
ND Self-Assembly 
 The ND self assembly procedure was repeated the same way for both 
OmpA and DsbB with slight adaptations from the previously reported 
procedures25. The reconstitution mixture contained Membrane Scaffold Protein 
MSP1D1(-) which lacked the His-tag, with mixed micelles of POPC and cholate 
at a ratio of 1:65:130. This reconstitution mixture was added to the OmpA or 
DsbB in detergent micelles (each with 10x the detergent CMC) in a volumetric 
ratio of 1:1 and incubated on ice for 4 hours. We always ensured a stoicheometry 
of MSP1D1(-) to OmpA or DsbB of 2:1. Upon addition of 0.7 g/ml of the 
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hydrophobic adsorbent Bio-Beads SM-2 (Biorad, Hercules, CA) and gently 
mixing for 4 hours at 4 ºC, the NDs underwent self-assembly, incorporating DsbB 
or OmpA in the lipid bilayer. This step was limiting, whereby detergent removal 
before 4 hours resulted in incomplete ND formation, but caused ND complex 
malformation if carried out for longer (i.e. 16h, data not shown). The His-tag of 
the embedded OmpA and DsbB was used to separate the empty non-tagged 
MSP1D1(-) complexes from the mixture by IMAC chromatography using Ni-NTA 
resin in a buffer containing 100 mM Tris, 300 mM NaCl, and imidazole at 0 mM, 
10 mM, and 100 mM for loading, washing, and elution respectively. The eluted 
fractions were applied to a gel filtration column (Superdex 200 10/300 from GE 
Healthcare) in order to remove the remaining aggregated, non-embedded OmpA 
and DsbB, and to exchange the ND-embedded proteins into phosphate buffered 
saline (PBS, pH 7.4) for compatibility with the immobilization step required for 
TINS. A set of standard proteins was used to calibrate the Stokes’ diameter vs. 
the retention time of the column. 
Protein Immobilization 
 Actigel ALD resin (Sterogene, Carlsbad, CA, USA) was used as a 50% 
slurry and all experiments were carried out at 4 ºC when possible. The resin was 
washed with cold phosphate buffer (50 mM Na2HPO4, 50 mM KH2HPO4, 100 mM 
NaCl) at pH 7.5. 200 nmol of DPC solubilized DsbB was added to 1 ml bed 
volume of resin. The reductant sodium cyanoborohydride (NaCNBH3) was added 
to a final concentration of 0.1 M. After an overnight incubation at 4 °C, residual 
unreacted aldehydes were blocked by addition of 50 mM Tris buffer and 
NaCNBH3 for another 2 hours. The same procedure was repeated for DPC 
solubilized OmpA. Quantification of immobilized protein was monitored by 
absorption of the supernatant at 280 nm before and after immobilization, and by 
SDS-PAGE gel with a known standard curve and band volume analysis. These 
data indicated that a final concentration of 100 µM of both immobilized DsbB and 
OmpA was achieved, equating to a 50% yield. The procedure was repeated 
identically to immobilize DsbB and OmpA solubilized in ND (after pooling 
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fractions containing particles ranging between 9.2 to 9.7 nm) and empty ND at a 
similar final concentration as the micelle solubilized protein. ND preparations 
could not be quantified by UV absorption; therefore, they were loaded on SDS-
page gels with a BSA standard curve for band volume quantification by Quantity 
One (Biorad), providing information on the concentration and ratio of ND 
molecules and incorporated proteins. The yield of immobilized, ND-solubilized 
protein was 75%. 
DsbB Activity Assays 
 DsbB activity was quantified by measuring the capacity of the enzyme to 
reoxidize the protein DsbA or reduce its cofactor Ubiquinone-5, also called 
Coenzyme Q1 (UQ1) at pH 6.2. DsbA was reduced with 10 mM DTT for 10 
minutes on ice. DTT was subsequently removed by gel filtration on a PD-10 
column pre-equilibrated with degassed, distilled water containing 0.1 mM EDTA.  
DsbA fluorescence (excitation at 295 nm and emission at 330 nm) was measured 
in the presence of DsbB and UQ1 in 50 mM sodium phosphate, 100 mM NaCl, 
0.1 % detergent [DPC or DDM depending on which was used to solubilize DsbB] 
and 0.1mM EDTA) at 30 ºC. Both UQ1 and DsbA were added at final 
concentrations of 30 µM. DsbB was added at a final concentration of 20 nM. The 
activity of DsbB in terms of moles ubiquinone reduced/moles DsbB min-1 could 
be calculated by using the initial slope of the fluorescence decrease upon DsbA 
oxidation, or by using the slope of absorption decrease at 275 nm upon reduction 
of UQ128. 
 To measure activity of immobilized DPC or ND solubilized DsbB, resin 
was aliquoted and diluted with degassed activity assay buffer to a final protein 
concentration of approximately 20 nM. For an appropriate baseline, an equivalent 
amount of resin without protein (blank resin) was prepared in the same manner. 
Quinone reduction was monitored in DPC samples after addition of 20 µM 




Target Immobilized NMR Screening 
 Immobilized, DPC solubilized DsbB or ND solubilized DsbB and OmpA 
were each packed into a separate cell of a dual-cell sample holder14. Mixes of the 
1,071 fragments were made by 200-fold dilution of a 100 mM stock of each 
compound in d6-DMSO such that the final DMSO concentration was never 
greater than 5%. Upon injection of each mix into the dual-cell sample holder, flow 
was stopped and spatially selective Hadamard spectroscopy31 was used to 
acquire a 1D 1H spectrum of each sample separately. A CPMG T2 filter of 80 ms 
was used to remove residual broad resonances from the sepharose resin. The 
cycle time was about 35 min, with 30 min required for the NMR experiment and 5 
min for sample handling, resulting in a total time of about 5.5 days to complete 
the screen. To maintain the proper fold of each protein, 5 mM deuterated DPC 
was included in the buffer (20 mM phosphate buffer in D2O, 100 mM NaCl, pH 




Yelena N. Grinkova (University of Virginia) provided the empty NDs. Dr. Virginie Früh 
performed TINS against micelle solubilized DsbB. Francis Figaroa (ZoBio BV) assisted 
with compounds preparations for TINS screening. Eiso AB (ZoBio BV) helped with 15N 
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Target Immobilized NMR Screening (TINS) of DsbB/DPC 
 The fragment collection was screened for binding to DsbB at 500 µM each, in 
182 mixtures. A spatially selective Hadamard NMR experiment1 was used to 
simultaneously acquire a 1D 1H spectrum of compounds in the presence of DsbB/DPC 
or OmpA/DPC. The data resulting from the screen could be analysed directly without 
deconvolution because fragments could be directly identified by comparing peaks from 
TINS spectra with reference spectra of the individual fragment. The screen resulted in 93 
hits for DsbB, defined as fragments which had a T/R ratio less than 0.3. This particular 
cut-off was chosen by virtue of a step-like relationship between the observed TINS effect 
and the number of “hits” whereby even slightly raising the cut-off gave a large increase 
(> 2-fold) in the number of compounds that were selected as hits (not shown). The 
resulting hit rate for DsbB was 8.7% which is well within the range we typically observe 
with soluble proteins using TINS (3-9.5%). Application of the same criteria to OmpA/DPC 
binding identified seven compounds as hits for a hit rate of 0.6%, validating the earlier 
data suggesting that OmpA/DPC has minimal small molecule binding capacity. 
Hit Validation using Enzymatic Assays 
 All fragments from the screen that were designated as positive for binding were 
assayed for DsbB inhibition at 250 µM. The amount of DMSO in all biochemical assay 
controls was adjusted to match the amount present when fragments were tested. Those 
compounds that showed more than 70% inhibition at 250 µM were further characterized 
by titration from 0.0001 mM to 10 mM to generate IC50 curves. The mode of action for 
the 8 most potent fragments was determined from competition enzyme assays. For this 
analysis either DsbA or UQ1 was titrated in from 0.2 to 40 µM, while the other was kept 
constant at 40 µM. For each titration point, slopes were measured in the presence of 5, 
10, and 75 µM of the fragment. DsbB activity data was analyzed using the non-linear 
regression curve fitting routines in Graph Pad Prism v. 5.01 (Graph Pad, San Diego, CA, 
U.S.A.). Statistical significance was evaluated with the student's T-test. Depending on 
the light absorbing properties of the fragments, they were used in either the fluorescence 
or UV-absorbance assay. Compounds which were not compatible with the assays due to 
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high intrinsic fluorescence, high UV absorbance or irregular baselines were not included 
in the analysis.  
 Each of the 93 fragments identified as TINS hits in the micelle screen was 
assayed for inhibition of DsbB-dependent reoxidation of DsbA at 250 µM. Eight 
compounds interfered with the assay when run in either fluorescence or absorbance 
mode and therefore were left out of the analysis. The remaining 85 hits exhibited a 
distribution of potencies against DsbB, including 60% with better than 30% enzymatic 
inhibition and 16% with either less than 20% inhibition or stimulation. This data confirms 
that a very high percentage of the hits found in the biophysical assay also modulate the 
enzymatic activity of DsbB and are functionally relevant. 
 To avoid the possibility of artifacts in the biochemical assay we selected the 13 
fragments from the micelle screen showing strong inhibition in the single concentration 
point assay for further analysis. We first assayed these 13 fragments for potency (IC50) 
by dose-response experiments (Figure A1). Dose response experiments were carried 
out with increasing fragment concentrations, from 0.0001 to 10 mM, while both DsbA 
and UQ1 were kept in excess. Three of the 13 fragments indeed showed artefacts 
including signs of protein precipitation at higher compound concentration and/or steeper 
than expected Hill coefficients. The remaining 10 fragments titrated over 2 Log orders 
and exhibited a Hill coefficient close to unity. By these criteria, the ten fragments are 
reversible inhibitors with a 1:1 stoichiometry and are therefore well-behaved. The eight 
most potent compounds had IC50 values between 7 and 170 µM (Table A1) and 
consisted of a variety of scaffolds (Figure A1). The calculated binding efficiency index2 
(Table A1) indicates that these fragments are all very good or excellent starting points for 
hit elaboration projects.  
Table A1. Biological characterization of fragment hits. 
Fragment IC50 (µM) Hill coefficient BEI2 
1 7 ± 1 0.80 ± 0.10 21.8 
2 100 ± 10 1.40 ± 0.15 14.7 
3 193 ± 11 1.20 ± 0.11 15.3 
4 13 ± 1 0.80 ± 0.10 21.2 
5 46 ± 12 0.80 ± 0.10 22.2 
6 70 ± 10 1.00 ± 0.10 14.0 
7 115 ± 11 1.15  ± 0.05 19.1 
8 168  ± 10 1.40 ± 0.10 14.2 






Figure A1.  Potency determination of selected hits from the TINS screen. An example of an inhibition curve 
used to determine the IC50 for compound 2. The curve represents the mean ± S.E.M. of three independent 
experiments performed in triplicate. The structures of the 8 most potent compounds are shown and the IC50 
values are provided in Table A1. 
 
 As a second validation step, we carried out a more detailed kinetic analysis of the 
mode of action of the 8 most potent fragments. Substrate-velocity experiments were 
performed in which either DsbA or UQ1 were titrated in the presence of saturating 
amounts of the other. The titrations were then repeated in the presence of increasing 
amounts of the inhibitory fragment (Figure A2, Table A2). In this analysis, fragments 1-3 
behaved similarly. This group is exemplified by fragment 2 where increasing 
concentrations result in moderate perturbation of the maximum enzymatic turn over rate 
(kcat) and apparent affinity of DsbA but a dramatic reduction (> 6-fold) in the apparent 
affinity of UQ1.  This result suggests that fragments 1-3 compete for the same binding 
site as UQ1. On the other hand, addition of fragments 4-8 simultaneously decreased 
both the apparent affinity and the kcat for UQ1 and DsbA as best exemplified by fragment 
8 (Figure A2). This data suggests a mixed model of inhibition of DsbB by these 
fragments. We next sought biophysical confirmation of these two different modes of 







Figure A2. Mode of action determination for the most potent DsbB inhibitors. Fragment 2 was assayed in 
competition with synthetic UQ1 (a), the electron acceptor, or DsbA (b) the electron source. Fragment 8 was 
assayed in the same manner (panels c and d respectively). The kcat and Km apparent determined from the 
data are shown in Table 2 in the absence and presence of the indicated amount of each inhibitor.  
 
Table A2. Kinetic analysis of two fragment hits. 
Fragment  Substrate 
kcat  




0 µM 3.7 ± 0.1  1.6 ± 0.1 
75 µM UQ1 3.1 ± 0.2 13.2 ± 1.7 
0 µM 4.3 ± 0.1   2.4 ± 0.2 
2 
75 µM DsbA 2.5 ± 0.1   2.8 ± 0.1 
0 uM 4.0  ± 0.1   2.2 ± 0.0 
75 µM UQ1 2.3 ± 0.1   9.7 ± 1.5 
0 µM 4.3 ± 0.1   1.9 ± 0.1 8 
75 µM DsbA 2.4 ± 0.2   4.1 ± 0.5 
 
  
Confirmation of Different Modes of Interaction with DsbB by NMR 
 Due to the poor quality of the NMR spectra of the wild-type DsbB, it was 
necessary to use a mutant that represents an intermediate in the disulfide oxidation 
pathway3.  Validated hits from the screen were titrated at 1, 5, and 10 mM into 15N-
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labelled DsbB[CSSC] mutant (C44S, C104S). [15N,1H] HSQC experiments were acquired 
at 40 ºC in a Bruker DRX 600 MHz spectrometer equipped with a cryoprobe. A reference 
titration of DMSO and a non-binding fragment from the screen were used to subtract 
chemical shift perturbations not related to fragment binding.  
 Chemical shift perturbations of the protein NMR spectrum (typically 2D 15N-1H 
HSQC or 13C-1H HSQC) in the presence of compounds can both confirm binding to the 
target and localize the binding site on a protein when resonance assignments are 
available4. While the sequential assignment of wildtype DsbB is not available due to the 
poor quality of the NMR spectra, spectra of the DsbB[CSSC] double cysteine mutant are 
of high quality, resulting in a complete backbone resonance assignment for this form of 
the protein3. When purified from E. coli, DsbB[CSSC] contains the endogenous 
ubiquinone-85, thus compounds specific for this site must compete with UQ-8 for binding. 
We first titrated the synthetic quinone UQ1 into a sample of 15N DsbB[CSSC]. Addition of 
UQ1 to 15N DsbB[CSSC] resulted in numerous chemical shift perturbations but two in 
particular afford a detailed analysis of the binding and allow a reliable comparison with 
the fragments found in TINS screening. As shown in Figure A3, the sidechain indole of 
Trp135 (in the vicinity of the quinone binding site) and the backbone amide of Arg109 
(close to the DsbA binding site) respond very differently to addition of UQ1. Titration of 
UQ1 resulted in the simultaneous disappearance of the Trp135ε-NH peak from 
DsbB[CSSC] bound to endogenous quinone and the appearance of a new peak close by 
in the spectrum. Due to its proximity and the unique chemical shift of the Trpε NH proton, 
in combination with the high level of conservation of this residue, the new peak is likely 
from the Trpε NH proton of the UQ1 bound DsbB[CSSC]. This pattern of peak changes 
is indicative of slow exchange on the NMR time scale (e.g. koff < 30 Hz Δδ  in Figure 
A3a). In contrast, the backbone amide of Arg109 is essentially unchanged by the 
addition of UQ1. 
 Addition of all 8 fragments to 15N labelled DsbB[CSSC] resulted in detectable 
changes in chemical shifts, suggesting that the fragments selected by TINS screening 
and biochemical assays on wild type protein also bind the cysteine mutated form. The 
presence of chemical shift perturbations both in solvent exposed loops and in portions of 
the protein buried within the micelle (data not shown) suggests that the fragments are 
specifically binding to the protein and not non-specifically partitioning into the micelle.  
64 
 
Fragment 2, which competitively inhibited ubiquinone binding, induced chemical shift 
perturbations in a variety of amino acids, including W135 and R109. The pattern of 
chemical shift perturbations induced by fragment 2 closely resembles that induced by 
UQ1. First, titration of 2 into 15N DsbB[CSSC] resulted in chemical shift changes in the 
W135ε-HN peak that were similar to those induced by UQ1 (i.e. slow exchange). 
Moreover, the resonance frequency of the new peak tentatively assigned to the 
DsbB[CSSC]-2 complex is similar to that of the DsbB[CSSC]-UQ1 complex. Similarly, 
R109HN, which is minimally affected by UQ1, undergoes only minor chemical shift 
perturbations in the presence of 2.   
 In contrast, the chemical shift changes induced by fragments 4-8 differ in both the 
overall pattern and the details from fragment 2 and UQ1 (Figure A3c). Addition of 8, for 
example, induced concentration dependent shifts in the Trp135ε-NH resonance to an 
entirely different chemical shift than did fragment 2 or UQ1. This concentration 
dependent shift is indicative of rapid exchange on the NMR time scale. There was no 
evidence for slow exchange for any of the fragments 4-8, although 4 and 7 show signs of 
line broadening of the backbone resonance of Q33 that may indicate intermediate 
exchange (not shown).  In contrast, the backbone amide of R109, which is only mildly 
perturbed by UQ1 or 2, is very dramatically perturbed by the addition of fragment 8. This 
data suggests that fragments 4-8, which exhibit mixed mode DsbB inhibition, bind in 
either a different mode or different site to fragment 2 which is competitive with 
ubiquinone. 
 The different behaviour of the resonances of the backbone amide of R109 and 
the sidechain indole of W135 upon titration with the fragments provides further support 
for two modes of action. Titration of UQ1 DsbB[CSSC] results in slow exchange between 
the endogenous quinone bound form and a newly arising peak at a nearby position 
which we assign to the UQ1 complex. Similarly, addition of 2 resulted slow exchange 
between the endogenous quinone bound form of W135ε-NH and the appearance of a 
new peak with similar chemical shift as the UQ1 complex. An additional chemical shift 
perturbation indicating fast exchange with the endogenous complex was also observed. 
The fast exchange is likely due to competition between 2 and the quinone moiety of the 
bound UQ8, consistent with the competitive kinetics observed for this inhibitor. However, 
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we have shown that the isoprenyl tail of UQ8 extends down the groove between TM1 
and TM4, making extensive interactions with the protein3. Therefore, displacement of the 
 
 
Figure A3: NMR analysis of fragment binding to DsbB. The eight most potent fragments were titrated into 
15N DsbB[CSSC]. Data for the synthetic quinone UQ1 (A), competitive fragment 2 (B), and the mixed model 
fragment 8 (C) are shown. For each of these three compounds, the structure of the compound is shown in 
the left column and the characteristic peak perturbations in the [15N,1H] HSQC spectrum (green 0 mM 
fragment, blue 5 mM fragment, and red 10 mM fragment) are shown in the middle (Tryptophan 135 side-
chain indole) and right columns (Arginine 109 backbone amide). 
quinone moiety apparently occurs on a slower timescale. Addition of 8 to DsbB[CSSC] 
also causes chemical shift perturbation of the W135ε-NH. But these suggest rapid 
exchange between a typical 2-state equilibrium rather than the more complex effects 
seen with 2. In addition, the bound state has a different resonance frequency than the 
bound state of UQ1 or 2. Additional large downfield chemicals shifts of the resonance of 






effects on this peak. From a drug discovery perspective, this data is exciting because it 
suggests, as with soluble enzymes, it is possible to find small molecule inhibitors with 
different modes of action and possibly non-overlapping or even different binding sites on 
membrane proteins. 
 We note that the concentration of the fragments required to induce chemical shift 
perturbations in DsbB[CSSC] is significantly higher than the IC50 values measured for 
the wild type protein but the same as required for UQ1. A likely explanation is that the 
conformation of the mutant differs slightly from the wildtype protein, against which the 
fragments were selected. In addition, either the affinity for the quinone is higher for the 
DsbB[CSSC] mutant or more likely, the quinone binding site may be partially occluded. 
This latter possibility is clearly consistent with the reduced dynamic behaviour of 
DsbB[CSSC] with respect to the wild type protein, which results in the substantial 
improvement in the quality of the NMR spectra. This reduced dynamic behaviour of the 
disulfide mutant may be responsible for the slow exchange kinetics observed for UQ1 
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 Fragment-based drug discovery (FBDD) has proven a powerful method to 
develop novel drugs with excellent oral bioavailability against challenging 
pharmaceutical targets such as protein-protein interaction targets. Very recently 
the underlying biophysical techniques have begun to be successfully applied to 
membrane proteins. Here we show that novel, ligand efficient small molecules 
with a variety of biological activities can be found by screening a small fragment 
library using thermostabilized (StaR) G protein-coupled receptors (GPCRs) and 
Target Immobilized NMR Screening (TINS). Detergent solubilized, StaR 
adenosine A2A receptor was immobilized with retention of functionality and a 
screen of 531 fragments was performed. Hits from the screen were thoroughly 
characterized for biochemical activity using the wild-type receptor. Both 
orthosteric and allosteric modulatory activity has been demonstrated in 
biochemical validation assays. Allosteric activity was confirmed in cell-based 
functional assays. The validated fragment hits make excellent starting points for a 





 G protein-coupled receptors (GPCRs) are one of the most popular classes 
of investigational drug targets due to their central role in a variety of biological 
and pathological processes, such as: neuromodulation, metabolic disorders, 
inflammation, cancer and viral infection.1,2 Thus, it is not surprising that about 
30% of all prescribed drugs on the market act on this class of receptors.3 In the 
last ten years, GPCR drug discovery has relied on cell-based assays combined 
with high-throughput screening (HTS) of large compound libraries4 for lead 
discovery as well as optimization. This paradigm has delivered compounds that 
modulate the behavior of GPCRs as desired, many of which have made it to 
patients. Nonetheless, only one small molecule drug targeting a novel GPCR has 
been approved in each of the last 10 years. Moreover, the majority of drugged 
GPCRs are members of families that are activated by small molecules such as 
the adrenergic, muscarinic and histamine receptors.5 In contrast, peptide and 
protein hormone receptors have represented a much greater challenge. In 
addition, achieving subtype selectivity has been difficult and where successful, 
has required quite substantial medicinal chemistry efforts. Furthermore, hits from 
HTS screens frequently must be deconstructed to remove liabilities that result in 
non-ideal absorption, distribution, metabolism, and excretion (ADME) properties.6  
 Fragment-based drug discovery (FBDD) uses low-molecular-weight (< 300 
Da), moderately lipophilic (clogP < 3) and highly soluble7 molecules or “drug 
fragments” as starting points for developing novel drugs. FBDD is particularly 
advantageous for its ability to more completely assess “compound space” for 
molecules that interact with the target of interest.8 Since the typical interaction of 
such small molecules with proteins is weaker than 1 µM KD, the types of assays 
employed in HTS screening are not easily capable of discriminating between 
positives and negatives. In order to detect such weak binding, sensitive 
biophysical techniques such as NMR, SPR or X-ray crystallography are most 
commonly used. FBDD has been successful in developing inhibitors of soluble 
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targets such as kinases,9 proteases10,11 and most recently protein-protein 
interactions.12 In principle, it could be advantageous to apply FBDD to GPCRs to 
identify molecules with novel modes of action.13 However, the application of 
biophysical techniques to membrane proteins is extremely challenging due to 
their instability when extracted from the cell membrane and the difficulty of large 
scale recombinant expression. Even when successful, significant levels of non-
specific partitioning of compounds into the media used to solubilize membrane 
proteins remains a significant source of false positives with biophysical studies. 
 We have developed an NMR-based, fragment screening approach which 
has been used to find new chemical starting points for further development of 
compounds targeting membrane proteins, including GPCRs.14,15 The approach, 
called target immobilized NMR screening (TINS),16 uses a target and a reference 
protein immobilized on a compatible solid support. Binding of fragments to the 
immobilized protein is monitored by changes in the 1D 1H NMR spectrum of a 
ligand. A powerful method, called StaRs (stabilized receptors), has been 
developed to overcome the instability and purification problems of GPCRs. StaR 
GPCRs, which contain a small number of point mutations for both enhanced 
thermostability and conformational homogeneity,17-20 can be produced in 
significant quantities and purified in correctly folded form in detergent micelles for 
structural and biophysical studies.21-23 
 We have previously demonstrated the feasibility of the combination of 
TINS and StaRs to screen fragment libraries for target specific binding.15 Here 
we use TINS to find fragment ligands for the human adenosine A2A receptor 
(A2AR) with novel modes of action. Screening of a moderate sized fragment 
library using an antagonist stabilized StaR yielded multiple hits that were 
pharmacologically validated with the wild-type (WT) receptor. Amongst these hits, 
we find multiple allosteric modulators of the A2AR with both positive and negative 





2. Results   
 
Functional Immobilization and Stability  
 In order to assess the feasibility of ligand screening studies, we first 
determined whether immobilized, micelle solubilized A2A-StaR2 retained 
functionality and if so, whether the preparation was sufficiently stable over time 
(Figure 1). We used an immobilization method that was successfully applied to 
the StaR β1 adrenergic receptor (β1AR),15 in which primary amines of the protein 
form a Schiff’s base with an aldehyde group on the solid support. Using this 
procedure, the DDM-solubilized A2A-StaR2 was efficiently immobilized on a 
sepharose resin at pH 7.4 with a yield of 70% and subsequently, unreacted 
aldehydes were blocked using deuterated Tris buffer. To determine whether the 
immobilized A2A-StaR2 remained competent for ligand binding, the binding of 
[3H]ZM241385, an inverse agonist that binds the orthosteric site of StaR and 
wild-type receptors with a KD of approximately 1 nM and 1:1 stoichiometry, was 
assessed as previously described.24 Initial measurement of [3H]ZM241385 
binding after immobilization indicated that nearly 95% of the immobilized A2A-
StaR2 was competent. Next, we compared the stability of immobilized A2A-StaR2 
with A2AR-WT in HEK cell membranes. After 5 days stored at 4 °C, more than 
60% of the immobilized A2A-StaR2 still remained competent for radioligand 
binding (Figure 1). In contrast, over the same time period, the A2AR-WT lost 75% 
activity, despite the fact that it was in 
a native environment.  
Figure 1. Functional immobilization and 
stability of micelle-solubilized A2A-StaR2 
(green) compared to A2AR-WT in HEK cell 
membranes (red). A2A-StaR2 was covalently 
bound to Sepharose resin (see text for 
details). Functionality was assessed by 
binding of [3H]ZM241385 upon storage of the 
protein at 4 °C for the indicated time. Specific 
[3H]ZM241385 binding at day 0 was set as 
100% for both A2A-StaR2 and A2AR-WT. 
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Fragment Screening  
 Having determined the functionality and stability of immobilized A2A-StaR2, 
we set out to screen a collection of fragments for binding to the receptor. A set of 
531 fragments was selected for their chemical and shape diversity.25 The TINS 
technique uses a reference to cancel out non-specific binding, thereby reducing 
the amount of false positives. Previously, we had determined that the E. coli 
outer membrane protein OmpA, a b-barrel structure that can be solubilized in 
various detergents, was an appropriate reference for micelle-solubilized 
membrane proteins14,15 and therefore, we have used it for the current study as 
well. The fragments were injected into the dual cell sample holder26 in mixtures of 
between 3 and 8 compounds. A spatially selective, one-dimensional 1H 
Hadamard experiment27 was used to acquire the NMR spectrum of the 
compounds in solution. Since the NMR relaxation of a spin is approximately 
1,000 times more efficient in the solid state than in solution, binding of a ligand to 
the immobilized protein causes the resonances of that molecule to further 
broaden into the kHz range. As a result, ligand binding is detected as a simple 
reduction in the amplitude of the NMR signals of that molecule in the presence of 
the target in comparison with those in the presence of the reference (Figure 2A).  
 In order to differentiate hits from non-hits, we analyzed a profile of the 
entire screen (Figure 2B). In this plot, the T/R ratio (the weighted average of the 
amplitude of well resolved resonances in the presence of target divided by that in 
the presence of reference) for each fragment has been bucketed and the number 
of fragments in each bucket is presented as a histogram. Similarly to the β1 
adrenergic receptor,15 the profile shows a peak at a T/R ratio of 1 indicating that 
the bulk of the fragments do not bind or bind non-specifically to both target and 
reference. Further, very few compounds have a T/R > 1 recapitulating that OmpA 
has minimal specific small molecule binding capacity and is therefore a good 
reference. In contrast, there are large numbers of fragments with a T/R ratio 
significantly less than 1, indicating that they preferentially bind to the A2A-StaR2. 
In order to make a selection of positives, a discontinuity in the histogram is 
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chosen and that value is used as a cutoff. Such a discontinuity can be found at a 
T/R ratio of about 0.7. Since the goal was to characterize how the interaction of 
small molecules with the micelle solubilized GPCR is reflected in the TINS assay, 
we opted for a very conservative hit selection (i.e. a larger than normal number of 
compounds were designated as hits), which resulted in 94 fragments defined as 
A2AR hits. Application of the same criteria to OmpA binding identified six 





Figure 2. (A) An example of a TINS experiment applied to a mixture of 6 fragments. The 1H NMR 
spectrum of each component in the mixture is presented, where extensive line broadening has 
been applied to simulate the linewidth of resonances in the heterogeneous TINS assay (a-f). The 
spectrum of the mixture in the presence of the reference protein (red) and A2A-StaR2 (blue) are 
overlaid. The reduction of peaks in the presence of A2AR indicates that primarily f binds. (B) 
Profile of the complete screen. The ratio of peaks in the presence of target & reference (T/R) for 
each compound has been binned and the number of compounds in each bin is shown. The cut-
off for hit selection is shown. 
 
Pharmacological Characterization of TINS Hits:  
1). Probing for Orthosteric Site Ligands. A biophysical assay such as TINS 
simply discovers fragments that specifically bind to the target. We wished to 
validate this binding and determine whether or not the fragments exhibited a 
biochemical activity. For these studies we used HEK293 cell membranes 
transiently expressing the wild-type A2A receptor. Initially we assessed the ability 
of each of the 94 fragment hits to displace the high affinity, orthosteric inverse 
agonist [3H]ZM241385 in an equilibrium binding assay. This assay primarily 
detects ligands binding to the orthosteric site (i.e. same site as [3H]ZM241385). 
Five of the fragment hits inhibited binding of ZM241385 by ≥ 30% at 500 µM, 
suggesting a biologically relevant interaction between the fragments and the wild-
type A2AR. Subsequent dose-response curves of these five hits were well 
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behaved, with IC50 values ranging from 70 µM to 1.9 mM (Table 1 and Figure 3). 
Analysis of the dose-response curves revealed that the Hill coefficient for each of 
the five compounds is not significantly different from unity which, in conjunction 
with the TINS data, indicates that these fragments reversibly bind A2AR with a 1:1 
stoichiometry. As expected for compounds binding to the orthosteric site, the five 
hits also significantly inhibited the binding of [3H]NECA, an adenosine receptor 
agonist, with IC50 values ranging from 80 µM to 7.7 mM (Table 1). Achieving 
receptor subtype selectivity is desirable but can be a challenge for fragments 
targeting the orthosteric site. Perhaps not unsurprisingly, the five compounds 
also displaced [3H]DPCPX, a well-characterized orthosteric antagonist for the 
closely related adenosine A1 receptor subtype. Moreover, the potency of each of 
the five compounds in the A1R assay was similar to the A2AR. It is not 
unexpected at this stage in hit finding for fragments to show binding to two 
closely related receptors. During a chemistry lead optimization program, such 
fragment hits could be optimized for selectivity using a variety of structure-based 
design approaches. Many known adenosine receptor ligands have been 
developed based on the adenosine28 and xanthine29 chemotypes. Newer 
adenosine receptor antagonists have modifications based on tricyclic derivatives 
of triazolopyrimidine,30 including Preladenant31 which has been evaluated in 
clinical trial (phase III) for the treatment of Parkinson’s disease, and exhibit high 
selectivity for A2AR. As shown in Table 1, the five fragment A2AR orthosteric 
ligands represent a diversity and novelty of chemical scaffolds. A hallmark of 
FBDD is that it generates ligands in which most of the atoms contribute to target 
binding, a characteristic termed ligand efficiency. Indeed, two of the fragments in 
Table 1 have high ligand efficiency (LEAN32 (pIC50/heavy atom count) ≥ 0.3), and 





Figure 3. Representative dose-response curves for displacement of binding of the radiolabeled 
A2AR inverse agonist ZM241385 (A) and agonist NECA (B) by A2A hits identified in the TINS 
screen. Each curve has been determined in triplicate in three independent experiments. The 
structures of the radiolabeled ligands are shown in C and D. 
 
2). Probing for Allosteric Site Ligands. We next looked whether any of the 94 
fragment hits bind to allosteric site(s) on the A2AR. In order to do so, we 
employed an assay that measures the effect of a fragment on the dissociation 
rate (koff) of an orthosteric ligand, but is not sensitive for competitive binding at 
the orthosteric site. Each of the 94 fragment hits were screened for their effect on 
the off rate of the inverse agonist [3H]ZM241385 and the agonist [3H]NECA 
dissociating from wild-type A2A receptor using a single time point at which 50% of 
the radioligand has dissociated under control conditions. Three fragments 
significantly (at least 30%) increased koff of the orthosteric ligand and hence are 
negative allosteric modulators (NAMs), while four significantly decreased koff and 
hence are positive allosteric modulators (PAMs) of both ZM241385 and NECA 




Table 1. Characterization of fragment hits by equilibrium radioligand displacement assays on 
wild-type A2A and A1 receptors. 
Displacement	  of	  [3H]ZM241385	  on	  A2ARa	   Displacement	  of	  [3H]NECA	  on	  A2ARa	  















%	  displacement	  of	  
[3H]DPCPX	  on	  A1Rb	  
ZB643	  
	  
0.07	  ±	  0.02	  
(91%)	  
-­‐0.87	  ±	  0.12	   0.43	  
0.08	  ±	  0.03	  
(90%)	  
-­‐1.02	  ±	  0.12	   0.42	   92%	  
ZB1703	  
	  	  	  
	  
0.79	  ±	  0.32	  
(65%)	  
-­‐1.23	  ±	  0.19	   0.23	  
1.07	  ±	  0.04	  
(57%)	  
-­‐1.11	  ±	  0.15	   0.22	   52%	  
ZB1166	  
	   	  
1.32	  ±	  0.26	  
(40%)	  
-­‐1.07	  ±	  0.24	   0.22	  
0.25	  ±	  0.02	  
(68%)	  
-­‐0.92	  ±	  0.09	   0.27	   48%	  
ZB2086	  
	  	  	  	  	  
	  
1.73	  ±	  0.47	  
(34%)	  
-­‐1.07	  ±	  0.26	   0.30	  
0.76	  ±	  0.05	  
(37%)	  
-­‐1.04	  ±	  0.07	   0.35	   21%	  
ZB1396	  
	  
1.88	  ±	  0.26	  
(30%)	  
-­‐1.13	  ±	  0.21	   0.23	  
7.71	  ±	  0.04	  
(26%)	  
-­‐1.24	  ±	  0.24	   0.19	   22%	  
a Displacement of specific [3H]ZM241385 or [3H]NECA binding in HEK293 cell membranes 
transiently expressing human adenosine A2ARs expressed as IC50 ± SEM (n=3) or % 
displacement of specific binding at 0.5 mM fragment concentration (n=2). b % displacement of 
specific [3H]DPCPX binding in CHO cell membranes stably expressing human adenosine A1Rs at 
0.5 mM fragment concentration. c  Hill slope ± SEM (n=3). d LEAN ligand efficiency is -logIC50 
divided by the heavy atom count.32  
 
 In addition, another four fragments allosterically enhanced either NECA 
binding or ZM241385 binding (Table 2). Subsequently, full dissociation curves of 
[3H]ZM241385 and [3H]NECA were measured in the absence (control) or 
presence of 2 mM of each of the active fragment hits. As shown in Table 2 and 
Figures 4A and 4B, the intrinsic dissociation rate of the radioligand was 0.011 ± 
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0.002 min-1 for [3H]ZM241385 and 0.015 ± 0.002 min-1 for [3H]NECA. Most of the 
fragment hits showed at least 2-fold modulation of radioligand dissociation. For 
example, in the presence of 2 mM ZB335, the koff of [3H]NECA was decreased 
2.9-fold to 0.0051 ± 0.0009 min-1. In combination with the lack of competitive 
binding, this data strongly suggests that ZB335 is acting at an allosteric site. 
Similarly, addition of 2 mM ZB418, resulted in an increase of the koff of 
[3H]ZM241385 by 3.5-fold to 0.039 ± 0.001 min-1, suggesting this fragment is a 
NAM. Interestingly, ZB418 showed a hill slope about -2 in the equilibrium 
displacement assay for both [3H]ZM241385 and [3H]NECA which can also be 
indicative of an allosteric mechanism.33 Importantly, the allosteric modulation by 
the fragment hits was concentration-dependent (Figure 4C and Table 3). In 
contrast to the fragments that were competitive with orthosteric ligands, the most 
potent allosteric modulators, such as ZB335 and ZB418, exhibited considerably 
reduced effects on the A1R, suggesting that they have some A2A subtype 
specificity.
 
Figure 4. Allosteric effects of fragment hits on the A2AR. A) [3H]ZM241385 and B) [3H]NECA 
kinetic dissociation assay. Fragments were assayed for their effect on the dissociation rate of two 
A2AR orthosteric ligands: [3H]ZM241385 and [3H]NECA. Dissociation was initiated by the addition 
of 10 µM ZM241385 or NECA in the absence (control) or presence of 2 mM of the indicated 
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fragment. C) Dissociation kinetics of [3H]ZM241385 binding to A2AR. Dissociation was initiated by 
the addition of 10 µM ZM241385 mixed with buffer (control) or the indicated concentration of the 
fragment. D) The effect of increasing concentration of the fragment ZB1854 on the cAMP 
production induced by the A2AR specific agonist CGS21680 in HEK293 cells transiently 
expressing the human A2A receptor. The % of cAMP accumulation is normalized to the effect of 
CGS21680 at 10 µM. 
 
Table 2. Characterization of fragment hits by kinetic radioligand dissociation assays on the wild-
type A2A and A1 receptors. 
koff	  (min-­‐1)	  or	  %	  allosteric	  modulation	  at	  2	  mMa	  
A2ARb	   A1Rc	  ID	  
	  	  
Fragment	  structure	  
	  	   [3H]	  ZM241385	   [3H]	  NECA	   [3H]	  DPCPX	   [3H]	  CCPA	  
Control	   	  
0.011	  ±	  0.002	  
(0%)	  	  
0.015	  ±	  0.002	  
(0%)	  	  
0%	  	   0%	  	  
	  
Negative	  Allosteric	  Modulators	  for	  both	  [3H]ZM241385	  and	  [3H]NECA	  binding	  
ZB418	  	  
	  
0.039	  ±	  0.001	  
(-­‐36%)	  	  
0.022	  ±	  0.003	  
(-­‐27%)	  
-­‐11%	   -­‐15%	  
ZB2044	  	  
	  
0.019	  ±	  0.001	  
(-­‐21%)	  
0.032	  ±	  0.003	  
(-­‐32%)	  
-­‐30%	   -­‐22%	  
ZB1153	  	  
	  
0.017	  ±	  0.004	  
(-­‐18%)	  
0.021	  ±	  0.002	  
(-­‐26%)	  
-­‐23%	   -­‐8%	  
	  
Positive	  Allosteric	  Modulators	  for	  [3H]ZM241385	  and/or	  [3H]NECA	  binding	  
ZB335	  
	  
0.0071	  ±	  0.0002	  
(20%)	  
0.0051	  ±	  0.0009	  
(41%)	  
16%	   -­‐6%	  
ZB1854	  
	  
0.0063	  ±	  0.0005	  
(31%)	  
0.0095	  ±	  0.0005	  
(18%)	  
1%	   -­‐29%	  
ZB391	  
	  
0.0066	  ±	  0.0006	  
(25%)	  
0.0085	  ±	  0.0005	  
(24%)	  









3%	   -­‐14%	  
ZB268	  
	  
0.0061	  ±	  0.0005	  
(31%)	  




0.0079	  ±	  0.0006	  
(30%)	  




0.0081	  ±	  0.0006	  
(28%)	  




0.0082	  ±	  0.0005	  
(26%)	  
3%	   -­‐4%	  
a koff ± SEM (n=3), % allosteric modulation (n=2). b The values of the kinetic dissociation rate 
constants were obtained by analysis of the exponential dissociation curve of [3H]ZM241385 or 
[3H]NECA bound to human adenosine A2ARs. c % allosteric modulation of [3H]DPCPX and 
[3H]CCPA binding at human adenosine A1Rs in the absence (control; 0 %) or presence of 2 mM 
of the fragment. 
 
Table 3. Effect of ZB1854 on the dissociation of [3H]ZM241385 from A2AR. 
Condition	   k
off
	  (min-­‐1)	  a	   Shift	  b	  
Control	  ([3H]	  ZM241385)	   0.0121	  ±	  0.0010	   -­‐	  
+	  0.5	  mM	  ZB1854	   0.0102	  ±	  0.0009	   1.2	  
+	  1	  mM	  ZB1854	   0.0072	  ±	  0.0011	   1.7	  
+	  2	  mM	  ZB1854	   0.0058	  ±	  0.0015	   2.1	  
a koff ± SEM (n=3). b The shift is defined as the ratio of the koff values in the absence (control) 
and presence of ZB1854, respectively. 
 
 Finally, we determined whether the fragments hits were active in a cell-
based assay. We therefore investigated the effect of fragments on A2AR 
activation by the agonist CGS21680 in a cyclic AMP accumulation assay (Table 4 
and Figure 4D). Addition of ZB1854 at three concentrations did not cause a shift 
in potency of CGS21680 (EC50 = 14.1 ± 0.3 nM). However, increasing 
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concentrations of ZB1854 did result in a dose-dependent increase of the maximal 
effect (Emax) of CGS21680.  The change in Emax is consistent with the previous 
data suggesting that ZB1854 acts via an allosteric mechanism.33,34 For other 
compounds, such as ZB418 (NAM) and ZB335 (PAM) which were tested at these 
high concentrations, we observed some cell toxicity and therefore it was not 
possible to confirm their allosteric effects in the cellular assay. 
 
Table 4. Receptor activation by CGS21680 in the presence of ZB1854. 
cAMP	  accumulation	  assay	  a	  
ID	  
EC50	  (nM)	   Emax	  (%)	  b	  
CGS21680	  	   14.1	  ±	  0.3	   100	  ±	  2	  
CGS21680	  +	  0.25	  mM	  ZB1854	   14.1	  ±	  0.3	   120	  ±	  3	  
CGS21680	  +	  0.5	  mM	  ZB1854	   13.8	  ±	  0.4	   134	  ±	  9	  
CGS21680	  +	  1	  mM	  ZB1854	   14.0	  ±	  0.3	   177	  ±	  13	  
a cAMP accumulation in HEK cells that transiently express the human adenosine A2AR. b 
Maximal effect of CGS21680 in the absence or presence of modulator, where CGS21680 in the 
absence of modulator was set at 100 %. Values are means ± SEM (n=3). 
 
3. Discussion 
 Traditionally, small molecule modulators of GPCRs have been discovered 
through pharmacological studies. More recently functional, cell-based assays 
have been coupled to high-throughput screening to discover novel molecules 
with selected activities such as positive allosteric modulation.35,36 However, for a 
number of reasons such molecules have failed to gain marketing approval. The 
combination of structure-based drug discovery and fragment-based drug 
discovery has demonstrated the ability to generate approved drugs with excellent 
pharmacological properties37 against soluble targets. It is becoming apparent that 
FBDD/SBDD can now be applied to GPCRs with great potential advantages.5 
 Use of a direct binding assay, such as TINS, selects for fragments that 
specifically bind to the target, regardless of the site. In principle it is possible to 
discover ligands with many different biological activities. Indeed here we have 
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found orthosteric ligands (although we have not investigated their pharmacology; 
Table 1), positive allosteric modulators and negative allosteric modulators (Table 
2), thereby substantiating the claim. One of the orthosteric ligands, ZB643, 
constitutes a scaffold in a series of thiadiazole derivatives previously found to 
interact with other adenosine receptor subtypes.38 Whether ZB643 can be a lead 
for further exploration needs careful consideration as other thiadiazoles have 
been reported to be protein modifiers due to their reactivity.39 Moreover, this 
study is one of the first reports of allosteric modulators for the adenosine A2A 
receptor, with indeed previously unknown chemistry.40 Giorgi et al have provided 
evidence of allosteric enhancement in a class of substituted 8-azaadenines 
before.41 As ZB1854 potentiates the action of an adenosine A2A receptor agonist, 
its therapeutic potential may be in wound healing and in combating 
inflammation.42 Given their apparent low potency, it is not clear whether the 
allosteric modulators would have been discovered by other methods. However, 
fragments typically bind in the µM to mM range from where they are developed to 
the potency ultimately required for in vivo efficacy. 
 The present study used a biophysical technique to discover novel 
fragment ligands. However, the various biochemical activities of these ligands 
were characterized by traditional radioligand binding methods and a functional 
assay. Likely these methods missed multiple, valid fragment ligands simply 
because their potency was too low to register in the selected assay. In order to 
take true advantage of the biophysical screening technique, it will be necessary 
to implement biophysical techniques to characterize the binding mode and 
discriminate orthosteric from allosteric ligands. This can be accomplished using a 
competition binding assay in TINS as we have demonstrated for the β1 
adrenergic receptor.15 Furthermore, the Biophysical Mapping technique 
developed by Zhukov et al,24 offers the possibility to refine the binding site to 
significantly better resolution than competition binding studies.  
 Evolving weakly binding hits to lead-like compounds remains a significant 
challenge for FBDD. It is well established that with the availability of high-
resolution 3D structures of target-fragment complexes, the success and 
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efficiency of fragment elaboration is quite high.9 One particular advantage of 
StaR GPCRs is that they are amenable to X-ray crystallographic analysis and 
indeed structure based drug design is beginning to be applied to this target 
class.5,43 In addition to X-ray, StaRs may enable NMR analysis of protein-small 
molecule complexes. The NMR resonance assignment and structure elucidation 
of sensory rhodopsin has recently been accomplished.44 Although the latter was 
a significant achievement, it is plausible that the enhanced thermostability and 
reduced conformational exchange of StaRs may enable resonance assignment, 
at least for putative allosteric sites at or near the extracellular loop region. If so, 
the ligand binding site can be mapped at low resolution using chemical shift 
perturbation techniques.45 The tremendous increase in crystal structures of 
GPCRs in various states has had a positive impact on the ability to model small 
molecule-GPCR interactions.46 The combination of biophysical mapping and/or 
NMR-based structural constraints with modeling should also provide 





amino] ethyl)phenol ([3H]ZM241385, specific activity 30 Ci mmol-1) and tritiated 
5'-N-ethylcarboxamido adenosine ([3H]NECA, specific activity 33 Ci mmol-1) were 
purchased from ARC Inc. (St. Louis, USA). Unlabelled ZM241385, NECA and 2-
[p-(2-carboxyethyl)phenethylamino]-5'-N-ethyl-carboxamido adenosine 
(CGS21680) were purchased from Sigma-Aldrich (Steinheim, Germany). All the 
compounds in the fragment library are commercially available. A 1D 1H spectrum 
of each fragment has been collected25 and is consistent with the manufacturer’s 
claim of > 95% purity. Bovine serum albumin (BSA, fraction V) was obtained from 
Sigma (St. Louis, MO, USA) and BCA protein assay reagent was from Pierce 
Chemical Company (Rockford, IL, USA). Human embryonic kidney 293 cells 
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transiently expressing the wild-type A2AR (HEK293 A2AR) were generated as 
described below. All other chemicals were of analytical grade and obtained from 
standard commercial sources. 
Protein Purification  
 For biophysical studies, the inverse agonist stabilized A2A-StaR2,47 
including a C-terminal His-10 tag, was expressed in Trichoplusia ni (Tni) cells 
and purified as previously described.18 OmpA, including an N-terminal His-6 tag, 
was expressed in BL21(DE3) cells under the control of the T7 promoter and 
purified as previously described.48 Successful refolding of OmpA from inclusion 
bodies was monitored by SDS-PAGE analysis.48 Both A2AR and OmpA were 
buffer-exchanged to PBS (0.1 M sodium phosphate, 0.15 M sodium Chloride, pH 
7.4) containing 0.47% n-dodecylphosphocholine (DPC) for OmpA or 0.1% n-
decyl-β-D-maltoside (DM) for A2AR.  
Protein Immobilization  
 DM-solubilized A2AR and DPC-solubilized OmpA were immobilized on 
Actigel ALD resin (Sterogene, Carlsbad, CA, USA) via Schiff’s base chemistry 
using the manufacturer’s protocol. After overnight incubation at 4 °C, residual 
unreacted aldehydes on the resin were blocked by addition of 50 mM d11-Tris 
buffer. Quantification of immobilized protein was monitored by absorption of the 
supernatant at 280 nm before and after immobilization, and by SDS-page gel 
with a known standard curve and band volume analysis. This data indicated that 
a final concentration of 50 µM of immobilized A2AR and 65 µM OmpA was 
achieved (nmol protein/ml settled bed volume), equating to an 80% and 75% 
yield respectively. Subsequently, the buffer of both protein samples was 
exchanged to PBS containing 0.01% n-dodecyl-β-D-maltopyranoside (DDM) for 





Target Immobilized NMR Screening  
 Immobilized, DDM solubilized A2AR (50 µM) and OmpA (65 µM) were 
each packed into a separate cell of a dual-cell sample holder.26 Mixes of the 531 
fragments were made by 200-fold dilution of a 100 mM stock of each compound 
in d6-DMSO such that the final DMSO concentration was never greater than 5%. 
Upon injection of each mix into the dual-cell sample holder, flow was stopped and 
spatially selective Hadamard spectroscopy was used to acquire a 1D 1H 
spectrum of each sample separately.27 A CPMG T2 filter of 80 ms was used to 
remove residual broad resonances from the sepharose resin. To maintain the 
proper fold of each protein, the screen was performed at 15 oC, and 0.01% DDM 
was included in the buffer (PBS in D2O) used to wash the fragment mixes from 
the sample holder.  
Pharmacological Characterization of TINS Hits  
Radioligand binding and kinetic dissociation studies on the adenosine A2A 
receptor:  
 HEK293 cells were maintained in culture in DMEM supplemented with 
10% newborn calf serum at 37 ºC in a moist, 7% CO2 atmosphere and passaged 
twice weekly. Cells were transfected with plasmids containing wild-type A2AR 
construct using the calcium phosphate precipitation method49 and harvested after 
48 hours. Cells were pelleted, re-suspended in 20 ml of ice-cold 50 mM Tris-HCl 
buffer, pH 7.4. An ULTRA-TURRAX® was used to homogenize the cell 
suspension. The cytosolic and membrane fractions were separated using a high-
speed centrifugation step of 100,000 x g for 20 min at 4 ºC. This process was 
repeated twice and subsequently the pellet was re-suspended in 50 mM Tris-HCl 
buffer, pH 7.4, the protein concentration was determined by the BCA method50 
and samples were aliquoted and stored at - 80 ºC until further use. 
 Firstly, all fragment hits from the TINS screen were assayed in a 
[3H]ZM241385 displacement assay at 500 µM. Fragments with more than 30% 
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displacement of [3H]ZM241385 were titrated to determine an IC50 curve. For 
displacement binding studies, membranes from cells transiently expressing A2AR-
WT (20 µg proteins/well) were incubated in a total volume of 100 µl Tris-HCl 
buffer (50 mM, pH 7.4) and 5% DMSO with fragments at either a single final 
concentration of 500 µM or 10 × 0.25 log unit dilutions and a final [3H]ZM241385 
(an inverse agonist of the A2AR) concentration of 3 nM or 20 nM of [3H]NECA (an 
agonist of the A2AR).42 Non-specific binding was determined using a final 
concentration of 10 µM ZM241385 and represented less than 10% of the total 
binding. Total binding was determined in the presence of buffer and was set at 
100% in all experiments, whereas non-specific binding was set at 0%. After 
incubation for 60 min (with [3H]ZM241385) or 150 min (with [3H]NECA) at 25 °C, 
assays were terminated by rapid filtration through 96-well GF/B UniFilter plates 
(PerkinElmer) followed by washing with 7 × 0.25 ml ice-cold Tris-HCl buffer (50 
mM, pH 7.4). Plates were dried, 25 µl P-E Microscint 20 was added per well and 
bound radioactivity measured using a Packard Microbeta counter (PerkinElmer). 
Data were analyzed using GraphPad Prism v5, normalized as ‘% specific binding’ 
from which the IC50 values were calculated. Experiments were performed three 
times in duplicate, unless stated otherwise. Experimental ligand efficiency 
(LEAN)32 was defined as LE = −RTln(IC50)/HAC, where HAC is the number of 
heavy atoms in the compounds. 
 Secondly, all TINS fragment hits were assayed in a kinetic A2AR-WT 
orthosteric radioligand dissociation assay using a single time point at which 50% 
of the radioligand has dissociated (under control conditions). Fragments that 
resulted in more than 30% increased or decreased radioligand dissociation (i.e. 
negative or positive allosteric modulation, respectively) were subsequently 
analyzed at multiple time points to determine the complete dissociation curve. 
For kinetic dissociation experiments, 3 nM [3H]ZM241385 or 20 nM [3H]NECA 
was pre-equilibrated with membranes (30 µg proteins/well) for 3 hours on ice; 
dissociation was initiated by addition of 10 µM ZM241385 in the absence 
(control) or presence of 2 mM test compound in a total volume of 5 µl. The 
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amount of radioligand (~50%) still bound to the receptor was measured after 50 
min of dissociation. The amount of specific radioligand binding obtained under 
control conditions was set at 0% for both positive and negative allosteric 
modulators (PAMs & NAMs); the total binding (t = 0 min) was set at 100% for 
PAMs, whereas non-specific binding (in the presence of 10 µM ZM241385) was 
set at -100% for NAMs. The amount of remaining radioligand bound to the 
receptor was measured at various time intervals for a total of 4 hours. 
Incubations were terminated and samples were obtained as described above. 
The dissociation data were fit globally in GraphPad Prism v5 to determine koff. 
Experiments were performed three times in duplicate, unless stated otherwise. 
Selectivity assays using CHO cell membranes stably expressing human 
adenosine A1 receptor:  
 The receptor subtype selectivity of compounds that were positive in the 
kinetic dissociation assay with A2AR-WT using [3H]NECA, was tested in 
[3H]DPCPX42 (an antagonist of the A1R) and [3H]CCPA42 (an agonist of the A1R) 
kinetic dissociation assays using wild type human adenosine A1 receptors stably 
expressed in CHO cell membranes as described previously in the literature.51  
Characterization of allosteric modulation of orthosteric ligand activity by 
intracellular cAMP assay:  
 HEK293 cells were grown and transfected as described above. 
Experiments were performed 48h after transfection. The cells were harvested 
and centrifuged two times at 275 x g for 5 min. For cyclic AMP production and 
determination, 3000 cells/well were used in 384-well Optiplates (PerkinElmer). 
The cells were incubated for 45 min at 37 °C with either the A2AR agonist 
CGS21680 alone or CGS21680 together with test compounds in different 
concentrations. The assay buffer used was PBS with the addition of 5 mM 
HEPES, 0.1% BSA, 50 µM rolipram, 50 µM cilostamide and 0.8 IU/ml adenosine 
deaminase. Basal activity was determined in the presence of assay buffer and 
was set at 0% in all experiments. Maximal receptor activity was determined in the 
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presence of 10 µM CGS21680 and was set at 100% in all experiments. Cells 
were then lysed and the amount of cAMP produced was quantified using a 
LANCE® ultra cAMP kit (PerkinElmer) according to the instructions of the 
manufacturer. Following addition of the detection mixture, plates were left for 1 
hour at room temperature prior to reading using an EnVision® plate reader 
(PerkinElmer Life Sciences).  
Fragment Collection  
 The fragment collection consists of about 1,500 compounds derived from 
a variety of vendors. The philosophy used to design the collection as well as the 
physicochemical properties have been described.25 For quality control purposes 
as well as for formatting the library for TINS, a 1D 1H NMR spectrum of each 
compound was acquired and compared to the expected spectrum based on the 
structure provided by the vendor. Compounds whose purity was less than the 
95% indicated by the vendor were rejected. A randomly selected sub-set of the 
complete collection was chosen to provide proof of principle while reducing the 
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Fragment-based lead discovery (FBLD) is becoming an increasingly 
important method in drug development. We have explored the potential to 
complement NMR-based biophysical screening of chemical libraries with 
molecular docking in FBLD against the A2A adenosine receptor (A2AR), a drug 
target for inflammation and Parkinson’s disease. Prior to an NMR-based screen 
of a fragment library against the A2AR, molecular docking against a crystal 
structure was used to rank the same set of molecules by their predicted affinities. 
Molecular docking was able to predict four out of the five orthosteric ligands 
discovered by NMR among the top 5% of the ranked library, suggesting that 
structure-based methods could be used to prioritize among primary hits from 
biophysical screens. In addition, three fragments that were top-ranked by 
molecular docking, but had not been picked up by the NMR-based method, were 
demonstrated to be A2AR ligands. While biophysical approaches for fragment 
screening are typically limited to a few thousand compounds, the docking screen 
was extended to include 328,000 commercially available fragments. Twenty-two 
top-ranked compounds were tested in radioligand binding assays, and 14 of 
these were A2AR ligands with Ki values ranging from 2 to 240 µM. Optimization of 
fragments was guided by molecular dynamics simulations. The results illuminate 
strengths and weaknesses of molecular docking and demonstrate that this 








1. Introduction  
 The adenosine receptors belong to the family of G protein-coupled 
receptors (GPCRs) and are expressed both in the central nervous system (CNS) 
and the periphery. The four adenosine receptor subtypes (A1, A2A, A2B, A3) are 
responsible for a wide range of physiological processes by acting on different 
signaling pathways. The A2A and A2B adenosine receptors increase cAMP levels 
by coupling to Gs whereas the A1 and A3 subtypes signal via Gi and decrease 
cAMP levels.1 A2A adenosine receptor (A2AR) activation occurs in response to 
stress or cell damage and protects tissues by controlling inflammation. For this 
reason, A2AR agonists are candidates for development of anti-inflammatory 
drugs.2 In the CNS, the A2AR is expressed in the basal ganglia and counter-
balances the action of the D2 dopamine receptor. The two receptors form 
heterodimers in the cell membrane and A2AR activation leads to a decrease in D2 
dopamine receptor signaling.3 Since Parkinson’s disease is characterized by a 
loss of dopamine receptor activity, A2AR antagonists have been studied 
intensively as drug candidates for Parkinson’s disease and several compounds 
are currently in clinical trials.1 
 The rapidly increasing number of crystal structures for G protein-coupled 
receptors (GPCRs) has made structure-based approaches an attractive strategy 
for drug design against these pharmaceutically important targets.4,5 Twelve high-
resolution structures, with bound antagonists or agonists, have been determined 
for the A2AR since the first one was solved in 2008.6-9 Structure-based 
computational ligand discovery based on these structures has been surprisingly 
successful. Two recent molecular docking screens against these structures have 
resulted in the discovery of several novel A2AR antagonists.10,11 The “hit rates” in 
these screens, i.e. the percentages of active compounds among those selected 
for experimental evaluation, were 35 and 41%, which is remarkably good for 
virtual screening. Similar results were achieved in docking screens against the β2 
adrenergic12,13, D3 dopamine14, CXCR415, and H1 histamine receptors16, which 
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further demonstrated the potential for structure-based drug design against these 
targets.  
 During the last decade, fragment-based lead discovery (FBLD) has 
steadily increased in popularity as an alternative to high-throughput screening 
(HTS).17,18 The idea behind FBLD is to identify ligands that are about half the size 
of a drug. The increased coverage of chemical space in fragment libraries makes 
it possible to identify ligands from screens of only a few thousand compounds. 
Ligands from fragment screens are often of low affinity and lack selectivity, but 
can serve as a starting point for the development of new lead compounds. There 
are now a large number of successful examples of where fragment ligands 
identified by crystallography, surface plasmon resonance (SPR), or nuclear 
magnetic resonance (NMR) techniques have been used to generate high-affinity 
leads.17 In fact, several compounds that originate from fragment screens are now 
in clinical trials and the first drug developed from FBLD was approved in 2011.19 
Fragment screens by NMR and SPR have also been carried out against 
GPCRs20,21, but this is still challenging because of difficulties in expressing these 
proteins in large quantities and their inherent instability outside the cell 
membrane. The use of in silico fragment-based screening has also been 
explored successfully, both for GPCRs16,22 and soluble proteins23,24, but 
structure-based approaches have been questioned in this context25. Most 
molecular docking programs were developed for and benchmarked on drug-like 
compounds and thus may have difficulties to rank fragment ligands, which 
typically are of low affinity and only occupy subpockets of a binding site. 
 In this work, we explored fragment-based ligand discovery by carrying out 
two prospective docking screens against a crystal structure of the A2AR. The 
questions that we wanted to address were if molecular docking could be used to 
discover fragment ligands and if in silico methods in combination with biophysical 
screening methods could improve the efficiency of FBLD. In a first step, we 
computationally docked a set of 500 fragments to an A2AR crystal structure and 
ranked these compounds by affinity prior to an NMR-based screen of the same 
library. As the entire library was screened both in silico and experimentally, our 
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blind prediction of the results made it possible to evaluate the utility of molecular 
docking in FBLD. The comparison of the computational and experimental 
screens for the small fragment library showed that a majority of the orthosteric 
ligands were among the top-ranked compounds in the docking screen. In a 
second step, we extended the docking screen to include several hundred 
thousand commercially available molecules and tested top-ranked compounds 
experimentally. The results from this second screen allowed us to directly 
compare the fragment ligands and hit-rates from biophysical and structure-based 
computational screening approaches. Fourteen fragment ligands were 
discovered from the docking screen of this larger set of commercially available 
molecules. The structure-activity relationships (SAR) were explored for three 
novel A2AR ligands, guided by molecular docking and molecular dynamics (MD) 
simulations.  
 
2. Results  
 
Ranking of a Fragment Library by Molecular Docking  
 To test the performance of molecular docking in FBLD against the A2AR, 
parallel experimental and computational screens of an in-house library of 500 
chemically diverse fragments were carried out. Prior to screening the fragment 
library using an NMR-based approach, the same set of molecules was 
computationally docked to the orthosteric site of an antagonist-bound crystal 
structure of the A2AR7 using the program DOCK3.626-28. Each molecule was 
sampled in, on average, 18700 orientations and 16 conformations. For each 
conformation that did not clash with the receptor, a physics-based scoring 
function was used to evaluate the complementarity of the fragment to the 
orthosteric site. The docking score was calculated from the sum of the receptor-
ligand electrostatic and van der Waals interaction energy, corrected for 
desolvation of the ligand. The best scoring conformation for each fragment was 
used to rank these molecules by their predicted affinity to the A2AR. In total, 487 
of the 500 fragments were successfully scored in the orthosteric binding site. The 
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average computation time per docked molecule was 10 seconds and, in total, 
only 80 minutes were required to screen the library. 
 
Comparison of NMR-Based and Molecular Docking Screens of a Fragment 
Library  
 Given the low affinity and specificity of typical fragment ligands, the 
molecular docking technique can be expected to have difficulties to rank such 
compounds by affinity. As every library molecule was tested for binding to the 
A2AR in the NMR-based screen, this gave a unique opportunity to assess the 
ability of molecular docking to discriminate between fragment ligands and 
experimentally verified non-binders.  
 The details of the methodology and experiments used to screen the 
fragment library against a thermostabilized mutant29 of the A2AR by NMR have 
been presented in separate publications.21,30 The results of the NMR-based 
screen of the fragment library are presented briefly in this section to enable a 
comparison to the docking predictions. Five hundred fragments, which were 
selected to represent a diverse set of molecules in terms of shape and 
chemistry31, were screened using the target immobilized NMR screening (TINS) 
technique30. The TINS screen resulted in 94 primary hits, which were further 
evaluated in radioligand displacement assays. Five molecules showed more than 
30% displacement of the radioligand at 500 µM and had well-behaved dose 
response curves, which corresponds to a hit-rate of 5% for the secondary screen. 
The five hits are shown in Table 1 and the Ki values for these compounds ranged 
from 14 to 600 µM. Another key metric for judging the potential of a fragment 
ligand is its ligand efficiency (LE). The LE value was calculated as RTlnKi/Ni, 
where Nl is the number of heavy atoms.32,33 The best LE value for the fragments 
discovered in the NMR-based screen was 0.53 kcal mol-1 atom-1, which is in the 
range considered to be promising for further optimization (typically >0.35 kcal 
mol-1 atom-1). Additional experiments revealed that 11 of the initial hits were 
either positive or negative allosteric modulators of the A2AR.21 The remaining 79 
hits were not found to displace radioligands from the orthosteric site or 
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allosterically modulate agonist or antagonist binding. These compounds were 
considered to be less potent fragment ligands, bind to regions that do not 
influence ligand binding to the A2AR orthosteric site, or be false positives.  
 To assess how well the docking was able to predict the results of the 
fragment screen, we generated receiver operating characteristic (ROC) curves 
for the identified ligands based on the predicted ranking for the compounds in the 
library. As the docking calculations only sampled fragment orientations in the 
orthosteric site, we did not expect to identify any allosteric ligands. For this 
reason, the ligands were divided into an orthosteric and allosteric group, which 
made it possible to directly compare the computational and NMR-based 
screening results. The ROC curves for the ortho- and allosteric ligands are 
shown in Figure 1. To quantify the ability of DOCK3.6 to identify ligands, we 
evaluated enrichment factors at different false positive rates (ROC_EFx%, where 
x denotes the false positive rate).34 For example, the ROC_EF5% value was 
calculated as the fraction of true positives (ligands) identified when 5% of the 
false positives (non-binders) had been found in the ranked list divided by the 
fraction of false positives at that point, i.e. 0.05 in this case.35 No enrichment of 
orthosteric ligands was found at 0.5%-1% false positive rate. One ligand was 
identified at a 2% false-positive rate, corresponding to an enrichment factor of 10. 
Four out of five orthosteric ligands were identified in the top 5% of the ranked 
database, which corresponded to an ROC_EF5% equal to 16, i.e. a 16-fold 
improvement over random selection (Figure 1, red curve). The fifth orthosteric 
ligand, compound 4, was not scored at all, which was due to the sampling 
scheme used in DOCK3.6. If the sampling parameters were (retrospectively) 
adjusted to determine a score for compound 4, it was ranked as ∼160 and would 
hence not have affected early enrichment. The enrichment of orthosteric ligands 
from the subset of 94 primary hits in the NMR-based screen was also calculated. 
The enrichment in this case was remarkably good, ranking four of the ligands in 
the very top of the database (Figure 1, gray curve, ROC_EF0.5% = 120). Finally, 
as may have been expected, the enrichment of allosteric modulators was poor, 
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as reflected by that the ROC curve was closer to random enrichment (Figure 1, 
blue curve). Predicted binding poses for two of the orthosteric ligands from the 
NMR-based screen, compounds 1 and 5, are shown in Figure 2. Both 
compounds interact with Asn2536.55 of the A2AR, a residue that been shown to be 
critical for recognition of both agonists and antagonists.36 
 
Figure 1. ROC curves for docking enrichment of orthosteric (red line) and allosteric (blue line) 
ligands discovered in the NMR-based screen. The enrichment of orthosteric ligands among the 
94 molecules from the NMR-based screen that were selected for follow-up radioligand assays is 
also shown (grey line). The black line represents the curve expected from random enrichment. 
 
 
Figure 2. Predicted binding modes for two ligands (1 and 5) that were discovered in the NMR-
based screen. The binding site is shown in white ribbons with selected side chains shown in 
sticks. The ligand is depicted with orange carbon atoms. Black dotted lines indicate hydrogen 
bonds. This figure was generated with PyMOL (version 1.4.1). 
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 After assessing the ability of molecular docking to predict the results of the 
NMR-based screen, the top-ranked fragments from the docking calculations were 
analyzed in more detail. It was encouraging that 80% of the orthosteric ligands 
were among the top 50 compounds of the ranked library. However, this also 
suggested that there were 46 top-ranked inactive compounds for which the 
docking algorithm had predicted similar or better binding energies. To try to 
understand the origin of these false positives from docking, the pose for each of 
the top-ranked 50 compounds was inspected visually. If general problems with 
the scoring function could be identified, this information could be valuable for 
further development of the molecular docking algorithm. Two observations were 
made from this analysis. First of all, there were several cases where polar groups 
of the fragments or the receptor did not form hydrogen bonds, but were still 
desolvated to a large extent, which should be energetically unfavorable. Whereas 
the ligand desolvation is taken into account by the scoring function in DOCK3.6, 
the receptor desolvation energy contribution is ignored.37 This may be a 
reasonable approximation for lead- or drug-like compounds that fill the entire 
binding site, resulting in a constant desolvation energy contribution. Fragments, 
on the other hand, often occupy subpockets of the binding site and in these 
cases the desolvation term could vary significantly and thus be crucial for 
accurate ranking.38 The second observation was that there were several top-
ranked fragments for which no obvious problems could be identified. Instead, we 
would likely have predicted several of them to be ligands in a prospective screen 
against the A2AR. To test if any of these were false negatives from the NMR-
based screen, we selected five compounds from the top 10% of the ranked 
library for experimental re-screening in radioligand displacement assays. These 
five molecules had all been screened by the NMR-based method, but were not 
among the 94 compounds that were tested in follow-up assays. Three out of five 
compounds showed >50% displacement of radioligand binding at 500 µM. The 
dose-response curves demonstrated that they were orthosteric ligands with Ki 
values equal to 17.6, 20.6 and 128 µM (Compounds 6-8, Table 1). Compound 6 
was ranked as number 34 in the docking screen and had the highest LE of all 
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A2AR fragment ligands discovered by docking or NMR (LE = 0.56 kcal mol-1 atom-
1) and the predicted binding mode for this compound is shown in Figure 3A. 
Given the potency of these three fragments, it is possible that they have relatively 
slow off-rates rendering them less sensitive to ligand observed NMR techniques 
such as TINS.  
 
 
Figure 3. Predicted binding mode for a fragment 
ligand (compound 6) from the small fragment library 
that was discovered by docking. The binding site is 
displayed as a white cartoon with selected side 
chains shown in sticks. The ligand is depicted with 
orange carbon atoms. Black dotted lines indicate 
hydrogen bonds. This figure was generated with 




Molecular Docking Screen of Commercially Available Fragments Against an 
A2AR Crystal Structure  
 Although the positive enrichment of A2AR ligands in the fragment library 
was encouraging, a more interesting test of docking performance would be to 
extend the number of molecules screened to all commercially available or even 
all synthetically feasible fragments, e.g. the 166 billion compounds in the GDB-
17.39 One major strength of the in silico approach comes from the ability to 
screen large libraries and reduce the fraction that is tested experimentally to a 
small number of chemicals. This would enable a more realistic comparison of a 
typical experimental fragment-based screen to a computational structure-based 
approach. Screening of a larger chemical library could be also advantageous 
because of better coverage of chemical space, which gives the opportunity to 
discover ligand chemotypes that were not available to the NMR-based screen. 
On the other hand, ranking several hundred thousand disparate fragments by 
affinity is a tremendous challenge and, as only a few hundred top-ranked 
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compounds are considered for experimental testing, one may actually expect that 
molecular docking would perform worse for screening of large chemical libraries. 
 To test the utility of large-scale docking screens in FBLD, we docked 
328,000 commercially available fragments from the ZINC library40 to an A2AR 
crystal structure using DOCK3.6. The same receptor structure, sampling scheme, 
and physics-based scoring function as in the first screen were used. The docking 
of the library was completed in seven hours on 222 cores at a local computer 
cluster and each molecule was sampled in, on average, 12800 orientations and 
40 conformations. The top-ranked 500 compounds, corresponding to 0.15% of 
the screened library, were considered for experimental testing. There was 
essentially no overlap of compounds between this set of molecules and the 
library screened by the NMR-based method. Only one molecule from the small 
library screened by NMR would have ranked among the top 500 in the docking 
screen. Twenty-two top ranked molecules from the docking screen of large 
fragment library (0.007%) were selected for experimental testing based on their 
complementarity to the orthosteric site and availability from commercial vendors.  
 The twenty-two predicted fragment ligands were first tested in radioligand 
assays at 500 µM and 14 molecules showed significant radioligand displacement. 
Subsequent dose-response curves were well behaved (Figure 4), and the Ki 
values ranged from 2 to 240 µM (Table 2, compounds 9-22). With the same 
affinity cut-off as in the NMR-based screen (Ki < 600 µM), the hit-rate from the 
docking screen was 64%. Although it is difficult to compare screens against 
different GPCRs, our results were similar to the fragment-based docking 
campaign against the histamine H1 receptor, which achieved an unprecedented 
hit-rate of 73% and identified several potent ligands.16 Compared to the two 
previous docking screens of lead-like libraries against the A2AR,10,11 we achieved 
higher hit-rates, but the affinities of the discovered ligands were typically lower, 
as expected for fragment screening. To enable a comparison between the hits 
from our fragment screen and those discovered from docking of lead-like libraries 
against the same crystal structure, LE values (at 310 K) were calculated for each 
study. The LE values for the fragments from our in silico screen ranged from 0.29 
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to 0.56 kcal mol−1 atom−1 with an average equal to 0.40, which was similar to the 
results of Carlsson et al. (0.29−0.44 kcal mol−1 atom−1, average = 0.37)10 and 
Katrich et al. (0.32−0.52 kcal mol−1 atom−1, average = 0.41).11 
 
 
Figure 4. Representative concentration-effect curves for displacement of binding of the 
radiolabeled A2AR inverse agonist [3H]ZM241385 by compounds 9, 10, 11, and 12.  
 
 The NMR-based and docking screens are summarized in Figure 5. Five 
orthosteric ligands were identified in the NMR-based screen, corresponding to a 
hit-rate of 5% from the secondary screen, and 14 fragment ligands or 64% of 
those tested experimentally were discovered by docking. Compared to the NMR-
based screen, the hits from the A2AR docking screen had lower Ki values. Four of 
the hits from the docking screen were more potent than the compound with the 
highest affinity from the NMR-based screen. A similar trend was observed for the 
LE values. Ten compounds from the docking screen had LE values >0.35 kcal 
mol-1 atom-1. In comparison, two compounds from the NMR-based screen 
reached this level. To investigate the novelty of the discovered fragment, we 
calculated the pairwise Tanimoto similarity with extended chemical fingerprints 
for four atoms (Tc, ECFP4) of each hit to the thousands of known A2AR ligands in 
the ChEMBL1441 database. The Tanimoto coefficient (Tc) quantifies the two- 
dimensional chemical similarity between two molecules by a value between 0 
and 1. A Tc value close to zero suggests no chemical similarity between a pair of 
molecules, whereas a value equal to one represents two identical molecules. For 
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each discovered ligand, the highest Tc value among the previously characterized 
A2AR ligands is presented in Tables 1 and 2. Some of the hits from the NMR-
based and docking screens were relatively similar to known adenosine receptor 
ligands, e.g. compounds 4 and 9 (Tc > 0.4), but in both cases relatively novel 
chemotypes for the A2AR were also discovered (e.g. compounds 2, 5, 11 and 14), 
as reflected by their lower Tanimoto coefficients (Tc = 0.28-0.33). Predicted 
binding modes for compounds 10, 11, 12, and 13 are shown in Figure 6 and 7. 
As shown in Figure 6, these compounds were predicted to bind deep in the 
orthosteric binding site. The key interactions for the fragments are hydrogen 
bonds to Asn2536.55 and Glu1695.30 together with π-stacking against the side 
chain of Phe1685.29 (superscripts denote Ballesteros-Weinstein numbers42), 
which is consistent with the ligand interactions observed in several of the twelve 
available A2AR crystal structures (Figure 7).6-9  
 
 
Figure 5. Summary of the discovery of orthosteric ligands from the NMR-based and docking 
screens. Primary screens were carried out using NMR-based (NMR/TINS) and docking 





Figure 6. Predicted binding modes for compounds 10, 11, 12, and 13 in the orthosteric site of the 
A2AR crystal structure. The A2AR is displayed as a white cartoon, and the four ligands are 
depicted with orange carbon atoms. This figure was generated with PyMOL (version 1.4.1).  
 
Structure-Activity Relationships and Molecular Dynamics Simulations for 
Analogs of Compounds 10, 11, and 12 
 To explore the SAR for the ligands and investigate how the fragments 
could be further optimized, we docked commercially available analogs of the 
three potent compounds 10, 11, and 12 to the A2AR orthosteric site. A series of 
23 compounds were selected based on their predicted interactions in the 
orthosteric site and were tested in radioligand binding assays. Molecular docking 
in combination with MD simulations was used to guide analog selection and to 
investigate the predicted binding modes of the screening hits. 
 Compound 10 was one of the most potent fragment ligands from the 
screen with a Ki value of 6.4 µM. The compound also had a promising LE value 
equal to 0.46 kcal mol-1 atom-1. The binding mode of compound 10 remained 
stable over one ns of MD simulation with no significant conformational changes in 
the orthosteric site. The exocyclic amine and triazole group formed strong 
interactions with Asn2536.55 in the simulation, whereas the phenyl group was 
deeply buried in a hydrophobic pocket created by Val843.32, Leu853.33, and 
Trp2466.48. MD simulations of compound 10b suggested that it substituents that 
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extended further towards the extracellular loops could be accommodated by the 
binding pocket. Six analogs of compound 10 were tested to further investigate 
the binding mode of the ligand (Table 3). Possibilities for optimization of this 
fragment were first explored by replacing the ethyl with a methyl and propyl 
substituent (10a and 10b). Reducing the alkyl chain to a methyl led to a 2-fold 
reduction of affinity, whereas the propyl substituent did not affect the potency. 
The retention of the potency by the compound with the longer substituent agreed 
with the predicted interactions with hydrophobic side chains in the opening of the 
orthosteric site, e.g. Ile2747.44 and Met2707.35. This suggests that further 
optimization could be achieved by combining 10b with fragments that extend 
further toward the extracellular loops. Substitutions on the phenyl ring in the para-
position with a methyl-, chlorine-, or methoxy-group led to reductions of the 
binding affinity in all cases (10c-e). The decrease in affinity for the largest 
substituent was consistent with the prediction that this group was located in an 
enclosed pocket, in agreement with the predicted binding mode (Figure 7A). 
Replacing the phenyl group of compound 10b with a pyridine ring led to a ten-fold 
decrease in binding affinity to 50 µM (10f). To investigate the reasons for this 
large reduction of affinity, we calculated the difference in free energy of binding 
for these compounds using MD free energy calculations. MD simulations were 
used to alchemically transform compound 10b to 10f in the A2AR orthosteric site 
and in aqueous solution by employing the free energy perturbation (FEP) 
technique. From these calculations, the difference in binding free energy between 
the two ligands can be calculated from a thermodynamic cycle.41 The calculated 
free energy difference between compounds 10b and 10f was +1.2 ± 0.1 kcal/mol, 
in close agreement with the experimental 10-fold loss of affinity caused by the 
pyridine group. Inspection of the MD trajectories suggested that the reason for 
the calculated reduction of binding affinity was a loss of favorable solvent 
interactions for the pyridine group in the bound state (Figure 8). 
 Compound 11 was one of the more novel fragment ligands identified in the 
docking screen (Tc = 0.28) and relatively potent with a Ki value of 6.3 µM. Based 
on molecular docking and MD simulations of selected fragments, eleven 
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compounds were selected for experimental testing in radioligand binding assays, 
which are summarized in Table 4. This congeneric series of fragments explored 
variations on the pyridine group of compound 11, which was predicted to interact 
with residues in the opening of the orthosteric site. Compound 11a, for which the 
nitrogen of the pyridine ring was moved to the ortho position, was slightly more 
potent than the initial hit. On the contrary, replacing the pyridine with a phenyl led 
to a 3-fold reduction of the Ki value to 18 µM (11b). For compounds 11c-i, the 
effects of polar and non-polar substituents on the phenyl ring of compound 11b 
were explored. In the ortho-position, polar (11c), non-polar (11d), and halogen 
substituents (11e-f) improved binding affinity with Ki values ranging from 5.5 to 
8.8 µM. In meta-position, a methyl substituent (11g) did not affect affinity relative 
to compound 11b, whereas an increase in polarity at this position was found to 
improve the affinity (11a). In para-position, a polar substituent (11h) led to a 2-
fold improvement of affinity whereas a methyl group was not tolerated and 
reduced the Ki value to 60 µM (11i). The observed effects on affinity for ortho- 
and meta- substitutions on the phenyl ring could be explained by the interactions 
with residues in the opening of the orthosteric site, as this position is close to 
both polar and non-polar groups in the opening of the orthosteric site. However, 
the changes in affinity for polar and non-polar substitutents in the para-position 
could not be explained by our model because this position was typically solvent 
exposed in the predicted binding mode and in the MD simulations (Figure 7B). 
This may be related to interactions with flexible parts of extracellular loop two, 
e.g. two rotamers of Glu1695.30 that have been observed in crystal structures.6-9 
Two additional compounds were designed by combining hydroxyl substituents in 
ortho- and para-postions with a methoxy group in meta-postion (compounds 11j 
and 11k, respectively). The most potent compound, 11k, had an affinity of 2.4 
µM, which is eight-fold better than compound 11b and a 2-fold improvement 
compared to the initial hit from the docking screen. The MD simulation of 
compound 11k suggested that the methoxy substituent complements the shape 




Figure 7. Predicted binding modes for four ligands discovered in the molecular docking screen: 
(A) 10 (B) 11, (C) 12, (D) 13. The binding site is shown in white ribbons with selected side chains 
shown in sticks. The ligand is depicted with orange carbon atoms. Black dotted lines indicate 
hydrogen bonds. This figure was generated with PyMOL (version 1.4.1). 
 
            
Figure 8. Representative molecular dynamics snapshot of 
the A2AR in complex with compound 10f. The binding site is 
shown in white ribbons and selected side chains shown in 
sticks. The ligand is depicted with orange carbon atoms. 
Water molecules are shown as red spheres. Black dotted 
lines indicate hydrogen bonds. This figure was generated 




Figure 9. Representative snapshot from molecular 
dynamics simulation of the A2AR in complex with compound 
11k. The extracellular part of the A2AR is shown in surface 
representation and the ligand is depicted with orange 





 The affinity of compound 12 was 6.8 µM and this fragment had a LE value 
of 0.43 kcal mol-1 atom-1. In the predicted binding mode of this ligand, it is almost 
completely buried in the orthosteric site with the 1,2,4-triazolo[1,5-a]pyrimidine-2-
amine group hydrogen bonding with Asn253 and forming stacking interactions 
with the side chain of Phe168 (Figure 7C). The phenyl group of compound 12 
occupied part of the sub-pocket where the ribose ring of A2AR agonists is located 
in crystal structures. MD simulations of this fragment suggested that the 
compound likely explores multiple conformations in the site. In these simulations 
hydrogen bonds to either Asn253 or Glu169 were conserved, but the phenyl ring 
explored several subpockets. Six additional compounds in this series were tested 
experimentally in radioligand binding assays and the results are summarized in 
Table 5. The compound without any substituents on the phenyl ring was 15-fold 
less potent than the initial hit, Ki = 101 µM (12a), demonstrating that the Cl in 
meta-position of compound 12 was essential for binding. In the next step, a Cl in 
para-position was tested, but this compound was also inactive. Subsequently, a 
methyl group was added to the pyrimidine group, which resulted in a 50-fold 
improvement of affinity to 2 µM and an increase of the LE to 0.47 kcal mol-1 atom-
1 (12c). Substituents in the para-position on the phenyl group on this compound 
(12d-f) did not further improve the affinity of the series. The predicted binding 
mode for compound 12c was in good agreement with the observed changes in 
affinity for the series. The methyl substituent that improved the affinity of 
compound 12c to 2.1 µM was positioned in a hydrophobic pocket formed by 
Val843.32, Leu853.33, and Trp2466.48. Almost complete 
burial of the compound in the orthosteric site was 
likely to be responsible for its high efficiency. 
(LE=0.47 kcal mol-1 atom-1, Figure 10) 
Figure 10. Predicted binding modes for compound 12c. The 
binding site is shown in white ribbons with selected side chains 
shown in sticks. The ligand is depicted with orange carbon 
atoms. Black dotted lines indicate hydrogen bonds. This figure 




Selectivity and Efficacy for the Discovered Fragment Ligands 
 One advantage of fragment-based screening is that high hit-rates are 
often achieved, but the ligands that are discovered are typically not selective for 
their target. To test the selectivity profile for the fragment ligands that emerged 
from the in silico screen, all compounds were also tested against the A1R 
subtype in radioligand binding assays. Two of the more potent fragments ligands 
were also tested in cyclic-AMP (cAMP) assays. For the fourteen fragments 
discovered in the docking screen (Table 2), no significant selectivity for the A2AR 
was found. On the contrary, several ligands actually had better affinities for the 
A1R, with an average 2-fold selectivity for this subtype. The maximal A1 
selectivity among the more potent compounds was a 4-fold difference in affinity 
for compound 15. A similar trend was observed for the analogs of compounds 10, 
11, and 12 (Tables 3, 4, and 5). For the two smaller fragments, 10 and 12, no 
significant selectivity for A2A over the A1 subtype was found for any of the 
analogs. Several of the analogs of compound 11 approached the size of lead-like 
compounds, and it was also among these compounds that some selectivity for 
the A2AR was observed. The most potent compound in the series (11k), had an 
affinity of 2.4 µM at the A2AR, but it was a 4-fold weaker ligand for the A1 subtype.  
 Two of the more potent fragments from the docking screen, compounds 
10 and 11, were also tested for their behavior in cAMP assays. Addition of 10 µM 
of each compound resulted in a rightward shift of the agonist (CGS21680) 
concentration-effect curve as expected for antagonists (Figure 11). This result is 
in agreement with previous docking screens of lead-like libraries against A2AR 
crystal structures in the inactive state 
that, to our knowledge, only have 
resulted in the discovery of 
antagonists.10,11,44 
Figure 11.  Functional assay based on 
measuring the concentration-dependent 
production of cAMP by A2AR agonist CGS21680 
for compounds 10 and 11. 
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3. Discussion   
 
 The revolution in GPCR structural biology during the last years has made 
it possible to take advantage of structure-based methods in ligand discovery 
against these pharmaceutically important targets. During the same period, FBLD 
has become widely used in drug discovery, but there are only a few examples of 
the use of experimental20,21,45,46 and in silico16,47 fragment screens against 
GPCRs. To assess the potential benefits of complementing biophysical screens 
against GPCRs with structure-based discovery of fragment ligands, we carried 
out two prospective molecular docking screens against the A2AR, a drug target 
for development of drugs against inflammation and Parkinson’s disease.2,3 The 
parallel screen of a small chemical library against the A2AR allowed us to 
evaluate the ability of molecular docking to distinguish fragment ligands of the 
receptor. A second comparison was made possible by the large-scale screen of 
commercially available fragments and subsequent experimental testing of top-
ranked compounds.  
 The first encouraging result was the ability of molecular docking to identify 
all but one of the hits from the NMR-based screen among the 30 top-ranked 
compounds. The results are similar to the parallel docking and HTS screen of 
200,000 drug- like compounds against Cruzain by Ferreira et al., in which several 
inhibitors were among the top-ranked compounds.48 It should be noted that 
significantly higher enrichment of ligands has been reported by Katritch et al. in a 
benchmark of molecular docking against the same A2AR crystal structure.11 As 
only lead- to drug-like compounds were used in these retrospective screens, this 
result could suggest that it is more challenging for docking to identify fragment 
ligands. However, it could also reflect differences in the scoring functions 
used and how the non-binders (decoys) were selected. The main finding from the 
two in silico screens that were undertaken in this work was the ability of the 
molecular docking to complement the biophysical screen for fragment ligands of 
the A2AR. One of the main advantages of fragment-based screening compared to 
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HTS is that the high hit-rates provide numerous starting points for development of 
lead compounds.17,18 However, prioritizing between a large number of primary 
hits from biophysical screens, a total of 94 from the NMR-based method 
analyzed here, is often difficult and time-consuming.21 The successful prediction 
of the NMR-based screening results strongly suggests that it is advantageous to 
carry out docking screens in parallel and use the results to select hits for follow-
up testing to reduce the number of false positives. This approach would also 
provide a starting point for structure-based optimization of fragments. 
Interestingly, a recent comparison between fragment-based screens with 
different biophysical approaches showed that different sets of ligands are 
identified using the two methods.49 To some extent, this likely reflects challenges 
in detecting low-affinity fragments and suggests that a combination of several 
orthogonal methods could reduce the number of false negatives and positives 
from biophysical screens. Our results demonstrate that molecular docking also 
could play such a role. Several fragments that were top-ranked by docking, but 
had not been identified by the NMR-based screen, were micromolar ligands with 
high ligand efficiencies.  
 The parallel screen also demonstrated major weaknesses of molecular 
docking screens. As in a majority of all structure-based virtual screens, the 
receptor volume searched by the docking algorithm was reduced to one pocket 
on the protein surface. The consequence of this approximation was that allosteric 
modulators could not be identified. On the contrary, the NMR-based screen led to 
one of the first discoveries of compounds with positive and negative allosteric 
effects on ligand binding to the A2AR.2,3 The obvious solution would be to extend 
the searched volume to include the entire receptor surface, but this would be too 
computationally expensive for screening of large chemical libraries. Multiple 
pockets could be considered, but it is not yet clear where the allosteric ligands 
bind to the A2AR, and it would also be a major challenge for docking scoring 
functions to rank molecules in sites of different sizes and chemical properties. 
Modulation of receptors via allosteric interactions may provide novel opportunities 
for development of completely new classes of drugs against the A2AR.50 
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 The second docking screen unleashed the full potential of the structure-
based approach. Several hundred thousand fragments were docked to the A2AR 
crystal structure to identify compounds that complement this receptor 
conformation. As only a few dozen compounds are evaluated experimentally in 
this case, more extensive testing can be carried out for each compound, which 
reduces the risk for false negatives. As in earlier in silico screens against A2AR 
and other GPCR crystal structures, the hit-rates were unusually high.10−16 It may 
be the combination of a highly ligandable orthosteric site48 and bias in chemical 
libraries toward GPCR chemotypes that make structure-based screens against 
these receptors so successful.10,12 If this is true, the successes for deep and 
enclosed binding sites, which are characteristic for the adenosine and aminergic 
receptors, may not be transferrable to GPCRs with more shallow and solvent 
exposed pockets. The observation that biophysical screens of fragments 
generally yield higher hit-rates than those that rely on lead- or drug-like libraries 
was also demonstrated to be true for in silico screens. Several ligands from the 
docking screen were also more potent than expected from the typical fragment 
screens, both in comparison to screens against soluble proteins and the NMR- 
based screen against the same target.20,21,45 
 Successful FBLD relies on the possibility to optimize the initial hits, and, in 
this step, access to atomic resolution structures provides valuable information. 
However, in the case of predicting affinities for a series of analogs, subtle 
structural changes of the receptor may be responsible for differences in potency, 
which may require a more accurate representation of protein−ligand interactions 
than molecular docking can provide.51 Initial attempts to use more rigorous 
methods in lead optimization of GPCR ligands have been encouraging, and such 
approaches will likely also play an important role in FBLD against these 
receptors.52,53 An increasing amount of computational resources has made it 
possible to use atomistic simulations to compute the relative affinities for large 
series of protein−ligand complexes.54,55 The small size and relatively good 
availability of force field parameters for fragment-like molecules make them ideal 
cases for MD simulations and free energy calculations. Here, three new scaffolds 
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from the in silico screen were further explored via analogs and MD simulations of 
several complexes. The MD simulations provided a deeper understanding of the 
SAR for analogs of the docking hits, and free energy calculations were used to 
explain changes in binding affinity due to changes in ligand structure. Two of the 
scaffolds were optimized to an affinity of 2 µM. In particular these compounds, as 
well as the 15 other discovered fragments that were left unexplored, provide new 
starting points for development of new lead compounds against this medically 
important target.  
 Drug design against GPCRs also involves identifying compounds with a 
specific efficacy and selectivity profile. The fragments that were tested for 
efficacy were all antagonists, and this was consistent with that the screen was 
carried out against a crystal structure in the inactive state. Fragment ligands are 
typically not selective for their targets, and this is also a general challenge for the 
A2AR because of the strong sequence conservation in the orthosteric site among 
the four subtypes.1 None of the ligands discovered in the NMR-based or docking 
screens showed significant selectivity for A2AR over the closely related A1 
subtype, which likely reflected that the fragment hits explored the conserved core 
of the binding site. If anything, the styryl moiety in compound series 11 had been 
found as a chemical substructure contributing to A2A receptor selectivity before, 
and indeed in this series there was some selectivity for this receptor subtype 
too.56 The refined binding modes for the most potent compounds now provide 
starting points for optimization of selectivity. In this case, future crystal structures 
and models of other adenosine receptor subtypes will be crucial for optimizing 





 The picture that emerges from this study is that fragment-based ligand 
discovery via biophysical and computational structure-based screens are highly 
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complementary approaches. Both the NMR- and molecular docking based 
screens identified novel A2AR fragment ligands with no overlap between the two 
sets of hits. Molecular docking was shown to be a highly efficient method for the 
identification of fragments ligands, as reflected by the 64% hit-rate achieved in 
this screen. On the other hand, the unbiased experimental screen of a relatively 
small fragment library unexpectedly discovered allosteric modulators of the A2AR, 
which will provide new opportunities for drug development against this receptor. 
The opportunities to combine biophysical and in silico screening methods with 
structure determination for GPCRs will likely position FBLD as one of the 
principal approaches for drug development against this pharmaceutically 




Molecular Docking Calculations  
 All docking calculations were carried out with the program DOCK3.626-28 
using a 2.6 Å resolution crystal structure of the human A2AR in complex with an 
antagonist (PDB accession: 3EML7). The receptor was prepared by removing all 
non-protein atoms and the intracellular T4-lysozyme insertion. The protonation 
states of ionizable residues of all Asp, Glu, Arg and Lys residues were set to the 
most probable in aqueous solution at pH 7. The protonation states of the 
histidines were set by manual inspection (His2787.43: protonated in delta position, 
His2506.52: protonated in epsilon position, His2646.66: double protonated). 
 The flexible ligand sampling algorithm in DOCK3.6 superimposes atoms of 
the docked molecule onto binding site matching spheres, which indicate putative 
ligand atom positions. Sixty matching spheres were used, and these were either 
based on the atoms of the crystallographic ligand or positioned manually.27,28 The 
spheres were also labeled for chemical matching based on the local receptor 
environment.59 The degree of ligand sampling was determined by the bin size, 
bin size overlap, and distance tolerance. These three parameters were set to 0.4 
Å, 0.2 Å, and 1.5 Å, respectively, for both the binding site matching spheres and 
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the docked molecules. An initial filter discarded conformations that had more than 
one overlapping heavy atom with the receptor. An overlap between two atoms 
was defined as a distance shorter than 2.3 and 2.6 Å for polar and non-polar 
atoms, respectively, and was calculated from a precalculated grid. For ligand 
conformations passing this steric filter, a physics-based scoring function was 
used to evaluate the fit to the binding site. For the best scoring conformation of 
each docked molecule, 100 steps of rigid-body minimization were carried out.27,28 
The score for each conformation was calculated as the sum of the 
receptor−ligand electrostatic and van der Waals interaction energy, corrected for 
ligand desolvation. These three terms were evaluated from precalculated grids. 
The three-dimensional map of the electrostatic potential in the binding site was 
prepared using the program Delphi.60 In this calculation, partial charges from the 
united atom AMBER force field61 were used for all receptor atoms except the side 
chain amide of Asn2536.55, for which the dipole moment was increased to favor 
hydrogen bonding to this residue.10 The program CHEMGRID was used to 
generate a van der Waals grid, which is based on a united atom version of the 
AMBER force field.62 The desolvation penalty for a ligand conformation was 
estimated from a precalculated transfer free energy of the molecule between 
solvents of dielectrics 78 and 2. The desolvation energy was obtained by 
weighting the transfer free energy with a scaling factor that reflects the degree of 
burial of the ligand in the receptor binding site.37,63 
 Prior to the DOCK3.6 calculation, each docked library was prepared for 
docking by pre-generating up to 600 conformations using the program OMEGA.64 
Partial atomic charges and transfer free energies were calculated using 
AMSOL63,66 and van der Waals parameters were derived from an all-atom 
AMBER potential.67 Two libraries were screened. The first was an in-house 
fragment library of 500 compounds.31 The second was the ZINC fragment-like 
library40 of 328,000 commercially available molecules (molecular weight < 250,  





Similarity Calculations  
 Similarity calculations for the fragments were carried out using Screenmd 
program from Chemaxon.68 We calculated the maximum Tanimoto coefficient 
with ECFP4 fingerprints between each discovered fragment ligand to the 6509 
compounds with recorded activity against the human A2AR in the ChEMBL1441 
database.  
 
Molecular Dynamics Simulations and Free Energy Calculations 
 The molecular dynamics simulations (MD) and binding free energy 
calculations for the A2AR were performed using a recently published high-
resolution crystal structure (PDB accession code: 4EIY9, 1.9 Å). In the first step, 
a hydrated POPC membrane was first equilibrated around the A2AR structure 
without any ligand using periodic boundary conditions in GROMACS69 using the 
OPLSAA force field,70 TIP3P waters,71 and Berger lipids.72 In this simulation, all 
protein atoms were tightly restrained to their initial coordinates, and the hydrated 
membrane was equilibrated for 40 ns at 300 K. All other MD simulations and free 
energy calculations of the protein-ligand complexes were carried out starting from 
the membrane equilibrated A2AR system using spherical boundary conditions in 
the program Q.73 All ligand force field parameters were obtained using 
Schrodinger’s program hetgrp_ffgen.74 The simulations were carried out at a 
constant temperature of 310 K in a sphere of 18 Å radius centered on the ligand. 
All protein, water, and ligand atoms within 18 Å of the center of the sphere were 
explicitly included in the simulations. All atoms outside the sphere were tightly 
restrained to their initial coordinates and excluded from nonbonded interactions. 
Asp, Glu, His, Lys, and Arg residues within the spherical system were protonated 
as in the docking calculation. All other ionizable residues close to the sphere 
edge or further away than 18 Å were set to their neutral state. The SHAKE75 
algorithm was applied to all solvent bonds and angles and the water molecules at 
the sphere surface were subjected to radial and polarization restraints.73,76 A 
nonbonded cutoff of 10 Å was used for all atoms except the ligand, for which no 
cutoff was applied. Long-range electrostatic interactions were treated with the 
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local reaction field (LRF) multipole expansion method.77 The time step was set to 
1 fs, and nonbonded pair lists were updated every 25 steps.  
 For the docking hits and analogs that were studied with MD simulations, 
each protein-ligand complex was equilibrated for 810 ps. During the equilibration, 
harmonic restraints on the protein and ligand atoms were gradually released, 
which was followed by one ns of unrestrained simulation. To compute the relative 
free energy of binding from a thermodynamic cycle, the ligands have to be 
transformed to each other in water and the A2AR binding site. The free energy of 
transforming ligand 10b to 10f was computed using the free energy perturbation 
(FEP) technique, and the calculation was carried out via several intermediates.78 
The potentials governing the intermediate states are defined by Um = λmUA + (1 − 
λm)UB where A and B represent two different ligands, respectively, and λm is a 
mapping parameter which varies from λ1 = 0 to λn = 1. The free energy difference 
between states A and B can be calculated by summing up the free energy 
differences of the n intermediate states using                            
     
where  represents an ensemble average on the potential Um, which is 
calculated from MD simulations.43 The free energy was computed in two steps. 
First the van der Waals parameters of the phenyl ring of compounds 10b were 
transformed to the pyridine of compound 10f. In a second step, the charges for 
the same group were changed to those representing pyridine. These calculations 
were carried out both for the ligand in aqueous solution and in the A2AR 
orthosteric site. The calculations in aqueous solution were carried out by 
solvating the ligand in a water droplet of radius 18 Å. In these simulations a weak 
harmonic restraint was applied to keep the ligand close to the center of the 
sphere. Each FEP calculation comprised a 700 ps heating scheme through eight 
steps of equilibration. The transformation of partial charges and LJ parameters 
were carried out with 11 λ states (from λ=0 to λ=1) each, with a production run 
time of 500ps for each lambda point and energies were extracted every 50 steps.  
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Cell Culture and Membrane Preparation 
 HEK293 cells were maintained in culture in DMEM supplemented with 
10% newborn calf serum at 37 ºC in a moist, 7% CO2 atmosphere and passaged 
twice weekly. Cells were transfected with plasmids containing wild-type A2AAR 
construct using the calcium phosphate precipitation method and harvested after 
48 hours. Cells were pelleted, re-suspended in 20 ml of ice-cold 50 mM Tris-HCl 
buffer, pH 7.4. An ULTRA-TURRAX® was used to homogenize the cell 
suspension. The cytosolic and membrane fractions were separated using a high-
speed centrifugation step of 100,000 x g for 20 min at 4 ºC. This process was 
repeated twice and subsequently the pellet was re-suspended in 50 mM Tris-HCl 
buffer, pH 7.4, the protein concentration was determined by the BCA method79 
and samples were aliquoted and stored at - 80 ºC until further use. 
 
Radioligand Binding Studies 
 Tritiated 4-(2-[7-Amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a]-[1,3,5]-triazin-5-yl-
amino] ethyl)phenol ([3H]ZM241385, specific activity 30 Ci/mmol) and tritiated 
1,3-dipropyl-8-cyclopentyl-xanthine ([3H]DPCPX, specific activity 120 Ci/mmol) 
were purchased from ARC Inc. (St. Louis, USA). Unlabelled ZM241385 and -
cyclopentyladenosine (CPA) were purchased from Sigma-Aldrich (Steinheim, 
Germany). The tested compounds were purchased from five different vendors 
(Asinex, ChemBridge, Vitas-M, Pharmeks and KeyOrganics). The identity of all 
tested compounds was verified by 1H-NMR and HPLC/MS was used to assess 
the purity for all of the molecular docking screening hits.  
 For the A2ARs, membranes containing 20 µg of protein were incubated in a 
total volume of 100 µl Tris-HCl buffer (50 mM, pH 7.4), 10 mM MgCl2, increasing 
concentrations of the test compounds (5% DMSO) and [3H]ZM241385 at final 
concentration of 3 nM. Non-specific binding was determined using a final 
concentration of 10 µM ZM241385 and represented less than 10% of the total 
binding. For the A1Rs, membranes containing 5 µg of protein were incubated in a 
total volume of 100 µl Tris-HCl buffer (50 mM, pH 7.4), [3H]DPCPX (final 
concentration 1.6 nM) and increasing concentrations of the test compounds (5% 
121 
 
DMSO). Non specific binding was determined using a final concentration of 100 
µM CPA. Total binding was determined in the presence of buffer and was set at 
100% in all experiments, whereas non-specific binding was set at 0%. After 
incubation for 1 hour at 25 °C in a shaking water bath, assays were terminated 
by rapid filtration through 96-well GF/B UniFilter plates (PerkinElmer) followed by 
washing with 7 × 0.25 ml ice-cold Tris-HCl buffer (50 mM, pH 7.4). Plates were 
dried, 25 µl P-E Microscint 20 was added per well, and after 3 hours, bound 
radioactivity measured using a Packard Microbeta counter (PerkinElmer). Data 
were analyzed using GraphPad Prism v5, normalized as ‘% specific binding’ from 
which the Ki values were calculated. Experiments were performed three times in 
duplicate, unless stated otherwise.  
 
Cyclic AMP Accumulation Assay 
 HEK293 cells were grown and transfected as described above. 
Experiments were performed 48 h after transfection. The cells were harvested 
and centrifuged two times at 1.000 rpm for 5 min. For cyclic AMP production and 
determination, 1500 cells/well were used in 384-well Optiplates (PerkinElmer). 
The cells were incubated for 30 min at 37 °C with either the A2AR agonist 
CGS21680 alone or CGS21680 together with test compounds in different 
concentrations. The assay buffer used was PBS with the addition of 5 mM 
HEPES, 0.1% BSA, 50 µM rolipram, 50 µM cilostamide, and 0.8 IU/mL 
adenosine deaminase. Basal activity was determined in the presence of assay 
buffer and was set at 0% in all experiments. Maximal receptor activity was 
determined in the presence of 10 µM CGS21680 and was set at 100% in all 
experiments. Cells were then lysed, and the amount of cAMP produced was 
quantified using a LANCE ultra cAMP kit (PerkinElmer) according to the 
instructions of the manufacturer. Following addition of the detection mixture, 
plates were left for 1 h at RT prior to reading using an EnVision plate reader 






 Analytical purity of the compounds 9-15,16-17,19, and 22 was determined 
by high-pressure liquid chromatography (HPLC) with a Phenominex Gemini 3u 
C18 110A column (50 x 4.6 mm, 3 µm), measuring UV absorbance at 254 nm. 
Sample preparation and HPLC method is - unless stated otherwise - as 
follows:  0.3-0.8 mg of compound was dissolved in 1 mL of a 1:1:1 mixture of 
CH3CN/H2O/tBuOH and eluted from the column within 15 minutes, with a three 
component system of H2O/CH3CN/1% TFA in H2O, decreasing polarity of the 
solvent mixture in time from 80/10/10 to 0/90/10.  
LC-MS analysis was performed on a Finnigan Surveyor HPLC system with a 
Gemini C18 50 × 4.60 mm column (detection at 200-600 nm), coupled to a 
Finnigan LCQ Advantage Max mass spectrometer with ESI using the same 




Anirudh Ranganathan and Jen Carlsson (Stockholm University) performed molecule 
docking screening and molecular dynamics simulations. Jacobus van Veldhoven 
(LACDR, Leiden) helped for HPLC/MS measurement.  
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Table 1. Fragment ligands and discovered in the NMR-based screen (1-5)21 and false 





Ki	  	  	  (LEc)	  





















586	  ±	  45	  (0.31)	   0.31 
6	  
(34)	   	  








128	  ±	  11.3	  (0.37)	   0.44 
   a Rank by docking screen of fragment library (500 compounds in total). 
b Not scored in molecular docking screen. 
c Ligand efficiency 







Table 2. Structures and experimental data for the fragment ligands discovered in the 
docking screen against the A2A adenosine receptor.  
Ki	  	  (LEb)	  	  µM	  or	  	  %	  displacement	  at	  10µM	  	  
(kcal	  mol-­‐1	  atom-­‐1)	  ID	  
(Rank)a	  
Ligand	  structure	  



























































240	  ±	  8	  (0.29)	   173	  ±	  6	   0.38 
a Rank by docking screen of fragment library with 328,000 commercially available compounds. 
bLigand efficiency 
































Table 3. Structures and experimental data for analogs of compounds 10. 
   
10, Ki=6.4 µM 10a-e 10f 
Ligand	  structure	   Ki	  (LE
a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  µM	  or	  %	  
displacement	  at	  10µM	  	  (kcal	  mol-­‐1	  atom-­‐1)	  
ID	  
X	   R	   A2A	   A1	  
10a	   H	   CH3	   11.0	  ±	  0.5	  (0.47)	   11.4 ± 1.0 
10b	   H	   (CH2)2CH3	   5.1	  ±	  0.2	  (0.44)	   1.0 ± 0.2 
10c	   Cl	   (CH2)CH3	   17.0	  ±	  3.2	  (0.40)	   44 % 
10d	   CH3	   (CH2)CH3	   10.6	  ±	  0.6	  (0.41)	   6.4 ± 0.3 
10e	   OCH3	   (CH2)2CH3	   42	  ±	  4	  (0.33)	   8.1 ± 0.3 
10f	   -­‐	   -­‐	   50	  ±	  5	  (0.36)	   47 % 




Table 4. Structures and experimental data for analogs of compound 11.  
   
11, Ki=6.3 µM 11a 11b-k 
Ligand	  structure	   Ki	  	  (LE
a)	  µM	  or	  	  %	  displacement	  at	  10	  µM	  	  (kcal	  
mol-­‐1	  atom-­‐1)	  ID	  
	  
R	   A2A	   A1	  
11a	   -­‐	   4.1	  ±	  0.3	  (0.40)	   20 ± 2 
11b	   H	   18.0	  ±	  1.3	  (0.35)	   29 % 
11c	   2-­‐OH	   8.8	  ±	  0.6	  (0.36)	   26 % 
11d	   2-­‐CH3	   7.8	  ±	  0.5	  (0.36)	   19 % 
11e	   2-­‐Cl	   7.0	  ±	  0.4	  (0.37)	   20 ± 3 
11f	   2-­‐F	   5.5	  ±	  0.3	  (0.37)	   3.5 ± 0.4 
11g	   3-­‐CH3	   22	  ±	  1	  (0.33)	   24 % 
11h	   4-­‐OH	   7.4	  ±	  0.8	  (0.36)	   34 % 
11i	   4-­‐CH3	   60	  ±	  5	  (0.30)	   18 % 
11j	   2-­‐OH,	  3-­‐OCH3	   9.6	  ±	  0.5	  (0.32)	   25 % 
11k	   3-­‐OCH3,	  4-­‐OH	   2.4	  ±	  0.2	  (0.36)	   9.6± 0.4 




Table 5. Structures and experimental data for analogs of compound 12.  
  
12 Ki = 6.8 µM 12a-f 
Ligand	  structure	   Ki	  	  (LE
a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  µM	  or	  	  %	  
displacement	  at	  10µM	  	  (kcal	  mol-­‐1	  atom-­‐1)	  ID	  
	  
X	   R	   A2A	   A1	  
12a	   H	   H	   101	  ±	  6	  (0.35)	   2 % 
12b	   H 4-­‐Cl	   99	  ±	  5	  (0.33)	   17 % 
12c	   CH3 H	   2.1	  ±	  0.2	  (0.47)	   3.5 ± 0.3 
12d	   CH3 4-­‐OCH3	   8.7	  ±	  0.1	  (0.40)	   2.8 ± 0.2 
12e	   CH3 4-­‐CH3	   3.4	  ±	  0.4	  (0.41)	   2.4 ± 0.3 
12f	   CH3 4-­‐Cl	   9.1	  ±	  0.2	  (0.38)	   2.5 ± 0.2 
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A New Strategy for Over-expression and 
Functional Reconstitution of G Protein-Coupled 
Receptors 
	  




 Structural information plays a key role in modern drug discovery, in 
combination with biophysical screening, enables hit identification and 
generates compounds with drug-like properties. An increasing number of 
GPCR structures enables virtual screening and structure-based drug 
discovery for these important pharmaceutical targets. Here, we aim to 
investigate solution NMR as a potential means to elucidate the structure of 
A2AR in complex with potential allosteric modulators discovered by previous 
fragment screening. For this, we overexpressed the recombinant receptor as 
inclusion bodies in the E. coli prokaryote system, using a human α5 integrin 
as fusion partner. With this strategy, the recombinant adenosine A2A receptor 
was produced and purified in large amounts. However, optimal refolding 
conditions to recover the isolated receptor in its native state have not yet been 
found. If successful, this novel approach could be powerful aid to investigate 




G-protein coupled receptors (GPCRs) are integral membrane proteins that 
respond to a variety of ligands such as biogenic amines, peptides and hormones, 
and create intracellular responses via G proteins, β-arrestins, and other 
downstream effectors. GPCRs mediate the majority of transmembrane signals in 
living cells, and represent 30–40% of the current drug targets which have been 
developed for cardiovascular, metabolic, neurodegenerative, psychiatric, and 
oncologic diseases.1 The adenosine A2A receptor is one of four adenosine 
receptor subtypes (A1, A2A, A2B, and A3), belongs to the family A of GPCRs, and 
is activated by endogenous adenosine.2 The A2A receptor plays a role in 
regulating the inflammatory response and ischemic brain damage. Several A2A 
receptor agonists and antagonists/inverse agonists have passed successfully into 
clinical trials: agonist developed by Biovitrum (BTV.115959, structure not 
disclosed) 3 may be used for treatment of inflammatory disease, whereas 
antagonists/inverse agonists such as preladenant and istradefylline, 4,5 may be 
used for treatment of Parkinson’s disease as a non-dopaminergic approach.  
To date, more than 70 high-resolution structures of GPCRs have been 
solved, several structures have been solved in their active-state conformations 
and as complexes with an agonist, an inverse agonist, an antibody and even a G-
protein.6 Such structures can provide detailed information on protein form and 
function at atomic level and are also useful for characterization of protein-ligand 
interactions. However, obtaining novel high-resolution GPCR structures in 
complex with multiple ligands is still very challenging, largely due to intrinsic 
protein flexibility, instability in detergent, and the requirement of specialized 
crystallization techniques like lipidic cubic phase crystallization.7  
Most of the efforts in the structural biology and medicinal chemistry of 
adenosine receptors have concentrated on orthosteric ligands. More recently, 
allosteric modulators appear to be an emerging class of therapeutically 
interesting agents that bind to receptors at a topographically distinct site of 
orthosteric ligands.8 These molecules have no intrinsic activity on their receptors, 
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they modulate the activity of the receptors when the orthosteric ligand is bound 
concurrently. Allosteric ligands that enhance the agonist activities are referred to 
as positive allosteric modulators (PAMs) while those that inhibit or decrease the 
activities are called negative allosteric modulators (NAMs). There are a number 
of therapeutic advantages of using allosteric modulators over orthosteric ligands, 
such as higher selectivity for the target, decreased toxicity or side effects, 
enhanced physiological specificity of action.9 However, allosteric modulators 
have only been described for a few GPCRs. Designing specific allosteric ligands 
for GPCRs has been hampered by a lack of structural information on their 
binding sites. However, biophysical methods like NMR and SPR can directly 
measure the GPCR-ligand/modulator interaction. Use of NMR techniques could 
be valuable for future allosteric modulator design with resonance assignment for 
the putative allosteric sites, and an improved molecular dynamic understanding 
of functional activities of GPCRs.  
Protein-observed NMR studies usually require isotope labelled protein at 
high concentration. Escherichia coli is the most widely used protein expression 
system for structure biology studies using NMR techniques. However, bacterial 
expression of GPCRs has been hampered by low levels of expression and cell 
toxicity caused by targeting the recombinant receptors to the bacterial inner 
membrane. Recent new techniques contribute to a breakthrough on the 
difficulties encountered in GPCR expression, purification and refolding, allowing 
preparation of active samples for further biophysical and structure studies. In this 
chapter, we combined several protein production strategies to prepare sufficient 
amount and functional samples for receptor–small molecule interaction 
determination using solution-state NMR. We took advantage of the stabilized 
receptor (StaR) strategy, which has been developed to overcome the instability 
and purification problems of GPCRs.10 Several point mutations are made outside 
of known orthosteric sites, and increase thermostability of the receptor by locking 
it in one conformation (i.e., agonist or antagonist conformation).11 The 
recombinant A2A StaR was produced in inclusion bodies (IBs) in E. coli. IBs are 
mechanically stable and not toxic to the cell, so GPCR production level can be 
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exceptionally high. Then the receptor was purified in a mixture of sodium dodecyl 
sulfate (SDS) and urea solution in an inactive form. The receptor was 
subsequently folded to its native state by transferring it from SDS to a polymeric 
surfactant called amphipols (APols). APols are amphipathic polymers that can 
keep individual integrated membrane proteins soluble in aqueous solutions, and 
preserve their functionality.12 It has been shown that several MPs are more 
stable in APols than in detergent micelles, and Apols are a highly efficient agent 
to fold MPs into their native state.13 Solution NMR techniques have been 
successfully applied to GPCRs in complex with APols for protein-ligand 
interaction and conformational transition characterization.14    
In chapter 3, we have shown that TINS is suitable to screen fragment 
libraries for target specific binding. We have been able to discover structurally-
independent new chemical series with functional activity on the human A2AR. In 
addition, one compound has shown to be active in an intracellular cAMP assay. It 
did not compete with radioactive orthosteric ligand binding, suggesting an 
allosteric mechanism of action.15 Due to the low potency of this compound, it is 
not clear whether the high-resolution crystal structure of A2AR in complex with 
this allosteric modulator could be solved. However, APol-trapped A2A-StaR may 
enable NMR analysis of protein-small molecule complexes. A StaR with high 
production yield, enhanced stability and reduced conformational exchange may 
enable NMR resonance assignment for the putative allosteric site near the 
extracellular loop domains.   
As a first step, in this study, we have shown that the recombinant A2A StaR 
can be produced in large quantities in inclusion bodies in E.coli, yielding 20-30 
mg recombinant protein per liter of cell culture. The first bottleneck in the 
determination of the GPCR structure pathway has thus been solved. However, 
the protein fusion partner needs to be efficiently removed, then the purified 
isolated target protein has to be refolded into APols. Fuctional APol-trapped A2A-





2. Results and Discussion 
Using a New Fusion Partner for Efficient GPCR Over-Expression in E. coli 
IBs 
Expression of GPCRs in E. coli is generally targeted to insoluble IBs in the 
cytoplasm to avoid toxicity associated with expression in membrane.16 However, 
when using a protein partner like maltose binding protein (MBP), some GPCRs 
can be produced in the E. coli inner membrane in the folded active state, albeit at 
very low yield.17,18 For example, the production of MBP fused A2A StaR in the E. 
coli inner membrane is very low, yielding only 0.4 mg purified protein per liter of 
cell culture (data not published). Here, we used an approach that had been 
successfully applied to expression of the leukotriene BLT1 and BLT2 
receptors.16,19 This approach is based on accumulation of the receptor protein in 
E. coli IBs as a fusion protein followed by in vitro refolding, which may eventually 
lead to their native state. A fragment of the extracellular β-propeller domain of the 
human α5 integrin (α5I) was selected as a fusion helper partner. The α5I contains 
a high proportion of charged residues (-19) and higher fraction of β-turn-forming 
residues (31.6%) than the usual fusion partner like glutathione S-transferase 
(GST) or phospholipase C.19 These two characteristics are important for efficient 
inclusion body formation.20  
In this study, pET21b was used as expression vector and several 
constructs were designed. A His10 tag was present at either terminus (Figure 1A), 
and a thrombin cleavage site was inserted between the α5I and A2AR gene. 
Furthermore, to get better separation of cleaved A2AR and non-cleaved fusion 
protein, the construct was optimized with His10 tag located in between the fusion 
partner and the receptor protein (Figure 1A), followed by two enzymatic cleavage 
sites: thrombin and Tobacco Etch Virus (TEV). In addition, a poly-glycine linker 
was introduced between the TEV cleavage site and the N-terminus of A2AR, in 
order to gain more accessibility for the enzyme.        





Figure 1. A) Schematic representation of designed constructs in pET20 expression vector in this 
study. And B) comparison of total expression levels of five different A2AR constructs expressed in 
Rosetta 2 (DE3) strain at 37 °C. Different samples were taken before IPTG induction (T0), and 
after 2 hours (T2) and/or 4 hours (T4) IPTG induction. Anti A2AR Western blots were performed 
with total lysates.  
 
GPCR Production and Purification 
The total expression level and integrity of the different expression 
constructs was monitored by Western blot (WB) using anti-A2AR antibodies 
(Figure 1B). According to the intensity of the protein band, α5I proved to be a very 
efficient fusion partner for GPCR over-expression in IBs. Without α5I, minimal 
protein expression was observed. When the His10 tag was present at the N-
terminus of the protein, expression was completely blocked. The apparent 
molecular weight on WB of each construct was compatible with the 
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corresponding calculated masses, 67 kDa for the construct DC3 and 35 kDa for 
the A2AR-His10.     
Expression of DC3 in Rosetta 2 (DE3) strain was scaled up at 37 °C, cells 
were harvested after four hours IPTG induction. In cell lysates, IBs can be easily 
isolated from other cell constituents by centrifugation, then solubilized in 
denaturing buffer, a mixture of urea and SDS and subsequently purified by 
immobilized metal affinity chromatography (IMAC) on a Ni2+ NTA column. 
Typically, 30 mg of purified recombinant protein was recovered from one liter of 
cell culture (Figure 2B). Before refolding, the integrin fusion partner must be 
removed. The protein was dialyzed in an aqueous buffer to eliminate most SDS 
and urea, which could inhibit the thrombin cleavage. In addition to driving protein 
into IBs, the α5I fusion can keep the receptor soluble after dialysis to remove 
detergents.21 Unfortunately, in this case, the enzymatic cleavage was not 
efficient, only 30-40% of the α5I partner was removed by thrombin cleavage from 
the recombinant protein. As illustrated in Figure 2B, inefficiently cleaved α5I-
A2AR-His10 appeared as three major bands, corresponding to uncleaved 
recombinant protein at 67 kDa, the cleaved α5I partner around 31 kDa and 
cleaved A2AR around 30 kDa. The cleaved A2AR and uncleaved protein cannot 
be further separated by a second IMAC purification, due to the His10 tag present 
at C-terminal for both cases. An additional gel filtration chromatography cannot 
separate them either (data not shown).           
 
Figure 2. Coomassie-stained 12.5 % SDS-PAGE of construct DC3 (A) after Ni2+ NTA column 
purification: FT flow through, wash, and elution peaks from Ni2+ NTA column and (B) thrombin 
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cleavage efficiency monitored after 0, 2, 4, and 6 hours incubation. Bands corresponding to the 
uncleaved α5I-A2AR (67 kDa), α5I (31 kDa), and isolated A2AR (35 kDa) are marked with red 
arrows.  
 
To solve the inefficient cleavage of the fusion partner, a new construct was 
designed with a His10 tag present at the C-terminus of integrin, before the 
enzymatic cleavage sites. A TEV cleavage site was also added (Figure 1A). 
These modifications did not improve the enzymatic cleavage efficiency either by 
thrombin or TEV protease (Figure 3A). According to the 3D crystal structure, 
A2AR has a very short N-terminal extension (6 amino acids) that projects out of its 
first transmembrane α-helix, suggesting that the enzymatic cleavage site might 
be shielded by the α-helix, thus not accessible for enzyme. Therefore, a 10 
glycine linker was introduced between the TEV cleavage site and the N-terminus 
of A2AR, which didn’t affect the expression level of fusion protein (Figure 1B). 
After eliminating most SDS and urea by dialysis, the fusion protein was incubated 
with TEV protease at a 1:1 molar ratio for 2, 4 or 6 hours at room temperature. As 
shown on the SDS PAGE gel (Figure 3B), approximately 80% of fusion protein 
was cleaved. Immediately, the α5I fusion was eliminated through a second IMAC 
step under denaturing condition, 0.8% SDS (Figure 3C). The A2AR was kept 
soluble in high concentration of SDS solution, in which GPCR displays a 
significant α-helix content.22 In the flow through of Ni NTA column, as shown in 
Figure 3C, a number of bands were observed on SDS PAGE, which might 
correspond to aggregation or precipitation of cleaved A2AR. Proteins tend to 
precipitate during enzymatic cleavage, because of the low level of detergent 
present in the reaction. Although a high concentration of SDS was added during 
the second IMAC purification, it is difficult to re-dissolve the precipitates.  Many of 
the membrane bound proteins show a smeared band or a dark band at the very 




Figure 3. Coomassie-stained 12.5 % SDS-PAGE analysis of enzymatic cleavage efficiency of 
DC4 (A) and DC5 (B). Figure 3A, thrombin cleavage product after 2, 4, or 6 hours incubation, 
overnight incubation of fusion protein with enzyme did not improve the cleavage efficiency. Figure 
3B, TEV cleavage product of DC5 after 2, 4, or 6 hours incubation. Figure 3C, FT, flow through 
after Ni NTA column; W, wash of Ni NTA column; E, elution of Ni-NTA column.  
 
In Vitro Refolding of A2AR 
 SDS was used as an artificial chaperone to keep the GPCR soluble and to 
ensure that the GPCR does not aggregate before it reaches its native form.23,24 In 
vitro refolding of GPCR can be achieved by exchange of SDS solubilized 
receptor into amphipols (A8-35) complex, with lipid supplementation. A8-35 was 
added at 1:5:1 protein/A8-35/asolectin mass ratio and SDS was removed by 
potassium chloride precipitation followed by dialysis. There was no significant 
protein loss through precipitation during amphipol-mediated folding. To compare 
Apol-mediated folding efficiency with that of detergent folding, 2.5%/0.5% 
DDM/CHS was added to the SDS solubilized receptor to induce folding. The 
functional fraction of A2AR was then assessed by [3H] ZM241385 radioligand 
competition assay. Unfortunately, there is no [3H] ZM241385 binding shown on 
the refolded receptor preparations, so both APol-trapped A2AR and the DDM 






3. Conclusions - What to Do Next? 
Overexpression of GPCRs has been carried out in several different 
expression systems such as yeast, insect cells, and mammalian cells. Among all 
the expression systems developed so far, E. coli is considered as an ideal host 
for producing isotope labeled proteins for NMR structure studies. However, 
GPCR expression in E. coli usually leads to cell toxicity and low levels of 
expression. For this reason, a limited number of receptors have been produced 
as functional proteins in E. coli inner membrane. In this chapter, an alternative 
approach has been investigated to overexpress recombinant GPCR targeting 
IBs.  
In order to increase the yield of expressed protein, an intergrin α5I 
fragment was introduced as fusion partner in the expression vector, which helps 
addressing GPCRs to IBs. α5I fused GPCR can accumulate in milligram amounts 
in IBs. Among the different constructs, N-terminal His10 tag presents a noticeable 
negative effect on protein expression. For purification purpose, a 10 glycine linker 
was introduced between the enzymatic cleavage site and the N-terminus of A2AR, 
which made TEV recognition site more accessible for enzyme. However, pure 
and well isolated protein is critical for further successful refolding. 1) More efforts 
need to be put into optimization of enzymatic cleavage conditions. Efficient 
removal of the fusion partner could provide purer isolated GPCR for further 
folding step. 2) Re-solubilization of GPCR after TEV cleavage could be tested in 
high concentration of a harsh detergent such as 0.6-0.8% SDS and 6-8 M urea; 
and 3) The second IMAC purification conditions need to be further optimized. 
Moreover, the GPCR refolding preparation is not yet fully successfully set up. 
Refolding of the StaR GPCR in APols might not be feasible, because StaR was 
designed for making protein more stable in short chain detergent, like n-decyl-β-




  An alternative method, directed evolution for high expression and high 
stability, has the potential to produce high levels of a thermostable neurotensin 
receptor 1 from E. coli for structural studies.25 This E. coli expression strategy 
can be suitable for producing isotope-labeled proteins, and therefore might be a 
viable alternative to the present approach. 
 
4. Materials and Methods 
Construction of A2AR Fusions 
The expression vector pET21a-α5I, containing coding sequence for the α5 
integrin (α5I) fragment (amino acid residues 231-514), was kindly provided by 
Jean-Louis Banère (Université de Montpellier). The coding sequence of A2A-
StaR2 was commercially synthesized, and optimized for bacterial expression. For 
GPCR expressed alone, the A2A-StaR2 coding sequence was inserted into the 
BamHI/XhoI sites of the pET20b vector. For GPCR expressed as a fusion, the 
A2A-StaR2 coding sequence was inserted into the BamHI/XhoI sites of the 
pET21a-α5I vector. A thrombin cleavage site or a Tobacco Etch Virus (TEV) 
cleavage site between the two regions coding for α5I and A2A-StaR2 was 
introduced to enable removal of the fusion partner α5I. A His10 tag was appended 
at the N-terminus or C-terminus to allow easy purification by immobilized metal 
affinity chromatography (IMAC).  
Expression of A2AR 
For expression, E.coli RosettaTM 2 (DE3) cells were transformed freshly 
each time with different expression constructs and grown overnight at 37 ºC on 
Luria-bertani (LB)-agar plates containing 100 µg/ml ampicillin. For each 
construct, an isolated colony was picked up from the plate and the bacteria were 
grown at 37 ºC in LB medium supplemented with 100 µg/ml ampicillin, 34 µg/ml 
chloramphenicol and 0.2 % glucose until an OD600 at 0.6. Protein expression was 
induced by adding 1 mM isopropylthio-β-D-galactoside (IPTG), and growth 
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continued at 37 ºC for 4 hours. Cells were harvested at 4 ºC by centrifugation at 
4,000 x g for 20 min, and the cell pellet was resuspended in lysis buffer (20 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1M urea and one tablet of complete protease 
inhibitor cocktail) then stored at −80 ºC. Total expression was visualized by 
Western blot using anti-A2AR antibody according to standard protocols.  
Purification of Recombinant A2AR 
The cell pellet was thawed on ice before adding 10 mg/ml lysozyme and 
20 µg/ml DNase, then lysed by French Press. IBs were recovered at 4 ºC  by 
centrifugation at 19,000 rpm for 45 min, washed with 40 ml of 20 mM Tris-HCl pH 
8.0 buffer containing 1 M urea and 0.5% Triton X-100, respectively. Solubilization 
of IBs was carried out in 40 ml of solubilization buffer (20 mM Tris-HCl pH 8.0, 
150 mM NaCl, 6 M urea, 0.4% SDS, 10% glycerol, 4 mM β-mercaptoethanol and 
protease inhibitors) overnight at 4 ºC on rotation. Solubilized proteins were 
clarified from insoluble material at 4 ºC by centrifugation at 19,000 rpm for 45 min 
and passed through a 0.22 µm filter.  
Solubilized IBs were applied to an Ni2+ NTA column equilibrated with 
solubilization buffer. The column was then washed with 10 column volumes of 
solubilization buffer supplemented with 10 mM imidazole. The recombinant 
GPCR was eluted with 20 column volumes of elution buffer (solubilization buffer 
+ 100 mM imidazole). Fractions of elution peak were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the protein 
concentration was determined by absorption at 280 nm.  
Thrombin Cleavage and TEV Cleavage of Recombinant A2AR 
The purified α5I fused A2AR was extensively dialyzed in 3 X 1L of 20 mM 
Tris-HCl pH 8.0 and 150 mM NaCl using dialysis membrane with a 12-14 KDa 
molecular weight cut-off. The first two dialyses were carried out at room 
temperature to prevent SDS crystallization, and the last dialysis was transferred 
to 4 ºC to prevent protein degradation. The thrombin (Millipore) cleavage was 
done at room temperature using 10 cleavage units per mg of fusion protein, 
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supplementing the solution with 2.5 mM CaCl2. The TEV cleavage was 
performed at room temperature using a TEV protease and cleavage buffer (25 
mM Tris-HCl pH 8.0, 150 mM NaCl and 2 mM DTT). The optimized 
enzyme:fusion protein ratio and incubation time were determined by monitoring 
the samples on SDS-PAGE. The reaction was stopped by adding 6 M urea and 
SDS up to 0.4 %.  
The cleaved sample was incubated with 6 ml 50% Ni2+ NTA superflow 
slurry for 3 hours at room temperature. The sample-resin suspension was 
transferred into a chromatography column. In the case of α5I-His-TEV-A2AR, the 
cleaved A2AR was present in the flow through. For other constructs, the cleaved 
A2aR was bound to the Ni2+ NTA agarose, and eluted with elution buffer (25 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 6 M urea, 0.4 % SDS and 100 mM imidazole). 
The purity of the protein was examined by SDS-PAGE. The purified and isolated 
A2AR was pooled and dialyzed for 24 hours at room temperature in 3 X 1L of 50 
mM Tris-HCl pH 8.0 and 0.8% SDS to eliminate urea and imidazole.   
Refolding of A2AR 
The quantity of A2AR was determined by absorption at 280 nm. For optimal 
refolding, the concentration of A2AR should be between 0.3-0.5 mg/ml. The 
GPCR renaturation was carried out by precipitating dodecyl sulfate as a 
potassium salt (KDS). Asolectine was added, at a mass ratio of 1 g lipid per g 
GPCR, to SDS-solubilized A2AR supplemented or not with 10 µM ZM241385. 
After 1 hour of incubation at room temperature, amphipol A8-35 was added to the 
sample, at the mass ratios of 5 or 10 g A8-35 per g GPCR. After 30 min of 
incubation, SDS was precipitated by addition of KCl. KCl was added to a final 
concentration equal to concentration of SDS + 150 mM. After 30 min incubation 
under vigorous stirring, the KDS precipitate was removed by centrifugation and 
the supernatant was dialyzed three times against 1 L of potassium buffer (30 mM 
potassium phosphate pH8.0 and 150 mM KCl). To determine whether amphipol 
could refold SDS denatured sample to an active receptor, a high affinity 
radioligand ([3H]ZM241385) binding competency was performed. For the 
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detergent folding preparation, the SDS solublized receptor was diluted in the final 
buffer, with 25 mM Tris-HCl pH 8.0 and 0.1% SDS, before the addition with 
stirring of 2.5 % n-dodecyl-β-D-maltopyranoside (DDM), 0.5 % cholesteryl 
hemisuccinate (CHS), and 10 µM ZM241385. After 48 hours stirring at 4 °C, the 
unsolubilized and aggregated receptors were removed through Superdex 200 
10/300 GL gel filtration column.      
Western Blot 
Proteins were transferred from a 12 % SDS-PAGE gel to Hybond PVDF 
membrane, which was blocked with 5 % non-fat milk powder in PBS buffer pH7.4 
at room temperature. Then, the membrane was treated with anti-A2AR primary 
antibodies, epitope mapping to the third intracellular loop. Protein specific bands 
were visualized by ECL chemiluminescence. 
Radioligand Binding Assays 
For the equilibrium binding assay, 25 µl of protein sample was incubated 
with [3H]ZM241385 at final concentrations of 1, 5 and 16 nM, in a total volume of 
100 µl Tris-HCl buffer (50 mM, pH 7.4), 10 mM MgCl2. Non-specific binding was 
determined using a final concentration of 10 µM ZM241385. After incubation for 1 
hour at 25 °C in a shaking water bath, assays were terminated by rapid filtration 
through Whatman GF/B filters pre-socked in 0.3 % polyethyleneimine under 
reduced pressure with a Brandell harvester. Filters were washed by 3 × 2 ml ice-
cold Tris-HCl buffer (50 mM, pH 7.4) and placed in scitillation vials. 3.5 ml of 
Emulsifer Safe was added, after 3 hours, radioactivity was counted in an LBK 
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 Chapter 6 















 Integral membrane proteins including GPCRs and ion channels are key 
regulators of cellular function and account for up to two thirds of known druggable 
targets,1 highlighting their critical pharmaceutical importance. Traditionally, new 
drugs against this class of proteins have been discovered through high-
throughput screening. However, not all GPCRs are amenable to traditional 
screening and pharmacological evaluation methods. Recently, fragment-based 
drug discovery (FBDD) in combination with structure-based drug discovery 
(SBDD) has emerged as a powerful strategy to generate approved drugs against 
soluble targets such as kinases and proteases.2–4 Now, FBDD/SBDD can be 
applied to GPCRs with great potential advantages.5 In recent years, a number of 
FBDD techniques have been validated for use with GPCRs. Biophysical methods 
(Chapter 2 and 3) are usually employed for hit identification. The impressive 
growth in GPCR structure information leads to broad use of structure-based 
methods for hit discovery and optimization (Chapter 4). However, the dynamic 
nature of GPCRs, and standard issues associated with low level expression and 
instability during purification, made biophysical and structural characterization of 
GPCRs particularly difficult. New advances in protein stabilization by using 
different protein engineering methods and alternative solubilization strategy 
(Chapter 2, 3, and 5) have shown the potential to facilitate GPCR structural and 
biophysical studies. The goal of the work described in this thesis was to develop 
and implement efficient fragment screening methods to discover ligands of 
GPCRs with novel biological activities, and new advances in receptor production 
and stabilization to facilitate structural biology of GPCRs in the early stages of 
drug discovery. Below some commentary on the current state and perspectives 
of these approaches is provided.   
 
Screening Techniques for Fragment-Based Drug Discovery 
 
 The first step in FBDD is the identification of fragment hits that have 
sufficiently high ligand efficiency and can be used as a starting point for hit-to-
151 
 
lead optimization. Fragments are low-molecular weight compounds, making only 
few interactions with the target protein and displaying low binding affinity. This 
makes the interaction particularly difficult to detect by conventional biochemical 
assays. However, biophysical methods such as nuclear magnetic resonance 
(NMR), surface plasmon resonance (SPR) and X-ray crystallography are 
commonly used to identify fragment hits. Especially, NMR based methods and 
SPR provide sensitivity that is required for detection of low affinity ligands. As 
described in Chapters 2 and 3, we have established the efficacy of TINS for 
fragment screening against membrane proteins, including GPCRs. TINS can 
detect small molecules that bind to different binding sites on the target protein. It 
has been shown that it is possible to discover ligands with different biological 
activities in a single screen. In Chapter 2, the fragments identified by TINS were 
validated as specific binders of DsbB and they turned out to be either inhibitors of 
native ligand binding or inhibitors of protein-protein interactions. In Chapter 3, 
among the TINS hits, it is possible to find at once orthosteric ligands and multiple 
allosteric modulators of the A2AR with both positive and negative effects. Several 
of these ligands can be a good chemical start for further lead exploration. Use of 
a biophysical fragment screening method allows identification of very weak 
binders, such as the allosteric modulators, which are unlikely to be discovered by 
a traditional cell-based assay. Ligands with a wide range of affinities can be 
detected because of the sensitivity of TINS, thereby minimizing false negatives. 
TINS, as a direct binding assay, also allows discovery of ligands that bind to new 
binding sites that would be silent in radioligand binding assays. A reference 
control was included in the screen, eliminating false positives and non-specific 
protein binders, thus insuring the specificity of hits. Furthermore, a strong 
correlation has been noted between the hit rate in NMR fragment screening and 
the ligandability of a target. Nevertheless, an issue for TINS is that the 
parameters of the NMR experiment are optimized to detect weak binders. Tight 
binding ligands, which have slow off rates, will not generate as much NMR signal 
amplification as weak binders. Furthermore, a target protein which has a deeply 
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buried binding site, might not be suitable for detection of fragment ligands using 
TINS.  
 Contrary to TINS, SPR is capable of detecting binding of fragments with 
wide range affinity to protein targets. It should be applicable when TINS is less 
effective i.e. for tightly bound ligands. A number of SPR fragment screens against 
GPCRs, either thermostabilised6,7 or solubilised wild type,8,9 have been reported. 
In addition, SPR requires much less protein (25-50 µg) than NMR or X-ray 
crystallography. It is possible to immobilize receptors directly from crude 
solubilised extracts, avoiding loss of functionality during purification process. In 
order to run a high-throughput biophysical screening on large numbers of 
fragment compounds, it is important to separate real binding from non-specific 
binding. Successful SPR fragment screening requires parallel immobilization of 
the target protein, reference protein(s) and leaving one channel blank as a 
reference surface.10 A known ligand must be available to assess the validity of 
the assay. The detectable minimal response level of fragment hits in the screen 
must be adjusted based on that of control compounds; this could be a limitation 
when there are no tool compounds available. Thereby, for many clinically 
validated targets, such as peptide and protein hormone binding receptors, hit 
identification using SPR methods is still challenging. An idea to conquer this 
limitation of SPR is to combine it with TINS. TINS can generate required tool 
compounds for SPR studies. 
 TINS and SPR have shown more advantages compared to traditional 
biochemical assay. Traditional biochemical assays are not generally applicable in 
FBDD due to their insufficient sensitivity to detect fragments with weak binding 
affinity to protein targets. Moreover, for peptide activated GPCRs, their native 
ligands, which bind with low nM affinities, are often too tight to be displaced by 
fragments that bind in the mM range. The high concentration of fragments 
required for screening may lead to a high level of false positives and negatives 
due to aggregation, compound reactivity, and artificial biological 
inhibition. Despite the disadvantages of biochemical assays, recent studies 
showed that good fragment hits could be identified by a screening with high 
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concentration of fragments.2,11 The high level of false positives and negatives can 
be minimized by removing fragments with poor solubility, reactive properties, and 
aggregators from the fragment library.  
 Recent insight into GPCR structure has enabled the use of SBDD 
techniques to be applied to this target class. In Chapter 4, we have investigated 
the ability to identify hits in new areas of chemical space through in silico 
screening against GPCRs with solved crystal structures. One major strength of 
the in silico approach is the ability to screen large libraries (328,000 fragments 
are commercially available) and have better coverage of chemical space, which 
gives the opportunity to discover ligands with different chemotypes. We have 
shown in Chapter 4 that the docking-based screen was able to identify novel hits 
that did not overlap with those detected by NMR fragment screening. The present 
study showed that these two approaches are highly complementary and the 
combination of biophysical and in silico screening methods will be a powerful 
strategy for future fragment-based hit discovery against GPCRs. However, 
majority of GPCR crystal structures are in the inactive state, and the identification 
of agonists remains challenging.  
 
Micelles vs. Nanodisc in Biophysical Fragment Screening 
 
 In order to detect binding of fragments to proteins, it is necessary to use 
highly sensitive biophysical methods such as NMR, SPR or X-ray 
crystallography, but the surfactants required to solubilize membrane proteins 
interfere with these methods. As membrane protein activity is enhanced in more 
bilayer-like environments, nanodiscs (NDs) offer the potential to enable a more 
generic approach to handling membrane proteins since they can be used to 
functionally solubilize a variety of membrane proteins.12 The results described in 
Chapter 2 show that the use of NDs as a solubilization/immobilization system for 
ligand screening is effective and empty NDs represent a high-quality reference 
system to remove false positives, thereby ameliorating issues with nonspecific 
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binding of fragments to detergent micelles. The NMR spectra of the fragments 
during the TINS screen were of better quality in the presence of NDs as 
compared to detergent micelles. The signal-to-noise ratio of fragments using NDs 
was double to that in micelles, which suggested 30-40% compounds were non-
specifically absorbed into the micelles. In addition, ligand screening in the 
presence of micelle-solubilized membrane proteins may bias the chemical nature 
of the fragment library toward more hydrophilic. This alternative solubilization 
method could enable more than just fragment screening for GPCRs that typically 
do not behave well in detergents. Several reports demonstrated a successful 
application of NDs for cell-free expression of membrane proteins.13 NMR 
structural studies of less stable membrane proteins such as GPCRs may strongly 
benefit from the use of this non-conventional solubilization approach.14 However, 
ND-embedded membrane proteins have relatively large size. The effective 
molecular weight of a protein-ND complex has important implications for the 
applicability of solution NMR. An increase in molecular size leads to wide 1H 
resonance line widths, associated with low sensitivity and resonance overlap.15 
 NDs represent a relatively new membrane mimic, whereas liposomes 
(phospholipid bilayers) and bicelles represent a well-established, native-like 
environment for solution and solid state NMR studies. In addition, liposomes 
are likely to keep GPCRs in their biologically active conformation, thus increase 
receptor stability. Recently, high-resolution structural information of membrane 
proteins in liposomes under physiological conditions (temperature, pH, 
hydration), has become accessible, by using solid-state NMR techniques.16,17 
However, the limited solubility and the inaccessibility of the lipid vesicle interior 
may interfere with functional studies. Bicelles have shown their ability to preserve 
protein function and stability. Unlike liposomes, bicelles provide full access to 
both sides of membrane protein, which is important for the activity assay. 
Successful use of bicelles to reconstitute GPCRs has been reported.18 Bicelles 
have been shown to be a suitable solubilization medium for both solution NMR 
and solid-state NMR studies,15 because their spontaneous orientation in NMR 
magnetic fields. A limitation of using bicelles in solution NMR is their large 
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molecular weight, which usually leads to broad resonance lines. However, recent 
research has reported that bicelles solubilized sensory rhodopsin is accessible to 
NMR structure determination.19 The observed sensitivity and resolution of NMR 
spectroscopy in non-detergent systems enables a detailed structural 
characterization. The use of non-detergent solubilization media should be 
strongly considered if protein stability needs to be increased and/or native 
structure can not be retained in a micelle environment. 
 
Fragment Hit Validation 
  
 Validation of fragment hits from a biophysical screening assay is a critical 
step in the drug discovery process. A number of different approaches were used 
to quantitatively confirm hit binding and provide information on the binding 
mechanisms, such as competition binding TINS, biochemical assays, and SPR. 
The studies presented in Chapters 2 and 3 used a biophysical technique, TINS, 
to discover novel fragment ligands for membrane proteins. The biological 
activities of these ligands were characterized by enzymatic inhibition studies for 
DsbB (Chapter 2), and by radiochemical binding methods and cell-based 
functional assay for A2AR (Chapter 3). Biochemical assays, when possible, 
present an ideal hit validation and prioritization tool after a biophysical assay. 
However, many active fragment ligands can be missed by biochemical validation, 
simply due to their low potency. In order to minimize the false negatives, it is 
necessary to implement biophysical techniques to characterize the binding mode 
and discriminate orthosteric from allosteric ligands. A competition binding assay 
in TINS has been reported to validate and characterize the fragment hits for the 
β1 adrenergic receptor.6 The target protein is immobilized in both cells of the 
sample holder and the same mix is applied to both cells while a competitor (a 
known ligand for the target) is present only in one of the cells. Competition 
binding studies can be carried out using small molecules, protein, or DNA as 
competitors. This method allows rapid characterization of the ligand binding site 
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and binding mode. SPR assays are often used in FBDD as a highly quantitative, 
complementary technique to confirm and validate hits from the primary screen. 
SPR experiments are able to provide information of both binding affinity and 
kinetics to aid the prioritisation of fragment hits. In particular, the combination of 
TINS for primary fragment screening, and SPR for validation/ prioritization of hits 
has been shown to a powerful combination to rapidly find and evaluate weak 
binding fragment hits for further structural studies and elaboration projects. 
 
Structure-Based Approaches for GPCR Drug discovery 
 
 Fragment based drug discovery (FBDD) involves the identification of low 
affinity fragments. Elaboration of lead-like compounds from weak binding 
fragment hits remains a significant challenge for FBDD.20 The availability of high-
resolution 3D structural information of target-fragment complexes makes 
structure based approaches a highly powerful strategy for fragment hit to lead 
elaboration. Both X-ray crystallography and NMR based techniques can provide 
atomic resolution structure of protein-ligand complexes, thereby allowing the 
optimization of molecules with increased affinity and selectivity for the receptor of 
interest. The field of GPCR structural biology has grown rapidly since the first 
high-resolution crystal structure of rhodopsin was obtained in 2000. At the time of 
writing, 70 high-resolution GPCR structures with different bound ligands and in 
different conformations have been reported. The great increase in crystal 
structures of GPCRs in different states has provided detailed insights into small 
molecule-GPCR interactions and highlighted key conformational changes in 
different receptors. New technical advances have been developed to overcome 
the obstacles associated with structure determination of GPCRs, such as i) 
overexpression of recombinant protein in different expression hosts; ii) increase 
of protein stability by introducing mutations, fusion partners and antibodies; iii) 
development of more native like environments for efficient solubilization. StaR® 
GPCRs developed by Heptares, enable biophysical (Chapter 3) and 
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crystallographic analysis, thus fragment and structure based drug design have 
been applied to this important pharmaceutical target.7,21,22 However, obtaining 
small molecule-protein co-crystal structures is still challenging. As half of the 
GPCR crystal structures were solved with a resolution of approximately 3 Å, the 
interpretation of electron density maps can be ambiguous. Some amino acid 
residues like asparagine, glutamine and threonine might be uncertainly placed, 
due to undistinguishable nitrogen from oxygen in side-chain.23 Interpretation of 
ligand binding site in crystal structures also becomes more difficult at low 
resolution. Poor electron density of non-covalently bound ligand can lead to 
incorrect orientation of ligand in the binding pocket. Moreover, obtaining novel 
GPCR structures in complex with different ligands is very challenging, primarily 
because of the requirement of highly potent ligands and new crystallization 
methods using a lipid environment for the protein. Complementary methods are 
required to enable the application of SBDD to GPCRs.  
 The biophysical mapping (BPM) method developed by Zhukov et al.24 can 
generate information on ligand receptor interactions within the known binding 
pocket of GPCRs. In BPM, mutations are designed in the ligand binding site (side 
chain replacement of each residue) of multiple StaR® receptors, and the effect of 
mutations on binding affinity are compared across a matrix of ligands and 
mutants. This method can be used to refine the binding site and provide the key 
structural information on ligand-GPCR interactions in the absence of X-ray 
crystallography data. BPM of known ligands can predict the orientation of the key 
residues in the binding site. It can also be used to predict novel binding modes 
with different chemotypes as well as analogues within a particular chemical 
class.25 This methodology facilitated the lead optimization of the hits identified by 
other screening methods like virtual screening.  
 Other structural biology techniques are starting to show promise, such as 
NMR based methods, which are sensitive to analyze weak protein-ligand 
interactions. They can be applied when X-ray crystallography is much less 
successful, such as weakly bound ligands, poorly diffracting crystals and low-
resolution structures. For example, the structure of CXCR1 has been solved 
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using rotationally aligned solid state NMR in combination with molecular fragment 
replacement.18 Interestingly, the uniformly 13C/15N labeled CXCR1 was 
expressed in E. coli in inclusion bodies and refolded in phospholipid bilayers.26 
While this structure provides information only about the protein backbone, solid 
state NMR has major potential to understand the ligand-receptor interaction. 
Recently technology of solution NMR has also made advances,27,28 the structure 
elucidation of sensory rhodopsin II in phospholipid bicelles19 and proteorhodopsin 
in detergent micelles29 has recently been accomplished. Furthermore, there are a 
variety of NMR based methods that can be used to obtain structural information 
on ligand-protein interactions, such as chemical shift perturbation (CSP),30 
sparse nuclear Overhauser effect (NOE) based methods,31 and paramagnetic 
NMR.32 As described in Chapter 2, NMR based CSP analysis was applied to 
map the ligand binding sites at low resolution and predict the binding mode of two 
classes of DsbB inhibitors. A simple structural model proposed by CSP analysis 
is consistent with the results of the biochemical mode of action study. The 
stabilized GPCRs, with enhanced thermostability and reduced conformational 
exchange might enable resonance assignment for the putative allosteric sites, to 
further map the ligand binding site using CSP techniques.  
 
Expression of GPCRs in E. coli 
 
 GPCRs generally express in very little amounts (<1 mg/L). A large number 
of expression systems such as bacteria, yeast, insect cells, and mammalian 
cells, have been evaluated in order to obtain large quantities of receptors 
necessary for structural studies. E. coli expression system presents several 
advantages compared with eukaryotes, including easy handling, inexpensive 
media, fast growth, high cell densities, and quick genetic modification. E. coli is 
suitable to produce fully isotope labeled protein, including deuteration, which is 
crucial for many NMR structural studies. A number of techniques have been 
developed, which enable efficient expression and correct folding of receptors: i) 
Expression of GPCRs as fusion proteins allows production of functional proteins 
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targeted to the inner membrane, such as the neurotensin receptor33 and the 
adenosine A2A receptor34. ii) An alternative approach is to overexpress the GPCR 
in inclusion bodies and subsequently refold it in vitro. Amphipols have been used 
to refold receptors like leukotriene receptors BLT1 and BLT2.35 This method has 
been investigated to overexpress A2AR as described in Chapter 5. If the A2AR can 
be successfully refolded in amphipols, this could enable production of significant 
amounts of isotope labeled receptor for NMR structural biology studies. If so, the 
ortho- and allo- steric binding sites can be mapped at low resolution using CSP 
techniques.36  
 In most cases, an efficient refolding of a GPCR from IBs is still 
challenging. An alternative technique, CHESS (cellular high-throughput 
encapsulation, solubilization and screening), developed by Plückthun and 
colleagues, enables production of a reasonable quantity of functional protein in E. 
coli.37 As E. coli is a suitable expression system for producing isotope labeled 
protein, CHESS provides the potential to apply NMR based structural biology to 
GPCRs for drug discovery. In addition, the improved stability of GPCR using 
directed evolution would facilitate biophysical fragment screening. However, in 
order to perform CHESS, many instruments are required and experiment set up 
is rather complex. Although it’s a very powerful technique for GPCR production 
and stabilization, the CHESS intellectual property is legally protected and cannot 
be used for commercial purposes without authorization. To investigate the 
potential of this method, a collaborative drug discovery project between ZoBio 
and the lab of Prof. Andreas Pluckthün at the University of Zürich, will use 
CHESS technology to produce large quantities of thermostabilized receptor in E. 
coli. The GPCR will be engineered to attach paramagnetic tags at different sites 
on the protein. The pseudo-contact shift (PCS)32 generated by the paramagnetic 
metal will be used to determine the binding site of small molecule ligands in rapid 





  To summarize, traditional GPCR drug discovery has focused on high-
throughput screening of large compounds libraries using cell-based assays to 
discover novel molecules with selective activities such as agonist and positive 
allosteric modulators. Since the end of the 20th century, the impressive progress 
with structural biology of GPCR has been coming to fruition. The combination of 
fragment-based drug discovery and structure-based drug design applied to 
GPCRs has shown the ability to establish FDA approved drugs with improved 
physiochemical properties and selectivity profiles. The power of FBDD and SBDD 
may deliver important breakthroughs that likely contribute to discover more 





1. Zheng, C., Han, L., Yap, C. W., Xie, B. & Chen, Y. Progress and problems in the exploration of therapeutic targets. 
Drug Discov. Today 11, 412–420 (2006). 
2. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical 
melanoma models. Cancer Res. 70, 5518–5527 (2010). 
3. Wada, C. K. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories. Curr. 
Top. Med. Chem. 4, 1255–1267 (2004). 
4. Park, C.-M. et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. 
J. Med. Chem. 51, 6902–6915 (2008). 
5. Congreve, M., Dias, J. M. & Marshall, F. H. Structure-based drug design for G protein-coupled receptors. Prog. Med. 
Chem. 53, 1–63 (2014). 
6. Congreve, M. et al. Fragment Screening of Stabilized G-Protein-Coupled Receptors Using Biophysical Methods. 
Method. Enzym. 493, 115–136 (2011). 
7. Christopher, J. A et al. Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity 
Arylpiperazine Leads Using Structure-Based Drug Design. J. Med. Chem. 56, 3446–3455 (2013). 
8. Iva Navratilova, Jeremy Besnard, A. L. H. Screening for GPCR Ligands Using Surface Plasmon Resonance. ACS Med. 
Chem. Lett. 2, 549–554 (2011). 
9. Aristotelous, T. et al. Discovery of β 2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged 
Wild-Type Receptor. ACS Med. Chem. Lett. 4, 1005–1010 (2013). 
10. Navratilova, I. & Hopkins, A. L. Fragment Screening by Surface Plasmon Resonance. ACS Med. Chem. Lett. 1, 44–48 
(2010). 
11. May, P. C., Dean, R. a, Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., Monk, S. a, Mathes, B. M., Mergott, 
D. J., Watson, B. M., Stout, S. L., Timm, D. E., Smith Labell, E., Gonzales, C. R., Nakano, M., Jhee, S. S., Yen, M., 
Ereshefsky, L., Lindstrom, T. D., Calligaro, D. O., Cocke, P. J., Greg Hall, D., Friedrich, S., Citron, M., and Audia, J. E. 
(2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J. 
Neurosci. 31, 16507–16516. 
12. Bayburt, T. H. & Sligar, S. G. Membrane protein assembly into Nanodiscs. FEBS lett. 584, 1721–1727 (2010). 
13. Lyukmanova, E. N. et al. Lipid-protein nanodiscs for cell-free production of integral membrane proteins in a soluble 
and folded state: comparison with detergent micelles, bicelles and liposomes. Biochim. Biophys. Acta 1818, 349–358 
(2012). 
14. Etzkorn, M. et al. Cell-free expressed bacteriorhodopsin in different soluble membrane mimetics: biophysical 
properties and NMR accessibility. Structure 21, 394–401 (2013). 
15. Raschle, T., Hiller, S., Etzkorn, M. & Wagner, G. Nonmicellar systems for solution NMR spectroscopy of membrane 
proteins. Curr. Opin. Struct. Biol. 20, 471–479 (2010). 
16. Serebryany, E., Zhu, G. A. & Yan, E. C. Y. Artificial membrane-like environments for in vitro studies of purified G-
protein coupled receptors. Biochim. Biophys. Acta 1818, 225–233 (2012). 
17. Park, S. H. et al. Local and Global Dynamics of the G Protein-Coupled Receptor CXCR1. Biochemistry 50, 2371–2380 
(2011). 
18. Park, S. H. et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491, 779–783 (2012). 
19. Gautier, A., Mott, H. R., Bostock, M. J., Kirkpatrick, J. P. & Nietlispach, D. Structure determination of the seven-helix 
transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy. Nat. Struct. Mol. Biol. 17, 768–774 (2010). 
20. Hajduk, P. J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. 
Drug Discov. 6, 211–219 (2007). 
21. Congreve, M., Langmead, C. J., Mason, J. S. & Marshall, F. H. Progress in structure based drug design for G protein-
coupled receptors. J. Med. Chem. 54, 4283–4311 (2011). 
22. Congreve, M. et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based 
Drug Design. J. Med. Chem. 55, 1898–1903 (2012). 
23. Chilingaryan, Z., Yin, Z. & Oakley, A. J. Fragment-based screening by protein crystallography: successes and pitfalls. 
Int. J. Mol. Sci. 13, 12857–12879 (2012). 
24. Zhukov, A. et al. Biophysical mapping of the adenosine A2A receptor. J. Med. Chem. 54, 4312–4323 (2011). 
25. Andrews, S. P. & Tehan, B. Stabilised G protein-coupled receptors in structure-based drug design: a case study with 
adenosine A2A receptor. Med. Chem. Comm 4, 52–67 (2013). 
26. Park, S. H. et al. Optimization of purification and refolding of the human chemokine receptor CXCR1 improves the 
stability of proteoliposomes for structure determination. Biochim. Biophys. Acta 1818, 584–591 (2012). 
27. Catoire, L. J. et al. Solution NMR mapping of water-accessible residues in the transmembrane beta-barrel of OmpX. 
Eur. Biophys. J. 39, 623–630 (2010). 
28. Langelaan, D. N. et al. Structural features of the apelin receptor N-terminal tail and first transmembrane segment 
implicated in ligand binding and receptor trafficking. Biochim. Biophys. Acta 1828, 1471–1483 (2013). 
29. Reckel, S. et al. Solution NMR structure of proteorhodopsin. Angew. Chemie 50, 11942–11946 (2011). 
30. Wang, B., Westerhoff, L. M. & Merz Jr, K. M. A Critical Assessment of the Performance of Protein-ligand Scoring 
Functions Based on NMR Chemical Shift Perturbations. J. Med. Chem. 50, 5128–5134 (2008). 
31. Pellecchia, M. et al. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov. 7, 
738–745 (2008). 
32. Guan, J. et al. Small-Molecule Binding Sites on Proteins Established by Paramagnetic NMR Spectroscopy. J. Am. 
Chem. Soc. 135, 5859–5868 (2013). 
33. Grisshammer, R., Duckworth, R. & Hendersont, R. Expression of a rat neurotensin receptor in Escherichia coli. 
Biochem. J. 576, 571–576 (1993). 
162 
 
34. Weiss, H. M. & Grisshammer, R. Purification and characterization of the human adenosine A2a receptor functionally 
expressed in Escherichia coli. Eur. J. Biochem. 269, 82–92 (2002). 
35. Dahmane, T., Damian, M., Mary, S., Popot, J.-L. & Banères, J.-L. Amphipol-assisted in vitro folding of G protein-
coupled receptors. Biochemistry 48, 6516–6521 (2009). 
36. Schieborr, U. et al. How much NMR data is required to determine a protein-ligand complex structure? Chem. Bio. 
Chem 6, 1891–1898 (2005). 
37. Egloff, P. et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia 





 The present thesis starts with an overview of G protein-coupled receptors 
(GPCRs) (Chapter 1), which represent the largest protein family in the human 
proteome. Currently, more than 30% of all drugs on the market target this class 
of proteins, highlighting their pharmaceutical importance. Traditional GPCR drug 
discovery efforts rely on cell-based assays, combined with high-throughput 
screening. However, not all GPCRs are amenable to traditional screening and 
pharmacological evaluation methods. The chapter introduces the notion of 
fragment-based drug discovery (FBDD) and biophysical methods that are widely 
used for fragment discovery, such as nuclear magnetic resonance (NMR), 
surface plasmon resonance (SPR) and X-ray crystallography. Until recently, 
research in GPCR drug discovery was very challenging, mainly because of the 
instability of these proteins when extracted from their native membrane 
environment. The chapter also describes recent new advances in receptor 
stabilization and solubilization to overcome these limitations for biophysical 
studies.  
 The work described in Chapter 2 proves that target immobilized NMR 
screening (TINS) can be applied to identify small molecule hits on membrane 
proteins. The bacterial membrane enzyme disulphide bond forming protein B 
(DsbB) was chosen as a target and was immobilized on a sepharose resin and 
screened against the bacterial reference protein outer membrane protein A 
(OmpA), both solubilized in dodecylphosphocholine micelles. The reference 
protein is expected to account for non-specific binding of fragments to the 
solubilization media. Chapter 2 also describes an alternative solubilization 
method for TINS in aqueous buffer. The proteins were encapsulated into a lipid 
bilayer surrounded by two amphipathic scaffold proteins in a complex named the 
nanodisc (ND). Compared to detergent solubilized DsbB, the ND embedded 
DsbB showed enhanced activity in enzymatic assays and higher immobilization 
efficiency. NDs offer the potential to enable a more generic method to handle 
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membrane proteins. Furthermore, the use of NDs alleviated issues of non-
specific partitioning of fragments into detergent micelles and improved the quality 
of NMR spectra of the fragments.  
 The work presented in Chapter 3 demonstrates the feasibility of combining 
TINS and stabilized GPCRs (StaRs®) to screen fragment libraries for target 
specific binding. StaRs® contain a small number of point mutations for both 
enhanced thermostability and conformational homogeneity. A moderate sized 
fragment library was screened for binding to an inverse agonist stabilized 
adenosine A2A receptor (A2AR), with OmpA as reference protein. Multiple TINS 
hits were validated by pharmacological assays with wild-type receptor. Among 
these hits, ligands with many different biological activities were discovered such 
as orthosteric ligands and positive and negative allosteric modulators. This study 
is one of the first reports of allosteric modulators for the adenosine A2AR. Several 
of these ligands could be a good start for further lead exploration. It is likely that 
these allosteric modulators would be missed by other screening methods, due to 
their apparent low potency. TINS, as a direct binding assay, shows its great 
potential to detect multiple fragments that bind to different sites on the receptor, 
thus to discover ligands with novel biological activities, despite of their low 
potency. 
 In recent years, the impressive growth in GPCR structure information 
leads to broad use of structure-based methods for hit discovery and optimization. 
The work reported in Chapter 4 shows the potential to complement NMR-based 
fragment screening with molecular docking screens in FBDD against the A2AR. 
The in silico screening approach can be extended to include 328,000 
commercially available fragments and has better coverage of chemical space, 
which provides the opportunity to discover ligands with different chemotypes.  
This study showed that the molecular docking based screen was able to identify 
fragment hits that do not overlap with those discovered by NMR-based 
screening. The combination of biophysical and in silico screening methods with 
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structure determination for GPCRs will provide considerable aid to the drug 
elaboration process.  
 The dynamic nature of GPCRs and issues associated with low level 
expression and instability during purification made biophysical and structural 
characterization of GPCRs particularly difficult. In Chapter 5, a new methodology 
to overexpress GPCR genes in Escherichia coli yielding the protein in inclusion 
bodies is investigated. If the receptor can be successfully refolded in its native 
state using amphipols, it could enable the production of a sufficient amount of 
isotope labeled GPCR for NMR structural studies. In this case, the ligand binding 
sites can be mapped at low resolution using chemical shift perturbation 
techniques.  
  Chapter 6 presents the general discussion of the research described in 
this thesis and further perspectives in field of GPCR drug discovery. In recent 
years, a number of FBDD techniques have been validated for application with 
GPCRs, including some of the most challenging targets. The impressive progress 
with structural biology of GPCRs has been coming to fruition. This new era of 
FBDD and SBDD for GPCRs has the great potential to yield safe and effective 







 In Hoofdstuk 1 van dit proefschrift wordt de grootste familie van eiwitten in 
het menselijk genoom, de G-eiwit gekoppelde receptoren (GPCRs), beschreven. 
GPCRs zijn belangrijke targets voor medicijnen en meer dan 30% van alle 
momenteel verkrijgbare geneesmiddelen grijpt dan ook aan op deze klasse van 
eiwitten. In het onderzoek naar nieuwe geneesmiddelen voor GPCRs worden 
doorgaans testsystemen met levende cellen gebruikt. Deze systemen zijn echter 
niet toepasbaar op alle GPCRs. In dit hoofdstuk introduceer ik daarom het 
gebruik van biofysische methodes, zoals nuclear magnetic resonance (NMR), 
surface plasmon resonance (SPR) en Röntgen-kristallografie, voor fragment-
gebaseerde medicijn ontwikkeling (FBDD). Omdat GPCRs moeilijk te isoleren 
zijn uit het celmembraan is geneesmiddelenontwikkeling met gebruik van deze 
biofysische methoden voor deze klasse van eiwitten zeer uitdagend. In dit 
hoofdstuk worden de laatste ontwikkelingen op het gebied van 
receptorstabilisatie beschreven.  
 In Hoofdstuk 2 toon ik aan dat target immobilized NMR screening (TINS) 
kan worden gebruikt om kleine moleculen te vinden die affiniteit voor 
membraaneiwitten hebben. Het enzym disulphide bond forming protein B (DsbB) 
werd hiervoor geïmmobiliseerd op een dragermateriaal en stabiel in oplossing 
gehouden door middel van micellen. Een TINS screen met dit geïmmobiliseerde 
eiwit werd vervolgens uitgevoerd, waarbij outer membrane protein A (OmpA) als 
referentie-eiwit diende om te corrigeren voor eventuele aspecifieke binding van 
de kleine moleculen aan de matrix. Een alternatieve methode om eiwitten stabiel 
in oplossing te houden voor TINS, wordt tevens beschreven in Hoofdstuk 2. 
Hierbij werd gebruik gemaakt van synthetische membraanmodellen, 
zogenaamde nanodiscs (NDs). In het geval van DsbB resulteerde het gebruik 
van NDs in een hogere enzymatische activiteit dan van het door middel van 
micellen gestabiliseerde DsbB. Tevens kon er een hogere immobilisatiegraad 
bereikt worden door gebruik te maken van NDs. Door NDs te gebruiken treedt er 
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bovendien minder aspecifieke binding op van de kleine moleculen en wordt de 
kwaliteit van de NMR-spectra van de moleculen sterk verbeterd.  
 In Hoofdstuk 3 wordt beschreven hoe gestabiliseerde GPCRs (StaRs®) 
gebruikt kunnen worden in TINS. StaRs® zijn GPCRs waarin een klein aantal 
punt mutaties zijn aangebracht om de thermostabiliteit van deze eiwitten te 
verbeteren en het aantal conformaties van de GPCRs te beperken. Een TINS-
screen tegen een inverse agonist gestabiliseerde STaR® van de adenosine A2A 
receptor (A2AR) werd uitgevoerd met een kleine hoeveelheid fragmenten, waarbij 
OmpA als referentie-eiwit diende. Meerdere hits uit deze TINS screen werden 
gevalideerd in farmacologische testsystemen, waarbij gebruik werd gemaakt van 
de niet-gemuteerde vorm van de A2A-receptor. Dit resulteerde in de identificatie 
van liganden met uiteenlopende biologische activiteiten, waaronder allostere 
modulatoren van de A2A-receptor. Verschillende van deze liganden zijn goede 
startpunten voor verdere optimalisatie naar grotere en meer potente 
verbindingen. Deze studie beschrijft als een van de eerste de identificatie van 
allostere modulatoren van de A2A-receptor. Met behulp van TINS kunnen 
moleculen worden geïdentificeerd die met lage affiniteit, op iedere willekeurige 
locatie met een eiwit binden. TINS is dan ook zeer geschikt om binding van 
meerdere fragmenten tegelijkertijd met een receptor te identificeren, ondanks de 
lage bindingsaffiniteit van deze liganden. Waarschijnlijk zouden eerder 
genoemde allostere modulatoren van de A2A-receptor niet gevonden zijn 
wanneer een andere, minder gevoelige, detectiemethode was gebruikt.  
 Hit identificatie- en validatie technieken, waarbij structurele informatie van 
het target nodig is (SBDD), worden steeds vaker toegepast op GPCRs. In 
Hoofdstuk 4 wordt beschreven hoe fragment-screening door middel van NMR, in 
combinatie met computer screening kan worden toegepast ter identificatie van 
liganden voor de A2A-receptor. Door gebruik te maken van in silico technieken 
kunnen liganden worden gevonden in een collectie van 328.000 commercieel 
verkrijgbare fragmenten. Deze vertegenwoordigen een grote chemische 
diversiteit, wat het mogelijk maakt om liganden met nieuwe chemotypen te 
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identificeren. Deze studie toont aan dat met behulp van de in silico screen 
liganden konden worden geïdentificeerd die geen structurele gelijkenis hadden 
met fragmenten die door middel van NMR screening waren gevonden. Het 
combineren van biofysische- en in silico screening technieken met 
structuuropheldering zal in de toekomst aanzienlijk bijdragen aan de ontwikkeling 
van nieuwe GPCR geneesmiddelen.  
Naast het flexibele karakter van GPCRs zijn lage cellulaire expressie en 
instabiliteit tijdens opzuiveren de grootste obstakels voor biofysische en 
structurele karakterisering van GPCRs. In Hoofdstuk 5 wordt een nieuwe 
methode beschreven waarin GPCRs tot over-expressie worden gebracht in 
Escherichia coli en waarbij de receptoren in onoplosbare vorm geproduceerd 
worden. Wanneer de receptoren uit deze zogenaamde inclusion bodies opnieuw 
gevouwen zouden kunnen worden tot een oplosbare vorm, biedt dit een 
mogelijkheid om voldoende isotoopgelabeld eiwit voor NMR-studies te 
produceren. De bindingsplaats van liganden aan de receptor kan vervolgens 
redelijk accuraat bepaald worden, door middel van het in kaart brengen van de 
“chemische verschuiving” van de pieken in het NMR spectrum.  
In Hoofdstuk 6 wordt het onderzoek dat is beschreven in dit proefschrift 
bediscussieerd en wordt vooruitgekeken naar de geneesmiddelenontwikkeling 
van de toekomst in het veld van GPCRs. In de recente jaren zijn meerdere FBDD 
technieken ontwikkeld en succesvol toegepast op GPCRs, waaronder een aantal 
zeer uitdagende targets. De indrukwekkende vooruitgang in het veld van 
structurele biologie met GPCRs wordt dan ook duidelijk zichtbaar. In de toekomst 
ligt een grote rol weggelegd voor FBDD en SBDD technieken bij de ontwikkeling 
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